RC
667
F813
sec.32
1977

THE FRAMINGHAM STUDY

An Epidemiological Investigation of Cardiovascular Disease

Section 32

Cardiovascular Diseases and Death Following Myocardial Infarction and Angina Pectoris: Framingham Study, 20-year Follow-up

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service   National Institutes of Health

THE

FRAMINGHAM

STUDY

An Epidemiological Investigation of Cardiovascular Disease

Editors: William B. Kannel, M.D., and Tavia Gordon

Section 32. Cardiovascular Diseases and Death Following Myocardial Infarction and Angina Pectoris: Framingham Study, 20-year Follow-up.

Paul Sorlie

March, 1977

National Heart, Lung, and Blood Institute

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service National Institutes of Health

DHEW PUBLICATION NO. (NIH) 77-1247

RC
667
F813
sec. 32
1977

Table of Contents

A. Highlights 1

B. Introduction 3

C. Definition of the population at risk with myocardial infarction and angina pectoris. 5

D. Definition of the events following myocardial infarction and angina pectoris 9

E. Dating the occurrence of disease 13

F. Methodology - Life tables. 15

G. Methodology - Factors associated with survival . . 25

H. Tables & Figures

- I. Number of persons developing angina pectoris and myocardial infarction and number of subsequent endpoint events. 33
- II. Number of persons developing angina pectoris and myocardial infarction and number of endpoint events by age and interval of occurrence. 37
- III. Life tables with observed and relative rates of endpoints in population with myocardial infarction and angina pectoris. 55

IV. Life tables for specified endpoints in the total Framingham population beginning at Examination one. 83
V. Graphs of the cumulative probability of having specified endpoint events in those with myocardial infarction and angina pectoris and in those free of myocardial infarction and angina pectoris. 105
VI. Survival following myocardial infarction and angina pectoris with reference to measured characteristics. 119
I. References and Previous Sections 145

A. Highlights

Uncomplicated angina pectoris doubles the risk of death in 5 years. (Table III-1)

A recognized myocardial infarction increases the risk of death more than fivefold over 5 years. (Table III-8)

A recognized myocardial infarction carries a worse prognosis for women than for men. (Table III-8)

A second documented myocardial infarction occurs in 13 percent of the men and 40 percent of the women in 5 years. (Table III-10)

Recognized and unrecognized myocardial infarctions carry similar relative survival rates for men. (Table III-8, Table III-12)

A man 32 years old has a 13 percent chance of developing cardiovascular disease in the next twenty years, a 52 year old man has a 46 percent chance. (Table IV-10)

The more severe prognosis following an MI in women is due to the higher early mortality. Subsequent mortality trends are similar for men and women. (Figure V-8)

Evidence of heart enlargement more than triples the risk of death in angina patients. (Table VI-2b)

A large drop in blood pressure after a myocardial infarction indicates a greater risk of death. (Table VI-8b)

B. Introduction

It is well known that the clinical manifestations of coronary heart disease (CHD) carry with them high subsequent mortality and morbidity. This Monograph describes the incidence of cardiovascular disease and death following CHD as found in the Framingham Heart Study. Using life tables, the mortality and morbidity following CHD is presented. The prognosis of individuals with CHD is compared to individuals free of CHD. Finally, there is a detailed analysis of the relation of characteristics measured at the Framingham examination to survival following CHD.

The Framingham Study began in 1948 with a cohort of 2336 men and 2873 women who were age 30 to 62 years at their first cardiovascular examination. These individuals were recalled and examined every two years thereafter. This Monograph analyzes experience for the first 20 years of follow-up.

The routine cardiovascular examination consisted of a medical history, physical examination, blood chemistries, body measurements, vital capacity, chest x-ray, and a 12-lead electrocardiogram. Mortality and cardiovascular morbidity were documented in detail from the routine biennial examination, hospital records, death certificates, physician records and next-of-kin. The criteria for cardiovascular events are presented below. The loss to mortality follow-up was extremely low with less than two percent completely unaccounted for.

In the twenty years following the first examination, approximately 21 percent of the men and 11 percent of the women developed their first manifestation of CHD. Analysis focuses on the prognosis of this subset of the Framingham cohort with CHD. These data on prognosis suffer from the disadvantage of small numbers. However, they have the unique advantages of being from a representative population and in having individual characteristics measured in a uniform manner both before and (if they survived) after the onset of disease, and in having all other cardiovascular disease endpoints systematically documented during all subsequent follow-up.

C. Definition of the population with coronary heart disease

The criteria for defining the specific manifestations of coronary heart diseases used in this Monograph - angina pectoris (AP), myocardial infarction (MI), or sudden death - are described in detail below. In reviewing these criteria it is critical to note the exact time at which an individual is considered to be at risk for subsequent mortality or morbidity, and the exact time at which subsequent morbidity is considered to have occurred. Myocardial infarction, for example, can ordinarily be dated fairly precisely. On the other hand angina pectoris is discovered by a medical history during the biennial Framingham examination, thus requiring an individual to survive and come to the examination before he can be at risk of death or disease following angina pectoris. The number of individuals with these manifestations of CHD and at risk of subsequent endpoints are shown in Table I.

Angina pectoris

Brief recurrent chest discomfort of up to 15 minutes duration, precipitated by exertion or emotion and relieved by rest or by nitroglycerine, was regarded as angina pectoris (AP) if two physicians interviewing the subject agreed that this condition was definitely present. This diagnosis was based on evaluation of the subjective manifestation; abnormality of the electrocardiographic tracing was not taken into account. An individual with AP who showed no other manifestation of CHD in that same interval or previous interval was called angina pectoris _uncomplicated_.

An individual with uncomplicated angina pectoris was considered at risk of subsequent death or disease on the date of the Framingham examination which diagnosed the angina by a history.

Myocardial infarction

Recent or acute myocardial infarction (MI) was designated when there were serial changes in the electrocardiograms indicating ST segment elevation in the electrocardiographic tracing (ECG) associated with terminal inversion of T waves and the loss of initial QRS potentials (that is, development of "pathologic" Q waves of 0.04 second duration or greater), followed by serial changes indicating reversion towards normal. An old or remote myocardial infarction was considered to be present when the electrocardiogram showed a stable pattern including a pathologic Q wave of 0.04 second or greater or loss of initial QRS potential (R wave) in those leads in which this would not be expected to occur. Also, an interim MI was indicated (with or without symptoms) when changes from a previous tracing showed development of loss of R-wave potential or appearance of pathologic Q waves not otherwise explained. More weight was given to this finding if a T-wave abnormality was also associated.

Beginning in 1956, a hospital report for a subject showing a rise in the serum glutamic oxalacetic transaminase (SGOT) to a level of at least 60 units along with a history of prolonged ischemic chest pain was accepted as evidence of myocardial infarction. Subsequently, in 1962, pathologic elevation of another enzyme was included: lactic dehydrogenase (LDH) greater than 500 units. At a later date, with a change in laboratory techniques, SGOT was abnormal at 50 and LDH at 200.

An autopsy report showing an acute, new, or recent infarction of the myocardium was accepted as evidence of myocardial infarction. Because it is not possible to date an old infarction found on autopsy such evidence was not used in the clinical diagnosis.

The MI was considered recognized if the onset of clinical symptoms brought the individual to the attention of a physician where the condition was then diagnosed.

An individual with MI recognized was considered at risk of subsequent death or disease on the date diagnosed by hospital or physician.

The MI was considered unrecognized if there were no clinical symptoms precipitating an examination by a physician thus leaving the diagnosis to be made on the basis of the repeat Framingham examination.

An individual with myocardial infarction *unrecognized* was considered at risk of subsequent death or disease on the Framingham examination at which it was diagnosed.

Sudden death

If a subject, apparently well, was observed to have died within a few minutes (operationally documented as under one hour) from onset of symptoms and if the cause of death could not reasonably be attributed to some potentially lethal disease other than coronary heart disease, this was called sudden death and was attributed to coronary heart disease.

Sudden death is included in some of the analyses as an MI with immediate mortality. This corresponds to the usage of some other investigators and has the advantage of giving proper emphasis to the lethality of coronary heart disease. Life tables are presented for death following a documented MI (which does not include sudden death as an initial manifestation) and for MI including sudden death (the sudden death is considered an MI with immediate mortality).

D. Definition of endpoint events following CHD

The lifetable analysis describes the incidence of death and a variety of cardiovascular diseases following CHD. The number of individuals with these endpoints following CHD are presented in Table I.

The criteria for the specific endpoint events are described below:

Death

The fact of death was supported by a death certificate. Additional information was obtained from records supplied by hospital, attending physician, pathologist, coroner, or family. A panel of staff physicians reviewed all evidence to arrive at the cause of death.

Sudden death

The endpoint definition is the same as previously defined.

Cardiovascular death

The underlying cause of death was any disease of the heart or blood vessels.

Myocardial infarction

As an endpoint, MI includes both recognized and unrecognized myocardial infarction.

Angina pectoris

See previous definition.

Coronary attack

Because an interest is often expressed in the incidence of "coronary attacks", this category is established to represent the occurrence of myocardial infarction, coronary insufficiency, or death from coronary heart disease.

Coronary insufficiency

The coronary insufficiency syndrome was designated when a history of prolonged ischemic chest pain was accompanied by transient ischemic S-T segment and T-wave abnormality in the electrocardiographic tracing but not accompanied by development of Q-wave abnormality or by serum enzyme changes characteristic of muscle necrosis.

Cerebrovascular accident

The diagnosis of overt vascular disease of the brain was based on the occurrence of stroke. Minimal criteria for *nonhemorrhagic stroke* consisted of sudden onset of a focal neurologic deficit (such as hemiparesis, aphasia, homonymous hemianopia); for stroke due to *intracranial hemorrhage*, a change in the state of consciousness, headache, and signs of meningeal irritation in association with bloody spinal fluid under increased pressure whether with or without other localizing neurological deficits. A diagnosis of *embolus* to the brain was made if a source embolus (that is, atrial fibrillation, rheumatic heart disease with mitral stenosis, recent myocardial infarction, bacterial endocarditis) was present, the clinical course consistent (that is, rapid onset and clearing, slightly bloody spinal fluid, a more localized deficit), or the occurrence of associated peripheral emboli elsewhere noted. A consultant neurologist and the clinical staff of the study reviewed hospital and clinic protocols. Starting with Examination eight they have examined patients in the hospital with stroke.

Congestive heart failure

A definite diagnosis of congestive heart failure required a minimum of two major or one major and two minor criteria, the criteria existing concurrently. The existence of other conditions was considered in evaluating the findings.

Major criteria:

1. Paroxysmal nocturnal dyspnea.
2. Distended neck veins (in other than the supine position).
3. Râles
4. Increasing heart size by X-ray.
5. Acute pulmonary edema described in hospital record.
6. Ventricular S(3) gallop.
7. Increased venous pressure (greater than 16 cm H_2O above right atrium).
8. Circulation time (greater than 24 seconds, arm to tongue).

9. Hepatojugular reflux.
10. Pulmonary edema, visceral congestion, and cardiomegaly shown on autopsy.

Minor criteria:

1. Bilateral ankle edema.
2. Night cough.
3. Dyspnea on ordinary exertion.
4. Hepatomegaly.
5. Pleural effusion.
6. Decrease in vital capacity by one-third from maximum recorded.
7. Tachycardia (120 beats per minute or more).

Arbitrary major or minor criterion:

Weight loss (ten pounds or more in five days) while on therapy for congestive heart failure.

E. Dating occurrence of disease

The rules for dating the occurrence of baseline disease were as follows:

Angina pectoris:	date at which a positive history was taken during a Framingham examination.
Recognized myocardial infarction:	date at which the infarction occurred, usually a physician or hospital visit.
Unrecognized myocardial infarction:	date at which electrocardiographic evidence documented the previous, unrecognized occurrence of an MI.

The rules for dating the occurrence of endpoint events were as follows:

Angina pectoris:	date of the midpoint between the last Framingham examination without AP and the first Framingham with AP. If the AP was known to occur with another CHD event, it was given the same date, if it was known to occur prior to another CHD event it was dated 3 months earlier, and if it was known to occur later, it was dated 3 months later.

Recognized myocardial infarction:	date at which the infarction occurred, usually a physician or hospital visit.
Unrecognized myocardial infarction:	date of the midpoint between the two electrocardiograms which documented the unrecognized infarction.
Coronary insufficiency:	date at which the insufficiency syndrome occurred, a physician or hospital visit.
Cerebrovascular accident:	date at which the stroke occurred, usually a physician or hospital visit.
Congestive heart failure:	date at which the heart failure victim was hospitalized, or date of the Framingham examination which elicited history of symptoms if not hospitalized.
Death:	date of death

F. Life table methodology

An individual enters the population at risk at the moment he is first defined to have the specific CHD event (angina pectoris uncomplicated, myocardial infarction recognized or unrecognized). These events could have occurred any time between October, 1950 and October, 1970. Examination one and Examination eleven events are not included. The individual is then followed to Examination eleven (which ended in 1971) or to death, whichever comes first.

It is then determined for fixed time intervals (I) whether an individual was alive at the beginning of that interval (L), whether he died in that interval (D), or whether he was withdrawn in that interval because of termination of follow-up (W), i.e., to Examination eleven. There are no losses to follow-up in these tables. Since less than two percent of the Framingham cohort have been lost, it is assumed that death and disease information can be determined for all participants.

Life tables are presented in yearly intervals except for myocardial infarction which shows a 30 day interval immediately following the MI. It is possible to calculate yearly intervals since all disease manifestations and deaths are precisely dated. Age-specific counts of events are presented by yearly intervals up to 15 years (Table II). The reader is cautioned that in many of these age-sex groups there is little information available on new events for the longer intervals of follow-up.

In addition to the usual statistics in life tables (e.g. interval and cumulative survival rates and their standard errors), relative survival and mortality ratios and their standard errors have also been calculated. These ratios show the ratio of the cumulative survival (or morbidity) rate of those with the specific disease to the cumulative survival (or morbidity) rate of those free of the disease. Thus, this ratio provides some measure of survival relative to a standard population. In this Monograph, the standard population is the Framingham Study cohort which is free of the particular disease in question.

Specifically, the life table for prognosis following angina pectoris uncomplicated (APU) requires a standard lifetable for the Framingham population free of APU; the life table for prognosis following any of the MI categories requires a standard life table for the

Framingham population free of all MI.

Life tables for the standard population are calculated in sex-specific and in five-year age groups. Life tables are calculated with the initial interval beginning in March and October of each year between 1950 and 1970. Thus there are 40 different life tables for each age-, sex- and disease-group and these life tables describe death (or disease) experience beginning at 40 different time points between 1950 and 1970. This is to insure that the life tables of the standard population would reflect any temporal changes in mortality or morbidity.

An age-matched reference life table of the population free of AP or MI is then constructed by summarizing the standard life tables. This is done by selecting the cumulative survival rate from the age-sex-time specific standard life table which matches the age, sex, and time-of-onset of CHD for the cohort with the specific manifestations of CHD. These specific cumulative survivals are then averaged to make the reference life table which is thus matched for age-sex and time of onset of the initial CHD episode. A relative rate is calculated by dividing the observed cumulative survival rate in the CHD population by the reference cumulative survival rate in those free of disease. The relative rates for all age groups combined is then a rate which has been adjusted for age.

Life tables with observed and relative rates are presented in Table III. These tables are not always carried out for the full fifteen years. Using an ad hoc prodecure, the display of follow-up was terminated when the expected number of events (D) in an interval was less than one. The expected number was determined by averaging the five previous interval probabilities of the disease (Q) and multiplying this probability by the number at risk within the interval. Life tables are presented only if there was at least five years of experience with sufficient number of incidence cases.

The following are the definitions for each column of the life tables:

(I) Interval length

This column gives the interval of follow-up following the CHD event. The first number indicates the time following CHD at which the individual is known to be alive (or free of disease endpoint). The second number is the time through which he is under observation. The interval is the exact time between the completion of the two times shown. The interval 1-2 years means the person was alive (or free of endpoint disease) at the first year and was observed through the second year. This is the interval between the completion of the first year and the completion of the second year following the particular CHD event. The interval is always one year except for the subdivision of 30 days in the first year following MI.

(L_i) Number alive (or number free of endpoint disease)

This column designates the number of individuals alive at the start of interval i following onset of the specific manifestation of CHD. If the endpoint is a disease (i.e., congestive heart failure) instead of mortality then the individual is required to be free of the endpoint disease (CHF) as well as being alive at the start of interval i.

(D_i) Number of deaths (or number with endpoint disease)

When the endpoint is death this column shows the number of deaths in the interval i. In those tables where the endpoint is another disease, this column shows the number of disease events first occurring in the interval i.

(W_i) Number of withdrawals

This column shows the number of withdrawals (for reasons other than the endpoint event) that occurred in the interval i. A withdrawal occurs when the observation on an individual terminates because follow-up does not go beyond Examination eleven. When the endpoint is a disease category other than death, then withdrawals also include those who died in that interval. The interval during which the individual is withdrawn depends upon the length of time between the onset of the specific CHD event and Examination eleven or death. For example, if an MI was diagnosed in June 1960, and the termination of follow-up , (i.e., Examination eleven) was December 1970, then he would be withdrawn in the interval 10-11.

(L_i^*) Adjusted number at risk

This column shows the effective number exposed to the risk of dying or of having another disease event. It is calculated by the equation $L_i^* = L_i - W_i/2$. This formula assumes that the subjects who were withdrawn were observed on the average for one-half the interval since withdrawals are assumed to be equally distributed through the interval. This formula often includes an adjustment for individuals lost to follow-up. Such an adjustment is not made in these tables since few persons in the cohort have been lost to follow-up.

(Q_i) Probability of an event (death or specific cardiovascular disease)

This column shows the probability of death (or of the specific endpoint disease) in the interval _i_. It is obtained by dividing the number of events in the interval by the effective number at risk.

$Q_i = D_i/L_i^*$, for any interval _i_.

($SE(Q_i)$) Standard error of Q

This column gives the standard error of Q_i and is calculated according to the normal approximation.

$SE(Q_i) = (P_i Q_i/L_i^*)^{1/2}$, where $P_i = 1-Q_i$, for any interval _i_.

(CP_i) Cumulative probability of survival (or probability of remaining free of specific disease)

This column shows the cumulative probability of surviving the specific diagnosis of CHD through the interval _i_. For the other disease endpoints, it shows the cumulative probability of remaining free of the specific endpoint from the moment of CHD onset through the interval $\underline{i}$. It is obtained by multiplying the successive proportions surviving each interval ($P_i = 1 - Q_i$).

$CP_k = \prod_{i=1}^{k} P_i$, cumulative probability from interval 1 through interval $\underline{k}$.

($SE(CP_i)$) Standard error of CP

This column shows the standard error of CP calculated according to Greenwood's approximation (1).

$SE(CP_k) = CP_k \left(\sum_{i=1}^{k} Q_i/L_i^{*}P_i\right)^{1/2}$, standard error for cumulative probability from interval 1 to interval $\underline{k}$.

(CSR_i) Cumulative survival ratio (or ratio of cumulative probability of remaining free of endpoint disease in those with CHD to those free of CHD)

As explained above, the cumulative probability of remaining free of endpoint disease (or death) is compared to a reference cumulative probability based on the Framingham population free of the specific CHD event and matched for age, sex, and onset of follow-up.

This ratio (CSR) is calculated dividing the CP of the CHD population by the CP of the reference population (denoted by CP^*) and multiplying by 100 to be expressed as a percent.

$CSR_i = 100 \times CP_i/CP_i^*$ for all intervals _i_, and where CP_i^* is from the matched reference population.

The reference probability CP_i^* is calculated in the following way:

$$CP_i^* = \frac{1}{N_i} \sum_{j=1}^{N_i} cp_{ij}^*$$, where cp_{ij}^* is the cumulative survival rate from the CP column for the _i_th interval from the standard life table matched to the _j_th person, N_i is the total number of individuals in the _i_th interval in the cohort with the specific manifestation of CHD.

$SE(CSR_i)$, standard error of the cumulative survival ratio

This column shows the standard error of the CSR and is calculated using Greenwood's approximation and assumes that the reference probabilities from the standard population are constant. This assumption is not strictly true and thus leads to an underestimate of the true standard error.

$$SE(CSR_k) = CSR_k \left(\sum_{i=1}^{k} \frac{Q_i}{L_i^* P_i}\right)^{1/2}$$

Life tables for the total Framingham cohort

Life tables for events occurring in the general Framingham cohort are found in Table IV. An individual enters the life table in his age group at Examination one if he is free of the endpoint disease specified. He is then followed until he develops the disease or is withdrawn from follow-up, approximately 20 years. These tables describe the occurrences of disease as it occurs in the total Framingham cohort, and not only those with AP or MI.

Life table graphs

Graphs of the incidence of death and disease following AP and MI are found in Figure V. These show the cumulative probability of disease for all ages taken from Table III. They also show the incidence of disease in the age-matched Framingham population which is free of AP or MI. This matched curve is from the life tables for the reference population which is used to calculate the relative morbidity and mortality ratios. They are not the same as the life tables for the total cohort in Table IV since those in Table IV are not necessarily free of AP or MI.

G. Methodology for analyzing factors associated with survival

The Framingham Study not only enables a description of survival following coronary heart disease, but it also enables an analysis of factors related to prognosis. Every two years, these subjects had a detailed cardiovascular examination under standard conditions. These measurements of blood chemistries, medical histories, ECG, etc., are available both before and after the MI or AP had taken place. For a few individuals this is not strictly true since they may have missed an examination and also those with immediate mortality would not have survived to take an examination following the CHD event.

Seventeen characteristics have been analyzed in relation to survival following MI and AP. These characteristics are listed in Table VI, and are described in Section 30 of the Framingham Monograph Series. Analysis has been presented which attempts to answer three questions:

1. Are there any characteristics which have been measured prior to the CHD event which are related to survival following the CHD event?
2. In those subjects who survived the initial CHD event and returned for an

examination are there any characteristics measured on the return examination which are related to subsequent survival?

3. Recognizing that an individual's characteristics may change during or following a CHD event, is the change in any characteristic related to subsequent survival?

To answer the first question all individuals with an MI and AP and with known values of the 17 characteristics on the Framingham examination prior to the onset of the MI or AP were considered in the population at risk. For the population with MI, the follow-up period was analyzed in three segments since the factors affecting mortality in one period could be different from another period. Thus, analysis was done for factors associated with survival to the end of the 30th day following the MI, factors associated with survival from the end of the 30th day to the end of the 5th year following the MI and from the beginning of the 6th year to the end of the 10th year following the MI.

To answer the second question, the population at risk was defined as those individuals with an MI or AP who survived the CHD episode at least long enough to come into the next Framingham examination. This examination would be an average of one year from the CHD episode. The characteristics measured on this examination are then analyzed in relation to survival in the next five years following the examination.

To answer question three, the population at risk is defined as in question two with the additional requirement that they had characteristics measured on the examination prior to the CHD event. The difference in the characteristics is then analyzed in relation to the survival in the next five years following the examination after the CHD event.

Two analytical methods were used to answer the above questions. Since age was almost always associated with survival, these techniques adjusted for age when appropriate.

The first analytic technique is an application of the logistic model which states that the conditional probability of dying (in a fixed period of time) is $P = 1/1 + \exp-(\alpha + \Sigma\beta_i x_i)$ where x_i are the characteristics measured on an individual and α and β_i are coefficients estimated by the method of Walker and Duncan (2). This model does not take the time of death into account except by requiring the death to occur in a specified interval. If the time interval is death in five years following an MI then the death one day after MI is treated the same as a death five years after the MI. The parameters in the model are estimated and the likelihood ratio statistics are presented as an indication of the statistical significance of a variable associated with death. The analysis is performed with one independent variable (age) and with two independent variables (age and the specific characteristic).

The second method is an application of the Mantel-Haenszel method of combining contingency tables and is outlined by Hankey and Myers (3). In this method, a contingency table is constructed at each time interval of the study. For categories of the independent variable, say systolic blood pressure, the population is divided into those who died and those who survived. Thus for $\underline{n}$ intervals of follow-up there would be $\underline{n}$ contingency tables from which a summary chi-square can be calculated, comparing survival within age-specific strata for different categories of the independent variable. These tables are aggregated over the age strata and an age-adjusted chi-square for regression of survival on the level of the independent variable can be calculated. The chi-square for regression (1 d.f.) is presented in this monograph as an indicator of the statistical significance of the independent variable. While this method takes advantage of the varying intervals to survival it has the disadvantage of using an arbitrary categorization of the independent variable.

The tables in Table VI, show the chi-square statistics for regression from the Mantel-Haenszel procedure, and the chi-square likelihood ratio statistics from the Walker-Duncan method. Each chi-square has one degree of freedom with a critical value of 3.84 at the .05 significance level. The direction of the association is presented by a + or - sign in parentheses. These two analytical methods sometimes give different results in both the significance levels and the direction of the association. This is expected because they are different analytical techniques and because the constraints of the methods require them to use different subsets of the data. The Walker-Duncan method uses a smaller population at risk than does the Mantel-Haenszel. An individual must be a risk for the full length of follow-up for the Walker-Duncan, but those with shorter follow-up are used in the Mantel-Haenszel and are withdrawn from the contingency tables when their follow-up is terminated.

Since these chi-square statistics give no indication of the magnitude of the association, the observed and expected number of deaths by categories of the independent variable are shown in the b tables in Part VI. The expected number of events (age-adjusted) are calculated using the life table application of the Mantel-Haenszel method under the null hypothesis of no association between mortality and the independent variable.

The relation between mortality and a specified factor in the AP or MI population may be compared with that found in persons free of coronary heart disease (Tables VI-10 to VI-13). These tables present the coefficients from the logistic model (age and factor as independent variables) for the three populations: those with AP uncomplicated, those with MI recognized, and those free of any CHD. The coefficients are standardized (coefficient times standard deviation of independent variable) to put them on a comparable scale. The standard errors are also shown.

Acknowledgement is made to Patricia McNamara, Velma Edwards and Barbara Geraci for their assistance in the production of this Monograph.

Part I

Number of Persons Developing Specified Diseases and Number of Subsequent Endpoint Events

TABLE I

COUNTS FOR LIFE TABLE ANALYSIS

NUMBER OF PERSONS

PROGNOSTIC ENDPOINT

DISEASE:	DEATH		SUDDEN DEATH		CVD DEATH		MI		AP		CORONARY ATTACK		CVA		CHF	
	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT	AT RISK	EVENT
MEN																
APU	126	50	126	15	126	36	126	27	---	---	126	43	122	6	123	11
MI REC.	193	98	---	---	---	---	193	32	100	34	---	---	190	5	188	31
MI UNREC.	45	27	---	---	---	---	45	7	---	---	---	---	44	9	43	10
MI REC. (INCL. SUDDEN DEATH)*	261	166	---	---	---	---	---	---	---	---	---	---	---	---	---	---
WOMEN																
APU	141	26	141	5	141	19	141	11	---	---	141	22	137	15	131	12
MI REC.	53	31	---	---	---	---	53	13	24	4	---	---	50	4	45	5
MI UNREC.	28	9	---	---	---	---	28	7	---	---	---	---	26	4	25	6
MI REC. (INCL. SUDDEN DEATH)*	72	50	---	---	---	---	---	---	---	---	---	---	---	---	---	---

*The rationale for including sudden deaths as a baseline myocardial infarction is given on page 8 under "sudden death".

APU : Angina Pectoris Uncomplicated
MI REC. : Myocardial Infarction Recognized
MI UNREC. : Myocardial Infarction Unrecognized

Part II

Number of Persons Developing Angina Pectoris and Myocardial Infarction and Number of Subsequent Endpoint Events by Age and Interval of Occurrence

Endpoint events following Angina Pectoris Uncomplicated:

Table No.	
II-1	Death
II-2	Sudden Death
II-3	Cardiovascular Death
II-4	Coronary Attack
II-5	Myocardial Infarction
II-6	Congestive Heart Failure
II-7	Cerebrovascular Accident

Endpoint events following Recognized Myocardial Infarction:

II-8	Death
II-9	Angina Pectoris
II-10	Second Myocardial Infarction
II-11	Congestive Heart Failure
II-12	Cerebrovascular Accident

Endpoint events following Unrecognized Myocardial Infarction:

II-13	Death
II-14	Second Myocardial Infarction
II-15	Congestive Heart Failure
II-16	Cerebrovascular Accident

Endpoint events following Recognized Myocardial Infarction (including Sudden Death):

II-17	Death

TABLE II-1

NUMBER OF DEATHS (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L)
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	21	0	33	0	37	0	19	0	4	0	1	0	126	0
30-365 D	0	0	0	0	4	0	7	0	21	1	33	0	37	2	19	1	4	0	1	0	126	4
1 - 2 YR	0	0	0	0	4	0	7	0	20	2	33	2	35	1	18	1	4	0	1	0	122	6
2 - 3 YR	0	0	0	0	4	0	7	0	15	0	30	1	33	2	15	0	2	0	1	0	107	3
3 - 4 YR	0	0	0	0	4	0	7	0	15	0	26	2	31	1	15	0	2	0	0	0	100	3
4 - 5 YR	0	0	0	0	4	0	7	0	14	1	23	0	29	2	14	0	2	1	0	0	93	4
5 - 6 YR	0	0	0	0	4	0	6	0	12	0	21	2	23	1	11	1	1	0	0	0	78	4
6 - 7 YR	0	0	0	0	4	1	6	0	12	0	17	0	21	4	9	0	1	0	0	0	70	5
7 - 8 YR	0	0	0	0	3	0	6	0	12	1	16	1	15	1	5	1	1	0	0	0	58	4
8 - 9 YR	0	0	0	0	3	1	4	0	11	1	15	0	14	1	3	0	0	0	0	0	50	3
9 -10 YR	0	0	0	0	2	0	4	0	9	0	12	1	12	0	3	3	0	0	0	0	42	4
10-11 YR	0	0	0	0	2	0	3	0	7	0	9	1	12	0	0	0	0	0	0	0	33	1
11-12 YR	0	0	0	0	2	0	3	0	7	0	7	1	11	3	0	0	0	0	0	0	30	4
12-13 YR	0	0	0	0	1	0	3	0	7	0	4	1	7	1	0	0	0	0	0	0	22	2
13-14 YR	0	0	0	0	0	0	3	0	4	0	2	0	5	0	0	0	0	0	0	0	14	0
14-15 YR	0	0	0	0	0	0	3	1	3	0	1	0	3	0	0	0	0	0	0	0	10	1

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	0	16	0	2	0	141	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	1	16	1	2	1	141	3
1 - 2 YR	0	0	0	0	3	0	6	0	16	1	31	0	39	1	27	0	15	2	1	0	138	4
2 - 3 YR	0	0	0	0	3	0	6	0	13	0	28	0	33	1	24	1	11	0	1	0	119	2
3 - 4 YR	0	0	0	0	3	0	6	0	12	0	26	1	30	0	20	1	10	1	0	0	107	3
4 - 5 YR	0	0	0	0	3	0	6	0	10	0	24	1	28	0	19	1	9	0	0	0	99	2
5 - 6 YR	0	0	0	0	3	0	5	0	9	0	23	0	28	1	14	0	8	0	0	0	90	1
6 - 7 YR	0	0	0	0	3	1	5	0	9	0	23	0	24	0	13	0	8	0	0	0	85	1
7 - 8 YR	0	0	0	0	2	0	4	0	9	1	22	1	23	2	12	0	4	0	0	0	76	4
8 - 9 YR	0	0	0	0	2	0	3	0	8	0	21	0	19	0	10	0	2	0	0	0	65	0
9 -10 YR	0	0	0	0	2	0	3	0	8	0	19	1	18	0	7	0	1	0	0	0	58	1
10-11 YR	0	0	0	0	2	0	3	0	7	0	16	0	15	0	6	0	1	0	0	0	50	0
11-12 YR	0	0	0	0	2	0	3	0	7	0	13	0	14	0	4	0	0	0	0	0	43	0
12-13 YR	0	0	0	0	2	0	3	0	7	0	12	0	12	0	2	0	0	0	0	0	38	0
13-14 YR	0	0	0	0	1	0	2	1	7	1	11	0	9	1	1	0	0	0	0	0	31	3
14-15 YR	0	0	0	0	1	0	1	0	6	0	8	0	6	0	0	0	0	0	0	0	22	0

TABLE II-2

NUMBER OF SUDDEN DEATHS (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L)
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	21	0	33	0	37	0	19	0	4	0	1	0	126	0
30-365 D	0	0	0	0	4	0	7	0	21	0	33	0	37	0	19	0	4	0	1	0	126	0
1 - 2 YR	0	0	0	0	4	0	7	0	20	1	33	1	35	1	18	0	4	0	1	0	122	3
2 - 3 YR	0	0	0	0	4	0	7	0	15	0	30	1	33	1	15	0	2	0	1	0	107	2
3 - 4 YR	0	0	0	0	4	0	7	0	15	0	26	0	31	0	15	0	2	0	0	0	100	0
4 - 5 YR	0	0	0	0	4	0	7	0	14	1	23	0	29	0	14	0	2	0	0	0	93	1
5 - 6 YR	0	0	0	0	4	0	6	0	12	0	21	1	23	0	11	0	1	0	0	0	78	1
6 - 7 YR	0	0	0	0	4	1	6	0	12	0	17	0	21	1	9	0	1	0	0	0	70	2
7 - 8 YR	0	0	0	0	3	0	6	0	12	0	16	0	15	1	5	0	1	0	0	0	58	1
8 - 9 YR	0	0	0	0	3	1	4	0	11	0	15	0	14	1	3	0	0	0	0	0	50	2
9 -10 YR	0	0	0	0	2	0	4	0	9	0	12	0	12	0	3	1	0	0	0	0	42	1
10-11 YR	0	0	0	0	2	0	3	0	7	0	9	1	12	0	0	0	0	0	0	0	33	1
11-12 YR	0	0	0	0	2	0	3	0	7	0	7	0	11	1	0	0	0	0	0	0	30	1
12-13 YR	0	0	0	0	1	0	3	0	7	0	4	0	7	0	0	0	0	0	0	0	22	0
13-14 YR	0	0	0	0	0	0	3	0	4	0	2	0	5	0	0	0	0	0	0	0	14	0
14-15 YR	0	0	0	0	0	0	3	0	3	0	1	0	3	0	0	0	0	0	0	0	10	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	0	16	0	2	0	141	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	1	16	1	2	0	141	2
1 - 2 YR	0	0	0	0	3	0	6	0	16	0	31	0	39	0	27	0	15	0	1	0	138	0
2 - 3 YR	0	0	0	0	3	0	6	0	13	0	28	0	33	0	24	0	11	0	1	0	119	0
3 - 4 YR	0	0	0	0	3	0	6	0	12	0	26	0	30	0	20	0	10	0	0	0	107	0
4 - 5 YR	0	0	0	0	3	0	6	0	10	0	24	1	28	0	19	1	9	0	0	0	99	2
5 - 6 YR	0	0	0	0	3	0	5	0	9	0	23	0	28	0	14	0	8	0	0	0	90	0
6 - 7 YR	0	0	0	0	3	0	5	0	9	0	23	0	24	0	13	0	8	0	0	0	85	0
7 - 8 YR	0	0	0	0	2	0	4	0	9	0	22	1	23	0	12	0	4	0	0	0	76	1
8 - 9 YR	0	0	0	0	2	0	3	0	8	0	21	0	19	0	10	0	2	0	0	0	65	0
9 -10 YR	0	0	0	0	2	0	3	0	8	0	19	0	18	0	7	0	1	0	0	0	58	0
10-11 YR	0	0	0	0	2	0	3	0	7	0	16	0	15	0	6	0	1	0	0	0	50	0
11-12 YR	0	0	0	0	2	0	3	0	7	0	13	0	14	0	4	0	0	0	0	0	43	0
12-13 YR	0	0	0	0	2	0	3	0	7	0	12	0	12	0	2	0	0	0	0	0	38	0
13-14 YR	0	0	0	0	1	0	2	0	7	0	11	0	9	0	1	0	0	0	0	0	31	0
14-15 YR	0	0	0	0	1	0	1	0	6	0	8	0	6	0	0	0	0	0	0	0	22	0

TABLE II-3

NUMBER OF CARDIOVASCULAR DEATHS (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L)
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	21	0	33	0	37	0	19	0	4	0	1	0	126	0
30-365 D	0	0	0	0	4	0	7	0	21	1	33	0	37	2	19	1	4	0	1	0	126	4
1 - 2 YR	0	0	0	0	4	0	7	0	20	2	33	1	35	1	18	1	4	0	1	0	122	5
2 - 3 YR	0	0	0	0	4	0	7	0	15	0	30	1	33	2	15	0	2	0	1	0	107	3
3 - 4 YR	0	0	0	0	4	0	7	0	15	0	26	1	31	0	15	0	2	0	0	0	100	1
4 - 5 YR	0	0	0	0	4	0	7	0	14	1	23	0	29	2	14	0	2	1	0	0	93	4
5 - 6 YR	0	0	0	0	4	0	6	0	12	0	21	2	23	0	11	1	1	0	0	0	78	3
6 - 7 YR	0	0	0	0	4	1	6	0	12	0	17	0	21	1	9	0	1	0	0	0	70	2
7 - 8 YR	0	0	0	0	3	0	6	0	12	1	16	0	15	1	5	1	1	0	0	0	58	3
8 - 9 YR	0	0	0	0	3	1	4	0	11	1	15	0	14	1	3	0	0	0	0	0	50	3
9 -10 YR	0	0	0	0	2	0	4	0	9	0	12	0	12	0	3	2	0	0	0	0	42	2
10-11 YR	0	0	0	0	2	0	3	0	7	0	9	1	12	0	0	0	0	0	0	0	33	1
11-12 YR	0	0	0	0	2	0	3	0	7	0	7	0	11	1	0	0	0	0	0	0	30	1
12-13 YR	0	0	0	0	1	0	3	0	7	0	4	0	7	1	0	0	0	0	0	0	22	1
13-14 YR	0	0	0	0	0	0	3	0	4	0	2	0	5	0	0	0	0	0	0	0	14	0
14-15 YR	0	0	0	0	0	0	3	1	3	0	1	0	3	0	0	0	0	0	0	0	10	1

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	0	16	0	2	0	141	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	1	16	1	2	1	141	3
1 - 2 YR	0	0	0	0	3	0	6	0	16	0	31	0	39	1	27	0	15	1	1	0	138	2
2 - 3 YR	0	0	0	0	3	0	6	0	13	0	28	0	33	1	24	1	11	0	1	0	119	2
3 - 4 YR	0	0	0	0	3	0	6	0	12	0	26	1	30	0	20	1	10	1	0	0	107	3
4 - 5 YR	0	0	0	0	3	0	6	0	10	0	24	1	28	0	19	1	9	0	0	0	99	2
5 - 6 YR	0	0	0	0	3	0	5	0	9	0	23	0	28	0	14	0	8	0	0	0	90	0
6 - 7 YR	0	0	0	0	3	0	5	0	9	0	23	0	24	0	13	0	8	0	0	0	85	0
7 - 8 YR	0	0	0	0	2	0	4	0	9	0	22	1	23	2	12	0	4	0	0	0	76	3
8 - 9 YR	0	0	0	0	2	0	3	0	8	0	21	0	19	0	10	0	2	0	0	0	65	0
9 -10 YR	0	0	0	0	2	0	3	0	8	0	19	1	18	0	7	0	1	0	0	0	58	1
10-11 YR	0	0	0	0	2	0	3	0	7	0	16	0	15	0	6	0	1	0	0	0	50	0
11-12 YR	0	0	0	0	2	0	3	0	7	0	13	0	14	0	4	0	0	0	0	0	43	0
12-13 YR	0	0	0	0	2	0	3	0	7	0	12	0	12	0	2	0	0	0	0	0	38	0
13-14 YR	0	0	0	0	1	0	2	1	7	0	11	0	9	0	1	0	0	0	0	0	31	1
14-15 YR	0	0	0	0	1	0	1	0	6	0	8	0	6	0	0	0	0	0	0	0	22	0

TABLE II-4

NUMBER OF CORONARY ATTACKS (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L) APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN) FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	21	1	33	0	37	1	19	0	4	0	1	0	126	2
30-365 D	0	0	0	0	4	1	7	0	20	1	33	0	36	0	19	1	4	1	1	0	124	4
1 - 2 YR	0	0	0	0	3	0	7	0	19	2	33	2	34	1	18	1	3	0	1	0	118	6
2 - 3 YR	0	0	0	0	3	1	7	1	14	0	29	1	32	4	15	1	1	0	1	0	102	8
3 - 4 YR	0	0	0	0	2	0	6	1	14	0	25	0	28	0	14	0	1	0	0	0	90	1
4 - 5 YR	0	0	0	0	2	0	5	0	13	2	22	1	26	2	13	0	1	0	0	0	82	5
5 - 6 YR	0	0	0	0	2	0	5	0	10	0	19	2	19	0	11	1	1	0	0	0	67	3
6 - 7 YR	0	0	0	0	2	0	5	0	10	1	15	0	17	1	9	1	1	0	0	0	59	3
7 - 8 YR	0	0	0	0	2	0	5	0	9	2	14	1	11	1	4	1	1	0	0	0	46	5
8 - 9 YR	0	0	0	0	2	0	3	0	7	0	12	0	10	0	2	0	0	0	0	0	36	0
9 -10 YR	0	0	0	0	2	0	3	0	7	0	9	0	9	0	2	1	0	0	0	0	32	1
10-11 YR	0	0	0	0	2	0	3	0	5	0	7	0	9	0	0	0	0	0	0	0	26	0
11-12 YR	0	0	0	0	2	0	3	1	5	0	6	0	8	0	0	0	0	0	0	0	24	1
12-13 YR	0	0	0	0	1	0	2	0	5	0	4	1	6	1	0	0	0	0	0	0	18	2
13-14 YR	0	0	0	0	0	0	2	0	2	0	2	1	4	0	0	0	0	0	0	0	10	1
14-15 YR	0	0	0	0	0	0	2	0	1	0	0	0	2	0	0	0	0	0	0	0	5	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	0	16	0	2	0	141	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	1	39	1	28	1	16	1	2	2	141	6
1 - 2 YR	0	0	0	0	3	0	6	0	16	0	30	0	38	1	27	0	15	1	0	0	135	2
2 - 3 YR	0	0	0	0	3	0	6	0	13	1	27	1	32	0	24	1	10	0	0	0	115	3
3 - 4 YR	0	0	0	0	3	0	6	0	11	0	24	0	29	1	19	1	9	0	0	0	101	2
4 - 5 YR	0	0	0	0	3	0	6	0	10	0	22	1	26	0	18	1	8	0	0	0	93	2
5 - 6 YR	0	0	0	0	3	0	5	1	9	0	21	0	26	1	13	0	7	0	0	0	84	2
6 - 7 YR	0	0	0	0	3	0	4	0	9	0	21	0	21	0	12	0	7	0	0	0	77	0
7 - 8 YR	0	0	0	0	2	0	3	0	9	0	20	1	20	1	11	0	3	0	0	0	68	2
8 - 9 YR	0	0	0	0	2	0	2	1	8	0	19	0	16	0	9	0	2	0	0	0	58	1
9 -10 YR	0	0	0	0	2	0	1	0	8	0	18	1	15	0	6	0	1	0	0	0	51	1
10-11 YR	0	0	0	0	2	0	1	0	7	0	14	0	12	0	5	0	1	0	0	0	42	0
11-12 YR	0	0	0	0	2	0	1	0	7	0	12	0	11	0	3	0	0	0	0	0	36	0
12-13 YR	0	0	0	0	2	0	1	0	7	0	12	1	9	0	2	0	0	0	0	0	33	1
13-14 YR	0	0	0	0	1	0	1	0	7	0	10	0	7	0	1	0	0	0	0	0	27	0
14-15 YR	0	0	0	0	1	0	1	0	6	0	7	0	6	0	0	0	0	0	0	0	21	0

TABLE II-5

NUMBER OF MYOCARDIAL INFARCTIONS (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L) APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN) FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	21	0	33	0	37	1	19	0	4	0	1	0	126	1
30-365 D	0	0	0	0	4	1	7	0	21	1	33	0	36	0	19	1	4	1	1	0	125	4
1 - 2 YR	0	0	0	0	3	0	7	0	20	1	33	1	34	0	18	1	3	0	1	0	119	3
2 - 3 YR	0	0	0	0	3	0	7	1	15	0	29	0	32	2	15	1	1	0	1	0	103	4
3 - 4 YR	0	0	0	0	3	0	6	1	15	0	25	0	28	0	14	0	1	0	0	0	92	1
4 - 5 YR	0	0	0	0	3	0	5	0	14	1	22	0	26	2	13	0	1	0	0	0	84	3
5 - 6 YR	0	0	0	0	3	1	5	0	11	0	20	0	19	0	11	0	1	0	0	0	70	1
6 - 7 YR	0	0	0	0	2	0	5	0	11	0	16	0	17	0	9	0	1	0	0	0	61	0
7 - 8 YR	0	0	0	0	2	0	5	0	11	2	15	2	11	0	5	2	1	0	0	0	50	6
8 - 9 YR	0	0	0	0	2	0	3	0	9	0	12	0	10	0	2	0	0	0	0	0	38	0
9 -10 YR	0	0	0	0	2	0	3	0	7	0	9	0	9	0	2	1	0	0	0	0	32	1
10-11 YR	0	0	0	0	2	0	3	0	5	0	7	0	9	0	0	0	0	0	0	0	26	0
11-12 YR	0	0	0	0	2	0	3	1	5	0	6	0	8	0	0	0	0	0	0	0	24	1
12-13 YR	0	0	0	0	1	0	2	0	5	0	4	1	6	0	0	0	0	0	0	0	18	1
13-14 YR	0	0	0	0	0	0	2	0	2	0	2	1	4	0	0	0	0	0	0	0	10	1
14-15 YR	0	0	0	0	0	0	2	0	1	0	0	0	2	0	0	0	0	0	0	0	5	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	28	0	16	0	2	0	141	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	1	39	1	28	0	16	0	2	0	141	2
1 - 2 YR	0	0	0	0	3	0	6	0	16	0	30	0	38	1	27	0	15	0	1	1	136	2
2 - 3 YR	0	0	0	0	3	0	6	0	13	0	27	1	32	0	24	0	11	0	0	0	116	1
3 - 4 YR	0	0	0	0	3	0	6	0	12	0	24	0	29	0	20	0	10	0	0	0	104	0
4 - 5 YR	0	0	0	0	3	0	6	0	10	0	22	0	27	0	19	0	9	0	0	0	96	0
5 - 6 YR	0	0	0	0	3	0	5	1	9	0	21	0	27	1	14	0	8	0	0	0	87	2
6 - 7 YR	0	0	0	0	3	0	4	0	9	0	21	0	22	0	13	0	8	0	0	0	80	0
7 - 8 YR	0	0	0	0	2	0	3	0	9	0	20	0	21	1	12	0	4	0	0	0	71	1
8 - 9 YR	0	0	0	0	2	0	2	1	8	0	19	0	17	0	10	0	2	0	0	0	60	1
9 -10 YR	0	0	0	0	2	0	1	0	8	0	18	1	16	0	7	0	1	0	0	0	53	1
10-11 YR	0	0	0	0	2	0	1	0	7	0	14	0	13	1	6	0	1	0	0	0	44	1
11-12 YR	0	0	0	0	2	0	1	0	7	0	12	0	11	0	4	0	0	0	0	0	37	0
12-13 YR	0	0	0	0	2	0	1	0	7	0	12	0	9	0	2	0	0	0	0	0	33	0
13-14 YR	0	0	0	0	1	0	1	0	7	0	11	0	7	0	1	0	0	0	0	0	28	0
14-15 YR	0	0	0	0	1	0	1	0	6	0	8	0	6	0	0	0	0	0	0	0	22	0

TABLE II-6

NUMBER OF CASES OF CONGESTIVE HEART FAILURE (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L) APU OCCURRING BETWEEN OCT, 1950 AND OCT, 1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN) FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	20	0	32	0	37	0	18	0	4	0	1	0	123	0
30-365 D	0	0	0	0	4	0	7	0	20	0	32	0	37	0	18	0	4	0	1	0	123	0
1 - 2 YR	0	0	0	0	4	0	7	0	20	0	32	0	35	0	17	1	4	0	1	0	120	1
2 - 3 YR	0	0	0	0	4	0	7	0	15	0	29	0	33	0	14	0	2	0	1	0	105	0
3 - 4 YR	0	0	0	0	4	0	7	0	15	0	25	0	31	1	14	0	2	0	0	0	98	1
4 - 5 YR	0	0	0	0	4	0	7	0	14	0	23	0	28	0	13	0	2	0	0	0	91	0
5 - 6 YR	0	0	0	0	4	1	6	0	12	0	21	0	22	1	10	0	1	0	0	0	76	2
6 - 7 YR	0	0	0	0	3	0	6	0	12	0	17	0	20	0	8	0	1	0	0	0	67	0
7 - 8 YR	0	0	0	0	3	0	6	0	12	0	16	0	14	1	4	0	1	0	0	0	56	1
8 - 9 YR	0	0	0	0	3	0	4	0	11	0	15	1	12	0	2	0	0	0	0	0	47	1
9 -10 YR	0	0	0	0	2	0	4	0	9	0	11	0	10	0	2	1	0	0	0	0	38	1
10-11 YR	0	0	0	0	2	0	3	0	7	0	8	0	10	0	0	0	0	0	0	0	30	0
11-12 YR	0	0	0	0	2	0	3	0	7	0	7	0	9	0	0	0	0	0	0	0	28	0
12-13 YR	0	0	0	0	1	0	3	0	7	0	4	0	6	0	0	0	0	0	0	0	21	0
13-14 YR	0	0	0	0	0	0	3	0	4	0	2	0	5	0	0	0	0	0	0	0	14	0
14-15 YR	0	0	0	0	0	0	3	1	3	0	1	1	3	0	0	0	0	0	0	0	10	2

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	15	0	29	0	35	0	27	0	15	0	1	0	131	0
30-365 D	0	0	0	0	3	0	6	0	15	0	29	0	35	0	27	0	15	0	1	0	131	0
1 - 2 YR	0	0	0	0	3	0	6	0	15	0	29	0	35	0	26	1	14	0	0	0	128	1
2 - 3 YR	0	0	0	0	3	0	6	0	12	0	26	1	29	1	22	0	11	0	0	0	109	2
3 - 4 YR	0	0	0	0	3	0	6	0	11	0	23	0	27	1	19	2	10	0	0	0	99	3
4 - 5 YR	0	0	0	0	3	0	6	0	9	0	21	1	25	0	16	0	9	0	0	0	89	1
5 - 6 YR	0	0	0	0	3	0	5	0	9	0	19	0	25	0	12	0	8	0	0	0	81	0
6 - 7 YR	0	0	0	0	3	0	5	0	9	0	19	0	22	0	11	0	8	0	0	0	77	0
7 - 8 YR	0	0	0	0	2	0	4	0	9	0	18	0	21	1	10	0	4	0	0	0	68	1
8 - 9 YR	0	0	0	0	2	0	3	1	8	0	18	0	18	0	8	0	2	0	0	0	59	1
9 -10 YR	0	0	0	0	2	0	2	0	8	0	16	0	18	0	6	0	1	0	0	0	53	0
10-11 YR	0	0	0	0	2	0	2	0	7	0	14	0	15	0	6	0	1	0	0	0	47	0
11-12 YR	0	0	0	0	2	0	2	0	7	0	11	0	14	1	4	0	0	0	0	0	40	1
12-13 YR	0	0	0	0	2	0	2	0	7	0	11	0	11	0	2	0	0	0	0	0	35	0
13-14 YR	0	0	0	0	1	0	2	0	7	1	10	0	8	0	1	0	0	0	0	0	29	1
14-15 YR	0	0	0	0	1	0	1	0	6	0	7	0	6	0	0	0	0	0	0	0	21	0

TABLE II-7

NUMBER OF CASES OF CEREBROVASCULAR ACCIDENT (D) FOLLOWING ANGINA PECTORIS UNCOMPLICATED (L) APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN) FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	4	0	7	0	20	0	33	0	34	0	19	0	4	0	1	0	122	0
30-365 D	0	0	0	0	4	0	7	0	20	1	33	0	34	0	19	0	4	0	1	0	122	1
1 - 2 YR	0	0	0	0	4	0	7	0	19	0	33	0	32	0	18	0	4	0	1	0	118	0
2 - 3 YR	0	0	0	0	4	0	7	0	15	0	30	0	31	0	15	0	2	0	1	0	105	0
3 - 4 YR	0	0	0	0	4	0	7	0	15	0	26	0	30	0	15	0	2	0	0	0	99	0
4 - 5 YR	0	0	0	0	4	0	7	0	14	0	23	0	29	0	14	0	2	0	0	0	93	0
5 - 6 YR	0	0	0	0	4	0	6	0	12	1	21	0	23	0	11	1	1	0	0	0	78	2
6 - 7 YR	0	0	0	0	4	0	6	0	11	0	17	0	21	0	8	0	1	0	0	0	68	0
7 - 8 YR	0	0	0	0	3	0	6	0	11	0	16	0	15	0	5	0	1	0	0	0	57	0
8 - 9 YR	0	0	0	0	3	0	4	0	10	0	15	1	14	0	3	0	0	0	0	0	49	1
9 -10 YR	0	0	0	0	2	0	4	0	8	0	11	0	12	0	3	1	0	0	0	0	40	1
10-11 YR	0	0	0	0	2	0	3	0	6	0	8	0	12	0	0	0	0	0	0	0	31	0
11-12 YR	0	0	0	0	2	0	3	0	6	0	6	0	11	0	0	0	0	0	0	0	28	0
12-13 YR	0	0	0	0	1	0	3	0	6	0	4	0	7	1	0	0	0	0	0	0	21	1
13-14 YR	0	0	0	0	0	0	3	0	4	0	2	0	4	0	0	0	0	0	0	0	13	0
14-15 YR	0	0	0	0	0	0	3	0	3	0	1	0	2	0	0	0	0	0	0	0	9	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	26	0	14	0	2	0	137	0
30-365 D	0	0	0	0	3	0	6	0	16	0	31	0	39	0	26	0	14	0	2	0	137	0
1 - 2 YR	0	0	0	0	3	0	6	0	16	0	31	0	39	2	25	1	14	0	1	0	135	3
2 - 3 YR	0	0	0	0	3	0	6	0	13	0	28	1	31	0	21	1	10	0	1	0	113	2
3 - 4 YR	0	0	0	0	3	0	6	0	12	0	25	0	29	0	17	0	9	1	0	0	101	1
4 - 5 YR	0	0	0	0	3	0	6	0	10	1	23	0	27	0	17	0	7	0	0	0	93	1
5 - 6 YR	0	0	0	0	3	0	5	0	8	0	22	0	27	0	12	0	6	0	0	0	83	0
6 - 7 YR	0	0	0	0	3	0	5	0	8	0	22	0	24	1	11	0	6	0	0	0	79	1
7 - 8 YR	0	0	0	0	2	0	4	0	8	0	21	0	22	0	10	0	3	0	0	0	70	0
8 - 9 YR	0	0	0	0	2	0	3	0	7	0	21	0	19	1	9	0	1	0	0	0	62	1
9 -10 YR	0	0	0	0	2	0	3	0	7	0	19	0	17	0	7	0	1	0	0	0	56	0
10-11 YR	0	0	0	0	2	0	3	0	6	0	16	1	14	1	6	0	1	0	0	0	48	2
11-12 YR	0	0	0	0	2	0	3	0	6	0	12	0	12	0	4	1	0	0	0	0	39	1
12-13 YR	0	0	0	0	2	0	3	0	6	0	11	0	10	1	2	0	0	0	0	0	34	1
13-14 YR	0	0	0	0	1	0	2	1	6	0	10	0	8	0	1	0	0	0	0	0	28	1
14-15 YR	0	0	0	0	1	0	1	0	5	0	7	0	6	0	0	0	0	0	0	0	20	0

TABLE II-8

NUMBER OF DEATHS (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION (L)
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	3	0	10	1	31	2	23	0	42	4	39	8	24	9	14	4	6	3	193	31
30-365 D	1	0	3	0	9	0	29	2	23	0	38	1	31	1	15	0	10	1	3	1	162	6
1 - 2 YR	1	0	3	0	9	0	27	1	23	0	37	2	30	0	15	0	9	3	2	0	156	6
2 - 3 YR	1	0	3	0	9	1	26	1	23	0	35	3	30	0	15	2	6	0	2	0	150	7
3 - 4 YR	1	0	3	0	8	0	25	1	21	1	32	1	30	2	12	2	4	1	1	1	137	9
4 - 5 YR	1	0	3	1	8	0	23	1	19	1	31	3	27	2	9	0	2	0	0	0	123	8
5 - 6 YR	1	0	2	0	8	0	21	1	17	0	27	1	22	1	9	1	1	0	0	0	108	4
6 - 7 YR	1	0	2	0	8	2	19	1	16	1	25	1	20	2	7	0	0	0	0	0	98	7
7 - 8 YR	1	0	2	0	6	0	15	0	14	3	20	1	18	0	6	1	0	0	0	0	82	5
8 - 9 YR	1	0	2	0	4	1	10	0	8	0	15	1	18	0	4	1	0	0	0	0	62	3
9 -10 YR	1	0	2	0	2	0	10	1	8	0	14	0	17	1	2	0	0	0	0	0	56	2
10-11 YR	1	0	2	0	2	0	7	0	6	0	11	0	15	2	0	0	0	0	0	0	44	2
11-12 YR	1	0	2	0	2	0	6	1	5	0	10	0	10	1	0	0	0	0	0	0	36	2
12-13 YR	1	0	2	0	2	0	3	0	5	1	9	0	8	0	0	0	0	0	0	0	30	1
13-14 YR	1	0	2	0	2	1	3	0	2	1	7	0	8	0	0	0	0	0	0	0	25	2
14-15 YR	1	0	2	0	1	0	3	0	1	0	5	0	8	0	0	0	0	0	0	0	21	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	2	1	1	0	6	0	10	3	12	2	10	2	11	6	1	1	53	15
30-365 D	0	0	0	0	1	1	1	0	6	1	7	0	10	1	8	0	5	0	0	0	38	3
1 - 2 YR	0	0	0	0	0	0	1	0	5	0	7	0	9	2	8	0	5	0	0	0	35	2
2 - 3 YR	0	0	0	0	0	0	1	0	5	1	7	0	6	0	8	0	4	0	0	0	31	1
3 - 4 YR	0	0	0	0	0	0	1	0	4	0	6	0	6	2	8	1	4	1	0	0	29	4
4 - 5 YR	0	0	0	0	0	0	1	0	4	0	6	1	4	0	6	0	1	0	0	0	22	1
5 - 6 YR	0	0	0	0	0	0	1	0	4	0	3	0	3	0	6	1	1	0	0	0	18	1
6 - 7 YR	0	0	0	0	0	0	1	0	4	0	3	1	2	0	3	0	1	0	0	0	14	1
7 - 8 YR	0	0	0	0	0	0	1	0	3	0	2	1	2	0	3	0	0	0	0	0	11	1
8 - 9 YR	0	0	0	0	0	0	1	0	2	0	1	0	2	0	3	1	0	0	0	0	9	1
9 -10 YR	0	0	0	0	0	0	1	1	1	0	1	0	1	0	2	0	0	0	0	0	6	1
10-11 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
11-12 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
12-13 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
13-14 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0

TABLE II-9

NUMBER OF CASES OF ANGINA PECTORIS (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION (L)
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	1	0	7	0	18	0	16	0	26	0	21	0	5	0	4	0	1	0	100	0
30-365 D	1	0	1	0	7	1	18	1	16	4	26	4	21	6	5	0	4	0	1	0	100	16
1 - 2 YR	1	0	1	1	6	0	16	0	12	1	22	2	14	0	5	0	4	0	0	0	81	4
2 - 3 YR	1	0	0	0	6	0	16	0	11	2	17	2	14	1	5	0	3	1	0	0	73	6
3 - 4 YR	1	0	0	0	6	2	16	0	7	0	15	0	13	1	4	0	2	0	0	0	64	3
4 - 5 YR	1	0	0	0	4	1	15	0	6	0	15	0	11	0	3	0	1	1	0	0	56	2
5 - 6 YR	1	0	0	0	3	0	12	0	5	0	13	0	8	1	3	0	0	0	0	0	45	1
6 - 7 YR	1	0	0	0	3	0	10	0	4	0	12	0	7	0	3	0	0	0	0	0	40	0
7 - 8 YR	1	0	0	0	2	0	8	0	3	0	10	0	5	0	2	0	0	0	0	0	31	0
8 - 9 YR	1	0	0	0	0	0	5	0	1	0	8	1	5	0	2	0	0	0	0	0	22	1
9 -10 YR	1	0	0	0	0	0	5	0	1	0	6	0	4	0	1	0	0	0	0	0	18	0
10-11 YR	1	0	0	0	0	0	2	0	0	0	3	1	3	0	0	0	0	0	0	0	9	1
11-12 YR	1	0	0	0	0	0	2	0	0	0	1	0	2	0	0	0	0	0	0	0	6	0
12-13 YR	1	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	4	0
13-14 YR	1	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	4	0
14-15 YR	1	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	0	0	4	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	1	0	0	0	3	0	3	0	7	0	6	0	4	0	0	0	24	0
30-365 D	0	0	0	0	1	0	0	0	3	0	3	0	7	3	6	1	4	0	0	0	24	4
1 - 2 YR	0	0	0	0	0	0	0	0	2	0	3	0	3	0	5	0	4	0	0	0	17	0
2 - 3 YR	0	0	0	0	0	0	0	0	2	0	3	0	2	0	5	0	3	0	0	0	15	0
3 - 4 YR	0	0	0	0	0	0	0	0	2	0	3	0	2	0	5	0	3	0	0	0	15	0
4 - 5 YR	0	0	0	0	0	0	0	0	2	0	3	0	2	0	3	0	1	0	0	0	11	0
5 - 6 YR	0	0	0	0	0	0	0	0	2	0	2	0	2	0	3	0	1	0	0	0	10	0
6 - 7 YR	0	0	0	0	0	0	0	0	2	0	2	0	2	0	2	0	1	0	0	0	9	0
7 - 8 YR	0	0	0	0	0	0	0	0	2	0	0	0	2	0	2	0	0	0	0	0	6	0
8 - 9 YR	0	0	0	0	0	0	0	0	1	0	0	0	2	0	2	0	0	0	0	0	5	0
9 -10 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	3	0
10-11 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	3	0
11-12 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0	3	0
12-13 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0
13-14 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0
14-15 YR	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0

TABLE II-10

NUMBER OF CASES OF SECOND MYOCARDIAL INFARCTION (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION (L)
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	3	0	10	0	31	0	23	0	42	0	39	0	24	0	14	0	6	0	193	0
30-365 D	1	0	3	0	9	1	29	0	23	1	38	1	31	3	15	0	10	0	3	0	162	6
1 - 2 YR	1	0	3	0	8	0	27	1	22	0	36	1	27	2	15	1	9	0	2	0	150	5
2 - 3 YR	1	0	3	0	8	1	25	0	22	0	33	1	25	0	14	0	6	1	2	0	139	3
3 - 4 YR	1	0	3	1	7	0	24	0	20	1	29	1	25	1	11	0	3	0	1	0	124	4
4 - 5 YR	1	0	2	0	7	0	22	0	18	0	27	0	21	1	9	0	2	0	0	0	109	1
5 - 6 YR	1	0	2	0	7	0	20	1	17	0	23	2	16	1	9	0	1	0	0	0	96	4
6 - 7 YR	1	0	2	0	7	0	17	0	16	1	19	1	13	0	7	0	0	0	0	0	82	2
7 - 8 YR	1	0	2	0	5	0	15	0	13	0	15	0	12	0	6	0	0	0	0	0	69	0
8 - 9 YR	1	0	2	1	3	1	10	0	7	0	11	1	12	1	4	0	0	0	0	0	50	4
9 -10 YR	1	0	1	0	1	0	10	0	7	0	9	0	10	0	2	0	0	0	0	0	41	0
10-11 YR	1	0	1	0	1	0	7	0	5	0	7	0	10	0	0	0	0	0	0	0	32	0
11-12 YR	1	0	1	0	1	0	6	1	4	0	7	0	8	0	0	0	0	0	0	0	28	1
12-13 YR	1	0	1	0	1	0	3	0	4	0	6	0	7	1	0	0	0	0	0	0	23	1
13-14 YR	1	0	1	0	1	0	3	0	1	0	5	0	6	0	0	0	0	0	0	0	18	0
14-15 YR	1	1	1	0	0	0	3	0	1	0	4	0	6	0	0	0	0	0	0	0	16	1

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	2	0	1	0	6	0	10	0	12	0	10	0	11	0	1	0	53	0
30-365 D	0	0	0	0	1	0	1	0	6	1	7	0	10	0	8	2	5	1	0	0	38	4
1 - 2 YR	0	0	0	0	0	0	1	0	5	1	7	1	9	1	6	0	4	0	0	0	32	3
2 - 3 YR	0	0	0	0	0	0	1	0	4	1	6	0	6	0	6	0	3	0	0	0	26	1
3 - 4 YR	0	0	0	0	0	0	1	0	3	0	6	1	6	2	6	0	3	1	0	0	25	4
4 - 5 YR	0	0	0	0	0	0	1	0	3	0	5	1	4	0	5	0	1	0	0	0	19	1
5 - 6 YR	0	0	0	0	0	0	1	0	3	0	2	0	3	0	5	0	1	0	0	0	15	0
6 - 7 YR	0	0	0	0	0	0	1	0	3	0	2	0	2	0	3	0	1	0	0	0	12	0
7 - 8 YR	0	0	0	0	0	0	1	0	2	0	2	0	2	0	3	0	0	0	0	0	10	0
8 - 9 YR	0	0	0	0	0	0	1	0	1	0	1	0	2	0	3	0	0	0	0	0	8	0
9 -10 YR	0	0	0	0	0	0	1	0	1	0	1	0	1	0	2	0	0	0	0	0	6	0
10-11 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
11-12 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
12-13 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
13-14 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0

TABLE II-11

NUMBER OF CASES OF CONGESTIVE HEART FAILURE (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION (L)
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	3	0	10	0	30	0	23	1	42	0	37	2	24	0	14	0	4	1	188	4
30-365 D	1	0	3	0	9	0	29	1	22	0	38	1	28	0	15	2	10	1	2	0	157	5
1 - 2 YR	1	0	3	0	9	0	27	0	22	1	36	0	28	0	13	2	8	0	1	1	148	4
2 - 3 YR	1	0	3	0	9	0	26	0	21	0	34	2	28	0	11	0	5	0	0	0	138	2
3 - 4 YR	1	0	3	0	8	0	25	0	19	0	30	2	28	1	9	1	4	0	0	0	127	4
4 - 5 YR	1	0	3	0	8	0	23	0	17	1	28	1	24	0	6	0	2	0	0	0	112	2
5 - 6 YR	1	0	2	0	8	0	21	0	15	0	24	0	20	1	6	0	1	0	0	0	98	1
6 - 7 YR	1	0	2	0	8	1	19	0	14	0	22	0	17	0	5	0	0	0	0	0	88	1
7 - 8 YR	1	0	2	0	5	0	15	0	12	0	18	2	17	0	4	0	0	0	0	0	74	2
8 - 9 YR	1	0	2	0	3	0	10	0	8	0	12	0	17	1	3	0	0	0	0	0	56	1
9 -10 YR	1	0	2	0	2	0	10	0	8	0	11	0	15	1	2	0	0	0	0	0	51	1
10-11 YR	1	0	2	0	2	0	7	1	6	0	9	0	12	0	0	0	0	0	0	0	39	1
11-12 YR	1	0	2	0	2	0	5	0	5	0	8	0	8	0	0	0	0	0	0	0	31	0
12-13 YR	1	0	2	0	2	0	3	0	5	1	7	1	6	0	0	0	0	0	0	0	26	2
13-14 YR	1	0	2	0	2	0	3	0	1	0	5	0	6	0	0	0	0	0	0	0	20	0
14-15 YR	1	0	2	0	1	0	3	0	0	0	3	0	6	0	0	0	0	0	0	0	16	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	2	0	1	0	6	0	9	1	12	0	7	0	7	1	1	0	45	2
30-365 D	0	0	0	0	1	0	1	0	6	0	5	0	10	0	7	0	4	0	0	0	34	0
1 - 2 YR	0	0	0	0	0	0	1	0	5	0	5	0	9	1	7	0	4	0	0	0	31	1
2 - 3 YR	0	0	0	0	0	0	1	0	5	1	5	0	5	0	7	0	3	0	0	0	26	1
3 - 4 YR	0	0	0	0	0	0	1	0	3	0	4	0	5	0	7	0	3	0	0	0	23	0
4 - 5 YR	0	0	0	0	0	0	1	0	3	0	4	0	4	0	6	0	1	0	0	0	19	0
5 - 6 YR	0	0	0	0	0	0	1	0	3	0	2	0	3	0	6	0	1	0	0	0	16	0
6 - 7 YR	0	0	0	0	0	0	1	0	3	0	2	1	2	0	3	0	1	0	0	0	12	1
7 - 8 YR	0	0	0	0	0	0	1	0	3	0	1	0	2	0	3	0	0	0	0	0	10	0
8 - 9 YR	0	0	0	0	0	0	1	0	2	0	0	0	2	0	3	0	0	0	0	0	8	0
9 -10 YR	0	0	0	0	0	0	1	0	1	0	0	0	1	0	2	0	0	0	0	0	5	0
10-11 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	0	0	0	0	0	4	0
11-12 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	0	0	0	0	0	4	0
12-13 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
13-14 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0

TABLE II-12

NUMBER OF CASES OF CEREBROVASCULAR ACCIDENT (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION (L)
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	3	0	10	0	31	0	23	0	42	0	37	0	23	0	14	0	6	0	190	0
30-365 D	1	0	3	0	9	0	29	0	23	0	38	0	29	0	14	1	10	0	3	0	159	1
1 - 2 YR	1	0	3	0	9	0	27	0	23	0	37	0	28	0	13	0	9	0	2	0	152	0
2 - 3 YR	1	0	3	0	9	0	26	1	23	0	35	0	28	0	13	0	6	0	2	0	146	1
3 - 4 YR	1	0	3	0	8	0	25	0	21	0	32	0	28	0	10	0	4	0	1	0	133	0
4 - 5 YR	1	0	3	0	8	0	23	0	19	0	31	0	25	0	9	0	2	0	0	0	121	0
5 - 6 YR	1	0	2	0	8	0	21	0	17	0	27	0	20	0	9	1	1	0	0	0	106	1
6 - 7 YR	1	0	2	0	8	0	19	0	16	0	25	0	18	0	6	0	0	0	0	0	95	0
7 - 8 YR	1	0	2	0	6	0	15	0	14	0	20	0	17	0	5	0	0	0	0	0	80	0
8 - 9 YR	1	0	2	0	4	0	10	0	8	0	15	0	17	0	3	0	0	0	0	0	60	0
9 -10 YR	1	0	2	0	2	0	10	0	8	0	14	0	16	0	2	0	0	0	0	0	55	0
10-11 YR	1	0	2	0	2	0	7	0	6	0	11	0	14	0	0	0	0	0	0	0	43	0
11-12 YR	1	0	2	0	2	0	6	0	5	0	10	0	9	0	0	0	0	0	0	0	35	0
12-13 YR	1	0	2	0	2	0	3	0	5	0	9	1	8	0	0	0	0	0	0	0	30	1
13-14 YR	1	0	2	0	2	0	3	0	2	0	6	0	8	1	0	0	0	0	0	0	24	1
14-15 YR	1	0	2	0	1	0	3	0	1	0	4	0	7	0	0	0	0	0	0	0	19	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	2	0	1	0	5	0	10	0	11	0	9	0	11	0	1	0	50	0
30-365 D	0	0	0	0	1	0	1	0	5	0	7	0	9	0	8	0	5	0	0	0	36	0
1 - 2 YR	0	0	0	0	0	0	1	0	5	0	7	0	8	0	8	0	5	0	0	0	34	0
2 - 3 YR	0	0	0	0	0	0	1	0	5	0	7	0	5	0	8	0	4	0	0	0	30	0
3 - 4 YR	0	0	0	0	0	0	1	0	4	0	6	0	5	0	8	0	4	0	0	0	28	0
4 - 5 YR	0	0	0	0	0	0	1	0	4	0	6	1	3	0	6	0	1	0	0	0	21	1
5 - 6 YR	0	0	0	0	0	0	1	0	4	0	3	0	3	0	6	1	1	0	0	0	18	1
6 - 7 YR	0	0	0	0	0	0	1	0	4	0	3	0	2	0	3	1	1	0	0	0	14	1
7 - 8 YR	0	0	0	0	0	0	1	0	3	0	2	1	2	0	2	0	0	0	0	0	10	1
8 - 9 YR	0	0	0	0	0	0	1	0	2	0	1	0	2	0	2	0	0	0	0	0	8	0
9 -10 YR	0	0	0	0	0	0	1	0	1	0	1	0	1	0	2	0	0	0	0	0	6	0
10-11 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
11-12 YR	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	0	0	0	0	0	5	0
12-13 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
13-14 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0

TABLE II-13

NUMBER OF DEATHS (D) FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION (L)
UMI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	0	0	3	0	2	0	3	0	8	0	12	0	9	0	5	0	2	0	45	0
30-365 D	1	0	0	0	3	0	2	0	3	1	8	0	12	1	9	0	5	1	2	0	45	3
1 - 2 YR	1	0	0	0	3	0	2	0	2	0	8	1	11	0	9	0	4	2	2	0	42	3
2 - 3 YR	1	1	0	0	3	0	2	0	2	1	7	2	11	0	9	1	2	0	1	0	38	5
3 - 4 YR	0	0	0	0	3	0	2	0	1	0	5	0	11	1	7	1	1	0	1	0	31	2
4 - 5 YR	0	0	0	0	3	0	2	1	1	0	5	0	9	1	5	0	1	0	1	0	27	2
5 - 6 YR	0	0	0	0	3	1	1	0	1	0	5	1	7	0	5	2	1	0	0	0	23	4
6 - 7 YR	0	0	0	0	2	0	1	0	1	0	4	1	7	0	2	0	1	0	0	0	18	1
7 - 8 YR	0	0	0	0	2	0	1	0	1	0	3	0	7	0	2	0	0	0	0	0	16	0
8 - 9 YR	0	0	0	0	2	0	1	0	1	0	3	1	7	0	2	0	0	0	0	0	16	1
9 -10 YR	0	0	0	0	2	0	0	0	1	1	2	0	7	1	1	0	0	0	0	0	13	2
10-11 YR	0	0	0	0	2	1	0	0	0	0	1	0	5	1	1	0	0	0	0	0	9	2
11-12 YR	0	0	0	0	1	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	7	0
12-13 YR	0	0	0	0	1	0	0	0	0	0	1	1	4	1	1	0	0	0	0	0	7	2
13-14 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	5	1	2	0	28	1
30-365 D	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	4	0	2	0	27	0
1 - 2 YR	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	4	0	2	0	27	0
2 - 3 YR	0	0	0	0	0	0	2	0	4	0	2	0	6	1	7	1	3	0	1	0	25	2
3 - 4 YR	0	0	0	0	0	0	2	0	3	0	2	0	5	0	6	0	3	0	1	0	22	0
4 - 5 YR	0	0	0	0	0	0	2	0	3	0	2	0	5	1	4	0	3	0	1	0	20	1
5 - 6 YR	0	0	0	0	0	0	2	0	3	0	2	0	3	1	4	0	1	0	0	0	15	1
6 - 7 YR	0	0	0	0	0	0	2	0	3	1	2	0	2	0	3	0	1	0	0	0	13	1
7 - 8 YR	0	0	0	0	0	0	1	0	2	0	2	0	1	1	3	0	1	0	0	0	10	1
8 - 9 YR	0	0	0	0	0	0	1	0	2	1	2	0	0	0	2	0	0	0	0	0	7	1
9 -10 YR	0	0	0	0	0	0	1	0	1	0	2	0	0	0	2	1	0	0	0	0	6	1
10-11 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
11-12 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
12-13 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
13-14 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	2	0

TABLE II-14

NUMBER OF CASES OF SECOND MYOCARDIAL INFARCTION (D) FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION (L)
UMI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	0	0	3	0	2	0	3	0	8	0	12	0	9	0	5	0	2	0	45	0
30-365 D	1	0	0	0	3	0	2	0	3	0	8	0	12	1	9	1	5	0	2	0	45	2
1 - 2 YR	1	0	0	0	3	0	2	0	2	1	8	1	10	0	8	0	4	0	2	0	40	2
2 - 3 YR	1	0	0	0	3	0	2	0	1	0	6	0	10	0	8	1	2	0	1	0	34	1
3 - 4 YR	0	0	0	0	3	0	2	0	1	0	4	0	10	0	6	0	1	0	1	0	28	0
4 - 5 YR	0	0	0	0	3	0	2	0	1	0	4	0	8	0	5	0	1	0	1	0	25	0
5 - 6 YR	0	0	0	0	3	0	1	0	1	0	4	0	6	0	5	0	1	0	0	0	21	0
6 - 7 YR	0	0	0	0	2	0	1	0	1	0	3	0	6	0	2	0	1	0	0	0	16	0
7 - 8 YR	0	0	0	0	2	0	1	0	1	0	3	0	6	0	2	0	0	0	0	0	15	0
8 - 9 YR	0	0	0	0	2	0	1	0	1	0	3	0	6	0	2	0	0	0	0	0	15	0
9 -10 YR	0	0	0	0	2	0	0	0	1	1	2	0	6	0	1	0	0	0	0	0	12	1
10-11 YR	0	0	0	0	2	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	8	0
11-12 YR	0	0	0	0	1	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	7	0
12-13 YR	0	0	0	0	1	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	7	0
13-14 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	5	1	2	0	28	1
30-365 D	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	4	0	2	0	27	0
1 - 2 YR	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	0	4	1	2	0	27	1
2 - 3 YR	0	0	0	0	0	0	2	0	4	0	2	0	6	0	7	1	3	0	1	0	25	1
3 - 4 YR	0	0	0	0	0	0	2	0	3	0	2	0	5	0	6	0	3	0	1	0	22	0
4 - 5 YR	0	0	0	0	0	0	2	0	3	0	2	0	5	1	4	0	3	0	1	0	20	1
5 - 6 YR	0	0	0	0	0	0	2	0	3	0	2	0	3	1	4	0	1	0	0	0	15	1
6 - 7 YR	0	0	0	0	0	0	2	0	3	0	2	0	1	0	3	0	1	0	0	0	12	0
7 - 8 YR	0	0	0	0	0	0	1	0	2	0	2	0	0	0	3	1	1	0	0	0	9	1
8 - 9 YR	0	0	0	0	0	0	1	0	2	1	2	0	0	0	1	0	0	0	0	0	6	1
9 -10 YR	0	0	0	0	0	0	1	0	1	0	2	0	0	0	1	0	0	0	0	0	5	0
10-11 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
11-12 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
12-13 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
13-14 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	2	0

TABLE II-15

NUMBER OF CASES OF CONGESTIVE HEART FAILURE (D) FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION (L)
UMI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	0	0	3	0	2	0	3	0	7	0	11	0	9	0	5	0	2	0	43	0
30-365 D	1	0	0	0	3	0	2	0	3	0	7	1	11	1	9	0	5	0	2	0	43	2
1 - 2 YR	1	0	0	0	3	0	2	0	2	0	6	0	9	0	9	0	4	0	2	0	38	0
2 - 3 YR	1	0	0	0	3	0	2	0	2	0	5	0	9	1	9	1	2	0	1	0	34	2
3 - 4 YR	0	0	0	0	3	0	2	0	1	0	5	1	8	1	7	0	1	0	1	0	28	2
4 - 5 YR	0	0	0	0	3	1	2	0	1	0	4	0	5	0	5	0	1	0	1	0	22	1
5 - 6 YR	0	0	0	0	2	0	1	0	1	0	4	0	5	0	5	0	1	0	0	0	19	0
6 - 7 YR	0	0	0	0	2	0	1	0	1	0	3	1	5	0	2	1	1	0	0	0	15	2
7 - 8 YR	0	0	0	0	2	0	1	0	1	0	2	0	5	0	1	0	0	0	0	0	12	0
8 - 9 YR	0	0	0	0	2	0	1	0	1	0	2	0	5	0	1	0	0	0	0	0	12	0
9 -10 YR	0	0	0	0	2	0	0	0	1	0	2	0	5	0	1	0	0	0	0	0	11	0
10-11 YR	0	0	0	0	2	1	0	0	0	0	1	0	4	0	1	0	0	0	0	0	8	1
11-12 YR	0	0	0	0	1	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	7	0
12-13 YR	0	0	0	0	1	0	0	0	0	0	1	0	4	0	1	0	0	0	0	0	7	0
13-14 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	3	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	0	0	2	0	4	0	2	0	5	1	6	0	4	1	2	0	25	2
30-365 D	0	0	0	0	0	0	2	0	4	0	2	0	4	0	6	0	2	0	2	0	22	0
1 - 2 YR	0	0	0	0	0	0	2	0	4	0	2	0	4	0	6	0	2	0	2	0	22	0
2 - 3 YR	0	0	0	0	0	0	2	0	4	0	2	0	4	1	6	0	2	0	1	0	21	1
3 - 4 YR	0	0	0	0	0	0	2	0	3	0	2	0	3	0	5	0	2	0	1	0	18	0
4 - 5 YR	0	0	0	0	0	0	2	0	3	0	2	0	3	0	4	0	2	0	1	0	17	0
5 - 6 YR	0	0	0	0	0	0	2	0	3	0	2	0	2	1	4	0	0	0	0	0	13	1
6 - 7 YR	0	0	0	0	0	0	2	0	3	0	2	0	1	0	3	0	0	0	0	0	11	0
7 - 8 YR	0	0	0	0	0	0	1	0	2	0	2	0	0	0	3	0	0	0	0	0	8	0
8 - 9 YR	0	0	0	0	0	0	1	0	2	0	2	0	0	0	2	0	0	0	0	0	7	0
9 -10 YR	0	0	0	0	0	0	1	0	1	0	2	0	0	0	2	1	0	0	0	0	6	1
10-11 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
11-12 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
12-13 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
13-14 YR	0	0	0	0	0	0	1	0	0	0	2	1	0	0	0	0	0	0	0	0	3	1
14-15 YR	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0

TABLE II-16

NUMBER OF CASES OF CEREBROVASCULAR ACCIDENT (D) FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION (L)
UMI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	0	0	3	0	2	0	3	0	8	0	11	0	9	0	5	0	2	0	44	0
30-365 D	1	0	0	0	3	0	2	0	3	0	8	1	11	0	9	2	5	0	2	0	44	3
1 - 2 YR	1	0	0	0	3	0	2	0	2	1	7	0	10	0	7	0	4	0	2	0	38	1
2 - 3 YR	1	1	0	0	3	0	2	0	1	0	6	0	10	1	7	0	2	0	1	0	33	2
3 - 4 YR	0	0	0	0	3	0	2	0	1	0	4	0	9	1	6	0	1	0	1	0	27	1
4 - 5 YR	0	0	0	0	3	0	2	0	1	0	4	0	6	0	4	0	1	0	1	0	22	0
5 - 6 YR	0	0	0	0	3	0	1	0	1	0	4	0	6	0	4	0	1	0	0	0	20	0
6 - 7 YR	0	0	0	0	2	0	1	0	1	0	4	0	6	0	2	0	1	0	0	0	17	0
7 - 8 YR	0	0	0	0	2	0	1	0	1	0	3	0	6	0	2	0	0	0	0	0	15	0
8 - 9 YR	0	0	0	0	2	0	1	0	1	0	3	0	6	1	2	0	0	0	0	0	15	1
9 -10 YR	0	0	0	0	2	0	0	0	1	0	2	0	5	0	1	0	0	0	0	0	11	0
10-11 YR	0	0	0	0	2	0	0	0	0	0	1	0	4	1	1	0	0	0	0	0	8	1
11-12 YR	0	0	0	0	1	0	0	0	0	0	1	0	3	0	1	0	0	0	0	0	6	0
12-13 YR	0	0	0	0	1	0	0	0	0	0	1	0	3	0	1	0	0	0	0	0	6	0
13-14 YR	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END T TO T+DT	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	0	0	0	0	2	0	3	0	2	0	6	0	7	0	4	0	2	0	26	0
30-365 D	0	0	0	0	0	0	2	0	3	0	2	0	6	0	7	1	4	0	2	0	26	1
1 - 2 YR	0	0	0	0	0	0	2	0	3	0	2	0	6	0	6	0	4	0	2	0	25	0
2 - 3 YR	0	0	0	0	0	0	2	0	3	0	2	0	6	1	6	0	3	0	1	0	23	1
3 - 4 YR	0	0	0	0	0	0	2	0	2	0	2	0	4	0	6	0	3	0	1	0	20	0
4 - 5 YR	0	0	0	0	0	0	2	1	2	0	2	0	4	0	4	0	3	0	1	0	18	1
5 - 6 YR	0	0	0	0	0	0	1	0	2	0	2	0	2	0	4	0	1	0	0	0	12	0
6 - 7 YR	0	0	0	0	0	0	1	0	2	0	2	0	1	0	3	0	1	0	0	0	10	0
7 - 8 YR	0	0	0	0	0	0	1	0	2	0	2	0	1	0	3	0	1	0	0	0	10	0
8 - 9 YR	0	0	0	0	0	0	1	0	2	0	2	0	0	0	2	0	0	0	0	0	7	0
9 -10 YR	0	0	0	0	0	0	1	0	1	0	2	0	0	0	2	0	0	0	0	0	6	0
10-11 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
11-12 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0	0	0	0	4	0
12-13 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
13-14 YR	0	0	0	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	0	0	3	0
14-15 YR	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	2	0

TABLE II-17

NUMBER OF DEATHS (D) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION INCLUDING SUDDEN DEATH (L)
MI OR SUDDEN DEATH OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	1	0	15	3	71	19	118	49	49	24	7	4	0	0	0	0	0	0	0	0	261	99
30-365 D	1	0	12	0	52	2	69	2	25	1	3	1	0	0	0	0	0	0	0	0	162	6
1 - 2 YR	1	0	12	0	50	1	67	2	24	3	2	0	0	0	0	0	0	0	0	0	156	6
2 - 3 YR	1	0	12	1	49	1	65	3	21	2	2	0	0	0	0	0	0	0	0	0	150	7
3 - 4 YR	1	0	11	0	46	2	62	3	16	3	1	1	0	0	0	0	0	0	0	0	137	9
4 - 5 YR	1	0	11	1	42	2	58	5	11	0	0	0	0	0	0	0	0	0	0	0	123	8
5 - 6 YR	1	0	10	0	38	1	49	2	10	1	0	0	0	0	0	0	0	0	0	0	108	4
6 - 7 YR	1	0	10	2	35	2	45	3	7	0	0	0	0	0	0	0	0	0	0	0	98	7
7 - 8 YR	1	0	8	0	29	3	38	1	6	1	0	0	0	0	0	0	0	0	0	0	82	5
8 - 9 YR	1	0	6	1	18	0	33	1	4	1	0	0	0	0	0	0	0	0	0	0	62	3
9 -10 YR	1	0	4	0	18	1	31	1	2	0	0	0	0	0	0	0	0	0	0	0	56	2
10-11 YR	1	0	4	0	13	0	26	2	0	0	0	0	0	0	0	0	0	0	0	0	44	2
11-12 YR	1	0	4	0	11	1	20	1	0	0	0	0	0	0	0	0	0	0	0	0	36	2
12-13 YR	1	0	4	0	8	1	17	0	0	0	0	0	0	0	0	0	0	0	0	0	30	1
13-14 YR	1	0	4	1	5	1	15	0	0	0	0	0	0	0	0	0	0	0	0	0	25	2
14-15 YR	1	0	3	0	4	0	13	0	0	0	0	0	0	0	0	0	0	0	0	0	21	0

WOMEN

AGE AT START OF FIRST INTERVAL

INTERVAL START-END	-35		35-39		40-44		45-49		50-54		55-59		60-64		65-69		70-74		75+		ALL AGES	
T TO T+DT	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D	L	D
0 - 30 D	0	0	2	1	10	3	28	11	31	18	1	1	0	0	0	0	0	0	0	0	72	34
30-365 D	0	0	1	1	7	1	17	1	13	0	0	0	0	0	0	0	0	0	0	0	38	3
1 - 2 YR	0	0	0	0	6	0	16	2	13	0	0	0	0	0	0	0	0	0	0	0	35	2
2 - 3 YR	0	0	0	0	6	1	13	0	12	0	0	0	0	0	0	0	0	0	0	0	31	1
3 - 4 YR	0	0	0	0	5	0	12	2	12	2	0	0	0	0	0	0	0	0	0	0	29	4
4 - 5 YR	0	0	0	0	5	0	10	1	7	0	0	0	0	0	0	0	0	0	0	0	22	1
5 - 6 YR	0	0	0	0	5	0	6	0	7	1	0	0	0	0	0	0	0	0	0	0	18	1
6 - 7 YR	0	0	0	0	5	0	5	1	4	0	0	0	0	0	0	0	0	0	0	0	14	1
7 - 8 YR	0	0	0	0	4	0	4	1	3	0	0	0	0	0	0	0	0	0	0	0	11	1
8 - 9 YR	0	0	0	0	3	0	3	0	3	1	0	0	0	0	0	0	0	0	0	0	9	1
9 -10 YR	0	0	0	0	2	1	2	0	2	0	0	0	0	0	0	0	0	0	0	0	6	1
10-11 YR	0	0	0	0	1	0	2	0	2	0	0	0	0	0	0	0	0	0	0	0	5	0
11-12 YR	0	0	0	0	1	0	2	0	2	0	0	0	0	0	0	0	0	0	0	0	5	0
12-13 YR	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
13-14 YR	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
14-15 YR	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0

Part III

Life Tables with Observed and Relative Rates of Endpoints in Populations with Myocardial Infarction and Angina Pectoris

Endpoint events following Angina Pectoris Uncomplicated:

Table No.

III-1 Death
III-2 Sudden Death
III-3 Cardiovascular Death
III-4 Coronary Attack
III-5 Myocardial Infarction
III-6 Congestive Heart Failure
III-7 Cerebrovascular Accident

Endpoint events following Recognized Myocardial Infarction:

III-8 Death
III-9 Angina Pectoris
III-10 Second Myocardial Infarction
III-11 Congestive Heart Failure

Endpoint events following Unrecognized Myocardial Infarction:

III-12 Death

Endpoint events following Recognized Myocardial Infarction (including Sudden Death):

III-13 Death

Analysis is not presented for those sex-age groups or yearly intervals with too few cases. See text for full description.

TABLE III-1 (MEN)

LIFE TABLES FOR DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	70	2	0	70.0	0.029	0.020	0.971	0.020	98.9 %	2.0	160 %
1 - 2 YR	68	3	2	67.0	0.045	0.025	0.928	0.031	96.1 %	3.2	210 %
2 - 3 YR	63	3	3	61.5	0.049	0.027	0.883	0.039	93.1 %	4.1	225 %
3 - 4 YR	57	3	2	56.0	0.054	0.030	0.835	0.045	90.0 %	4.9	229 %
4 - 5 YR	52	2	6	49.0	0.041	0.028	0.801	0.050	87.9 %	5.4	224 %
5 - 6 YR	44	3	3	42.5	0.071	0.039	0.745	0.056	83.9 %	6.3	227 %
6 - 7 YR	38	4	3	36.5	0.110	0.052	0.663	0.063	76.5 %	7.3	252 %
7 - 8 YR	31	2	0	31.0	0.065	0.044	0.620	0.066	73.4 %	7.8	245 %
8 - 9 YR	29	1	4	27.0	0.037	0.036	0.597	0.067	72.8 %	8.2	224 %
9 -10 YR	24	1	2	23.0	0.043	0.043	0.571	0.069	72.2 %	8.7	206 %
10-11 YR	21	1	2	20.0	0.050	0.049	0.543	0.071	71.5 %	9.4	190 %
11-12 YR	18	4	3	16.5	0.242	0.106	0.411	0.079	56.7 %	10.9	214 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	126	4	0	126.0	0.032	0.016	0.968	0.016	98.6 %	1.6	174 %
1 - 2 YR	122	6	9	117.5	0.051	0.020	0.919	0.025	95.2 %	2.6	232 %
2 - 3 YR	107	3	4	105.0	0.029	0.016	0.893	0.028	94.1 %	3.0	208 %
3 - 4 YR	100	3	4	98.0	0.031	0.017	0.865	0.031	93.0 %	3.4	192 %
4 - 5 YR	93	4	11	87.5	0.046	0.022	0.826	0.036	90.7 %	3.9	194 %
5 - 6 YR	78	4	4	76.0	0.053	0.026	0.782	0.040	88.0 %	4.5	196 %
6 - 7 YR	70	5	7	66.5	0.075	0.032	0.723	0.045	82.9 %	5.1	217 %
7 - 8 YR	58	4	4	56.0	0.071	0.034	0.672	0.048	78.4 %	5.7	229 %
8 - 9 YR	50	3	5	47.5	0.063	0.035	0.629	0.051	74.7 %	6.1	235 %
9 -10 YR	42	4	5	39.5	0.101	0.048	0.566	0.055	69.2 %	6.7	237 %
10-11 YR	33	1	2	32.0	0.031	0.031	0.548	0.056	68.2 %	7.0	230 %
11-12 YR	30	4	4	28.0	0.143	0.066	0.470	0.060	60.1 %	7.7	243 %
12-13 YR	22	2	6	19.0	0.105	0.070	0.420	0.063	54.6 %	8.2	251 %
13-14 YR	14	0	4	12.0	0.0	0.0	0.420	0.063	56.4 %	8.5	227 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-1 (WOMEN)

LIFE TABLES FOR DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 65-74 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	44	2	0	44.0	0.045	0.031	0.955	0.031	97.1 %	3.2	261 %
1 - 2 YR	42	2	5	39.5	0.051	0.035	0.906	0.045	93.9 %	4.6	269 %
2 - 3 YR	35	1	4	33.0	0.030	0.030	0.879	0.051	92.6 %	5.4	236 %
3 - 4 YR	30	2	0	30.0	0.067	0.046	0.820	0.062	88.4 %	6.7	250 %
4 - 5 YR	28	1	5	25.5	0.039	0.038	0.788	0.068	87.7 %	7.5	210 %
5 - 6 YR	22	0	1	21.5	0.0	0.0	0.788	0.068	91.4 %	7.8	154 %

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	141	3	0	141.0	0.021	0.012	0.979	0.012	98.9 %	1.2	199 %
1 - 2 YR	138	4	15	130.5	0.031	0.015	0.949	0.019	97.0 %	1.9	230 %
2 - 3 YR	119	2	10	114.0	0.018	0.012	0.932	0.022	96.4 %	2.3	204 %
3 - 4 YR	107	3	5	104.5	0.029	0.016	0.905	0.026	94.7 %	2.7	216 %
4 - 5 YR	99	2	7	95.5	0.021	0.015	0.886	0.029	94.2 %	3.1	194 %
5 - 6 YR	90	1	4	88.0	0.011	0.011	0.876	0.030	94.6 %	3.3	167 %
6 - 7 YR	85	1	8	81.0	0.012	0.012	0.865	0.032	95.0 %	3.5	152 %
7 - 8 YR	76	4	7	72.5	0.055	0.027	0.818	0.038	90.6 %	4.2	186 %
8 - 9 YR	65	0	7	61.5	0.0	0.0	0.818	0.038	91.7 %	4.3	168 %
9 -10 YR	58	1	7	54.5	0.018	0.018	0.803	0.040	91.2 %	4.6	164 %
10-11 YR	50	0	7	46.5	0.0	0.0	0.803	0.040	92.8 %	4.6	146 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-2 (MEN)

LIFE TABLES FOR SUDDEN DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	# SD IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL RATE OF SD Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O SD CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O SD CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	126	0	4	124.0	0.0	0.0	1.000	0.0	100.4 %	0.0	0 %
1 - 2 YR	122	3	12	116.0	0.026	0.015	0.974	0.015	98.0 %	1.5	411 %
2 - 3 YR	107	2	5	104.5	0.019	0.013	0.955	0.019	96.6 %	2.0	427 %
3 - 4 YR	100	0	7	96.5	0.0	0.0	0.955	0.019	97.0 %	2.0	302 %
4 - 5 YR	93	1	14	86.0	0.012	0.012	0.944	0.022	96.1 %	2.3	318 %
5 - 6 YR	78	1	7	74.5	0.013	0.013	0.932	0.025	95.2 %	2.6	320 %
6 - 7 YR	70	2	10	65.0	0.031	0.021	0.903	0.032	92.6 %	3.2	392 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT SD FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-2 (WOMEN)

LIFE TABLES FOR SUDDEN DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TOC FEW CASES

TABLE III-3 (MEN)

LIFE TABLES FOR CARDIOVASCULAR DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)

FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	CVD DTH IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORTALITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CVD DTH CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CVD DTH CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	70	2	0	70.0	0.029	0.020	0.971	0.020	98.2 %	2.0	278 %
1 - 2 YR	68	2	3	66.5	0.030	0.021	0.942	0.028	96.2 %	2.9	277 %
2 - 3 YR	63	3	3	61.5	0.049	0.027	0.896	0.037	92.7 %	3.8	311 %
3 - 4 YR	57	1	4	55.0	0.018	0.018	0.880	0.040	92.4 %	4.2	253 %
4 - 5 YR	52	2	6	49.0	0.041	0.028	0.844	0.046	89.6 %	4.8	267 %
5 - 6 YR	44	2	4	42.0	0.048	0.033	0.804	0.052	86.6 %	5.6	274 %
6 - 7 YR	38	1	6	35.0	0.029	0.028	0.781	0.055	85.3 %	6.0	260 %
7 - 8 YR	31	1	1	30.5	0.033	0.032	0.755	0.059	83.7 %	6.5	251 %
8 - 9 YR	29	1	4	27.0	0.037	0.036	0.727	0.063	82.0 %	7.1	241 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	CVD DTH IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORTALITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CVD DTH CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CVD DTH CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	126	4	0	126.0	0.032	0.016	0.968	0.016	97.8 %	1.6	305 %
1 - 2 YR	122	5	10	117.0	0.043	0.019	0.927	0.023	94.6 %	2.4	360 %
2 - 3 YR	107	3	4	105.0	0.029	0.016	0.900	0.027	93.0 %	2.8	315 %
3 - 4 YR	100	1	6	97.0	0.010	0.010	0.891	0.029	93.1 %	3.0	252 %
4 - 5 YR	93	4	11	87.5	0.046	0.022	0.850	0.034	90.0 %	3.6	269 %
5 - 6 YR	78	3	5	75.5	0.040	0.022	0.817	0.038	87.6 %	4.0	270 %
6 - 7 YR	70	2	10	65.0	0.031	0.021	0.791	0.040	85.8 %	4.4	271 %
7 - 8 YR	58	3	5	55.5	0.054	0.030	0.749	0.045	82.0 %	5.0	287 %
8 - 9 YR	50	3	5	47.5	0.063	0.035	0.701	0.050	77.7 %	5.5	307 %
9 -10 YR	42	2	7	38.5	0.052	0.036	0.665	0.054	74.9 %	6.0	298 %
10-11 YR	33	1	2	32.0	0.031	0.031	0.644	0.056	73.5 %	6.4	288 %
11-12 YR	30	1	7	26.5	0.038	0.037	0.620	0.059	71.6 %	6.8	283 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CVD DEATH FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-3 (WOMEN)

LIFE TABLES FOR CARDIOVASCULAR DEATH FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	CVD DTH IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORTALITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CVD DTH CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CVD DTH CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	141	3	0	141.0	0.021	0.012	0.979	0.012	98.4 %	1.2	382 %
1 - 2 YR	138	2	17	129.5	0.015	0.011	0.964	0.016	97.5 %	1.6	319 %
2 - 3 YR	119	2	10	114.0	0.018	0.012	0.947	0.020	96.3 %	2.0	313 %
3 - 4 YR	107	3	5	104.5	0.029	0.016	0.920	0.025	94.1 %	2.5	354 %
4 - 5 YR	99	2	7	95.5	0.021	0.015	0.900	0.028	92.9 %	2.8	319 %
5 - 6 YR	90	0	5	87.5	0.0	0.0	0.900	0.028	93.7 %	2.9	256 %
6 - 7 YR	85	0	9	80.5	0.0	0.0	0.900	0.028	94.5 %	2.9	212 %
7 - 8 YR	76	3	8	72.0	0.042	0.024	0.863	0.034	90.9 %	3.6	272 %
8 - 9 YR	65	0	7	61.5	0.0	0.0	0.863	0.034	91.3 %	3.6	251 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CVD DEATH FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-4 (MEN)
LIFE TABLES FOR CORONARY ATTACK FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	#ATCK IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O ATCK CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O ATCK CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	28	2	0	28.0	0.071	0.049	0.929	0.049	93.6 %	4.9	911 %
1 - 2 YR	26	2	3	24.5	0.082	0.055	0.853	0.068	86.7 %	6.9	904 %
2 - 3 YR	21	1	0	21.0	0.048	0.046	0.812	0.076	83.4 %	7.8	716 %
3 - 4 YR	20	1	1	19.5	0.051	0.050	0.771	0.083	80.0 %	8.6	632 %
4 - 5 YR	18	2	1	17.5	0.114	0.076	0.682	0.094	72.0 %	9.9	610 %

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	#ATCK IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O ATCK CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O ATCK CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	70	1	2	69.0	0.014	0.014	0.986	0.014	100.1 %	1.4	91 %
1 - 2 YR	67	3	3	65.5	0.046	0.026	0.941	0.029	96.8 %	3.0	211 %
2 - 3 YR	61	5	3	59.5	0.084	0.036	0.862	0.043	90.0 %	4.5	326 %
3 - 4 YR	53	0	5	50.5	0.0	0.0	0.862	0.043	91.1 %	4.5	256 %
4 - 5 YR	48	3	7	44.5	0.067	0.038	0.803	0.051	86.3 %	5.5	287 %
5 - 6 YR	38	2	4	36.0	0.056	0.038	0.759	0.057	82.2 %	6.2	312 %
6 - 7 YR	32	1	6	29.0	0.034	0.034	0.733	0.061	80.9 %	6.8	285 %
7 - 8 YR	25	2	1	24.5	0.082	0.055	0.673	0.069	75.3 %	7.8	307 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#ATCK IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O ATCK CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O ATCK CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	126	6	2	125.0	0.048	0.019	0.952	0.019	96.5 %	1.9	364 %
1 - 2 YR	118	6	10	113.0	0.053	0.021	0.902	0.027	92.5 %	2.8	394 %
2 - 3 YR	102	8	4	100.0	0.080	0.027	0.829	0.035	86.3 %	3.6	439 %
3 - 4 YR	90	1	7	86.5	0.012	0.011	0.820	0.036	86.5 %	3.8	343 %
4 - 5 YR	82	5	10	77.0	0.065	0.028	0.767	0.041	82.2 %	4.4	347 %
5 - 6 YR	67	3	5	64.5	0.047	0.026	0.731	0.044	79.1 %	4.7	352 %
6 - 7 YR	59	3	10	54.0	0.056	0.031	0.690	0.047	75.8 %	5.2	348 %
7 - 8 YR	46	5	5	43.5	0.115	0.048	0.611	0.053	67.8 %	5.9	394 %
8 - 9 YR	36	0	4	34.0	0.0	0.0	0.611	0.053	68.7 %	6.0	351 %
9 -10 YR	32	1	5	29.5	0.034	0.033	0.590	0.055	67.4 %	6.3	330 %
10-11 YR	26	0	2	25.0	0.0	0.0	0.590	0.055	68.6 %	6.4	294 %
11-12 YR	24	1	5	21.5	0.047	0.045	0.563	0.059	66.0 %	7.0	296 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CORONARY ATTACK FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-4 (WOMEN)

LIFE TABLES FOR CORONARY ATTACK FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#ATCK IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O ATCK CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O ATCK CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	141	6	0	141.0	0.043	0.017	0.957	0.017	96.3 %	1.7	800 %
1 - 2 YR	135	2	18	126.0	0.016	0.011	0.942	0.020	95.3 %	2.0	536 %
2 - 3 YR	115	3	11	109.5	0.027	0.016	0.916	0.024	93.1 %	2.5	519 %
3 - 4 YR	101	2	6	98.0	0.020	0.014	0.898	0.027	91.9 %	2.8	449 %
4 - 5 YR	93	2	7	89.5	0.022	0.016	0.878	0.030	90.5 %	3.1	409 %
5 - 6 YR	84	2	5	81.5	0.025	0.017	0.856	0.033	88.7 %	3.4	410 %
6 - 7 YR	77	0	9	72.5	0.0	0.0	0.856	0.033	89.5 %	3.4	329 %
7 - 8 YR	68	2	8	64.0	0.031	0.022	0.829	0.037	87.1 %	3.9	358 %
8 - 9 YR	58	1	6	55.0	0.018	0.018	0.814	0.039	85.8 %	4.1	361 %
9 -10 YR	51	1	8	47.0	0.021	0.021	0.797	0.042	84.4 %	4.5	364 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CORONARY ATTACK FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLES III-5 (MEN)

LIFE TABLES FOR MYOCARDIAL INFARCTION FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT, 1950 AND OCT, 1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	# MI IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL RATE OF MI Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O MI CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O MI CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	70	1	2	69.0	0.014	0.014	0.986	0.014	99.6 %	1.4	137 %
1 - 2 YR	67	1	5	64.5	0.016	0.015	0.970	0.021	98.9 %	2.1	155 %
2 - 3 YR	61	2	6	58.0	0.034	0.024	0.937	0.031	96.5 %	3.2	215 %
3 - 4 YR	53	0	5	50.5	0.0	0.0	0.937	0.031	97.3 %	3.2	170 %
4 - 5 YR	48	2	7	44.5	0.045	0.031	0.895	0.041	94.1 %	4.3	215 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	# MI IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL RATE OF MI Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O MI CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O MI CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	126	5	2	125.0	0.040	0.018	0.960	0.018	96.9 %	1.8	454 %
1 - 2 YR	119	3	13	112.5	0.027	0.015	0.934	0.022	95.1 %	2.3	385 %
2 - 3 YR	103	4	7	99.5	0.040	0.020	0.897	0.028	92.2 %	2.9	384 %
3 - 4 YR	92	1	7	88.5	0.011	0.011	0.887	0.030	92.0 %	3.1	314 %
4 - 5 YR	84	3	11	78.5	0.038	0.022	0.853	0.034	89.5 %	3.6	311 %
5 - 6 YR	70	1	8	66.0	0.015	0.015	0.840	0.036	88.7 %	3.8	301 %
6 - 7 YR	61	0	11	55.5	0.0	0.0	0.840	0.036	89.7 %	3.9	250 %
7 - 8 YR	50	6	6	47.0	0.128	0.049	0.733	0.052	78.9 %	5.6	377 %
8 - 9 YR	38	0	6	35.0	0.0	0.0	0.733	0.052	79.5 %	5.6	339 %
9 -10 YR	32	1	5	29.5	0.034	0.033	0.708	0.056	77.6 %	6.1	331 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT MI FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLES III-5 (WOMEN)

LIFE TABLES FOR MYOCARDIAL INFARCTION FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT, 1950 AND OCT, 1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TOO FEW CASES

TABLE III-6 (MEN)

LIFE TABLES FOR CONGESTIVE HEART FAILURE FOLLOWING ANGINA PECTORIS UNCOMPLICATED APU OCCURRING BETWEEN OCT, 1950 AND OCT, 1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)

FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TCC FEW CASES

TABLE III-6 (WOMEN)

LIFE TABLES FOR CONGESTIVE HEART FAILURE FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#CHF IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CHF CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CHF CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	131	0	3	129.5	0.0	0.0	1.000	0.0	100.3 %	0.0	0 %
1 - 2 YR	128	1	18	119.0	0.008	0.008	0.992	0.008	99.7 %	0.8	161 %
2 - 3 YR	109	2	8	105.0	0.019	0.013	0.973	0.016	98.1 %	1.6	338 %
3 - 4 YR	99	3	7	95.5	0.031	0.018	0.942	0.023	95.4 %	2.3	475 %
4 - 5 YR	89	1	7	85.5	0.012	0.012	0.931	0.025	94.8 %	2.6	382 %
5 - 6 YR	81	0	4	79.0	0.0	0.0	0.931	0.025	95.2 %	2.6	311 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CHF FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-7 (MEN)

LIFE TABLES FOR CEREBROVASCULAR ACCIDENT FOLLCWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT, 1950 AND OCT, 1970 (ENTERS RISK ON THE DATE AP HISTCRY WAS TAKEN)
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TCC FEW CASES

TABLE III-7 (WOMEN)

LIFE TABLES FOR CEREBROVASCULAR ACCIDENT FOLLOWING ANGINA PECTORIS UNCOMPLICATED
APU OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON THE DATE AP HISTORY WAS TAKEN)
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#CVA IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CVA CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CVA CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	137	0	2	136.0	0.0	0.0	1.000	0.0	100.4 %	0.0	0 %
1 - 2 YR	135	3	19	125.5	0.024	0.014	0.976	0.014	98.3 %	1.4	319 %
2 - 3 YR	113	2	10	108.0	0.019	0.013	0.958	0.018	96.9 %	1.9	366 %
3 - 4 YR	101	1	7	97.5	0.010	0.010	0.948	0.021	96.3 %	2.1	339 %
4 - 5 YR	93	1	9	88.5	0.011	0.011	0.937	0.023	95.7 %	2.4	301 %
5 - 6 YR	83	0	4	81.0	0.0	0.0	0.937	0.023	96.2 %	2.4	247 %
6 - 7 YR	79	1	8	75.0	0.013	0.013	0.925	0.026	95.3 %	2.7	251 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CVA FOR THE FRAMINGHAM POPULATION FREE OF APU, SEE TEXT

TABLE III-8 (MEN)
LIFE TABLES FOR DEATH FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	54	2	0	54.0	0.037	0.026	0.963	0.026	96.3 %	2.6	9070 %
30-365 D	52	2	0	52.0	0.038	0.027	0.926	0.036	93.1 %	3.6	1299 %
1 - 2 YR	50	1	0	50.0	0.020	0.020	0.907	0.039	91.8 %	4.0	779 %
2 - 3 YR	49	1	2	48.0	0.021	0.021	0.889	0.043	90.6 %	4.4	584 %
3 - 4 YR	46	2	2	45.0	0.044	0.031	0.849	0.049	87.4 %	5.1	531 %
4 - 5 YR	42	2	2	41.0	0.049	0.034	0.808	0.055	83.9 %	5.7	517 %
5 - 6 YR	38	1	2	37.0	0.027	0.027	0.786	0.058	82.3 %	6.0	469 %
6 - 7 YR	35	2	4	33.0	0.061	0.042	0.738	0.063	78.2 %	6.7	467 %
7 - 8 YR	29	3	8	25.0	0.120	0.065	0.650	0.073	69.9 %	7.9	492 %

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	81	12	0	81.0	0.148	0.039	0.852	0.039	85.3 %	4.0	13042 %
30-365 D	69	2	0	69.0	0.029	0.020	0.827	0.042	83.9 %	4.3	1263 %
1 - 2 YR	67	2	0	67.0	0.030	0.021	0.802	0.044	82.8 %	4.6	633 %
2 - 3 YR	65	3	0	65.0	0.046	0.026	0.765	0.047	80.3 %	4.9	503 %
3 - 4 YR	62	3	1	61.5	0.049	0.027	0.728	0.049	77.6 %	5.3	441 %
4 - 5 YR	58	5	4	56.0	0.089	0.038	0.663	0.053	71.9 %	5.7	431 %
5 - 6 YR	49	2	2	48.0	0.042	0.029	0.635	0.054	70.2 %	6.0	386 %
6 - 7 YR	45	3	4	43.0	0.070	0.039	0.591	0.056	66.5 %	6.3	367 %
7 - 8 YR	38	1	4	36.0	0.028	0.027	0.575	0.057	66.2 %	6.6	322 %
8 - 9 YR	33	1	1	32.5	0.031	0.030	0.557	0.058	66.2 %	6.9	280 %
9 -10 YR	31	1	4	29.0	0.034	0.034	0.538	0.059	65.3 %	7.2	262 %
10-11 YR	26	2	4	24.0	0.083	0.056	0.493	0.062	61.2 %	7.7	261 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	193	31	0	193.0	0.161	0.026	0.839	0.026	84.0 %	2.6	15453 %
30-365 D	162	6	0	162.0	0.037	0.015	0.808	0.028	81.9 %	2.9	1432 %
1 - 2 YR	156	6	0	156.0	0.038	0.015	0.777	0.030	79.9 %	3.1	832 %
2 - 3 YR	150	7	6	147.0	0.048	0.018	0.740	0.032	77.0 %	3.3	664 %
3 - 4 YR	137	9	5	134.5	0.067	0.022	0.691	0.034	72.7 %	3.5	614 %
4 - 5 YR	123	8	7	119.5	0.067	0.023	0.644	0.035	68.7 %	3.7	572 %
5 - 6 YR	108	4	6	105.0	0.038	0.019	0.620	0.036	67.0 %	3.9	512 %
6 - 7 YR	98	7	9	93.5	0.075	0.027	0.573	0.037	62.8 %	4.1	492 %
7 - 8 YR	82	5	15	74.5	0.067	0.029	0.535	0.038	59.8 %	4.3	439 %
8 - 9 YR	62	3	3	60.5	0.050	0.028	0.508	0.039	58.4 %	4.5	382 %
9 -10 YR	56	2	10	51.0	0.039	0.027	0.489	0.040	56.9 %	4.7	361 %
10-11 YR	44	2	6	41.0	0.049	0.034	0.465	0.042	54.8 %	4.9	352 %
11-12 YR	36	2	4	34.0	0.059	0.040	0.437	0.044	52.4 %	5.2	340 %
12-13 YR	30	1	4	28.0	0.036	0.035	0.422	0.045	51.3 %	5.4	325 %
13-14 YR	25	2	2	24.0	0.083	0.056	0.387	0.047	48.2 %	5.9	309 %
14-15 YR	21	0	6	18.0	0.0	0.0	0.387	0.047	49.9 %	6.1	272 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

TABLE III-8 (WOMEN)

LIFE TABLES FOR DEATH FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	53	15	0	53.0	0.283	0.062	0.717	0.062	71.8 %	6.2	30855 %
30-365 D	38	3	0	38.0	0.079	0.044	0.660	0.065	66.7 %	6.6	3394 %
1 - 2 YR	35	2	2	34.0	0.059	0.040	0.622	0.067	63.5 %	6.8	1729 %
2 - 3 YR	31	1	1	30.5	0.033	0.032	0.601	0.068	62.2 %	7.0	1201 %
3 - 4 YR	29	4	3	27.5	0.145	0.067	0.514	0.071	54.1 %	7.4	971 %
4 - 5 YR	22	1	3	20.5	0.049	0.048	0.489	0.071	51.6 %	7.5	957 %
5 - 6 YR	18	1	3	16.5	0.061	0.059	0.459	0.073	49.3 %	7.8	779 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

TABLE III-9 (MEN)

LIFE TABLES FOR ANGINA PECTORIS FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970 (AT RISK 30 DAYS FOLLOWING MI)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	#AP IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O AP CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O AP CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	47	10	1	46.5	0.215	0.060	0.785	0.060	79.3 %	6.1	1997 %
1 - 2 YR	36	2	3	34.5	0.058	0.040	0.739	0.065	75.2 %	6.6	1578 %
2 - 3 YR	31	3	0	31.0	0.097	0.053	0.668	0.070	68.5 %	7.2	1312 %
3 - 4 YR	28	1	1	27.5	0.036	0.036	0.644	0.072	66.6 %	7.4	1059 %
4 - 5 YR	26	0	5	23.5	0.0	0.0	0.644	0.072	66.9 %	7.5	933 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#AP IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O AP CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O AP CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	100	16	3	98.5	0.162	0.037	0.838	0.037	84.4 %	3.7	2297 %
1 - 2 YR	81	4	4	79.0	0.051	0.025	0.795	0.041	80.4 %	4.1	1781 %
2 - 3 YR	73	6	3	71.5	0.084	0.033	0.728	0.046	74.1 %	4.6	1542 %
3 - 4 YR	64	3	5	61.5	0.049	0.027	0.693	0.048	70.9 %	4.9	1313 %
4 - 5 YR	56	2	9	51.5	0.039	0.027	0.666	0.050	68.6 %	5.1	1143 %
5 - 6 YR	45	1	4	43.0	0.023	0.023	0.650	0.051	67.4 %	5.3	986 %
6 - 7 YR	40	0	9	35.5	0.0	0.0	0.650	0.051	68.0 %	5.3	813 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT AP FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

TABLE III-9 (WOMEN)

LIFE TABLES FOR ANGINA PECTORIS FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION MI OCCURRING BETWEEN OCT,1950 AND OCT,1970 (AT RISK 30 DAYS FOLLOWING MI)
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TCC FEW CASES

TABLE III-10 (MEN)

LIFE TABLES FOR SECOND MYOCARDIAL INFARCTION FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	#MI IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O 2ND MI CP	ST ERR OF CP SE(CP)
0 - 30 D	81	0	12	75.0	0.0	0.0	1.000	0.0
30-365 D	69	4	2	68.0	0.059	0.029	0.941	0.029
1 - 2 YR	63	3	2	62.0	0.048	0.027	0.896	0.037
2 - 3 YR	58	1	3	56.5	0.018	0.018	0.880	0.040
3 - 4 YR	54	2	4	52.0	0.038	0.027	0.846	0.045
4 - 5 YR	48	1	8	44.0	0.023	0.022	0.827	0.048
5 - 6 YR	39	3	4	37.0	0.081	0.045	0.760	0.058
6 - 7 YR	32	1	4	30.0	0.033	0.033	0.734	0.061
7 - 8 YR	27	0	4	25.0	0.0	0.0	0.734	0.061

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#MI IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O 2ND MI CP	ST ERR OF CP SE(CP)
0 - 30 D	193	0	31	177.5	0.0	0.0	1.000	0.0
30-365 D	162	6	6	159.0	0.038	0.015	0.962	0.015
1 - 2 YR	150	5	6	147.0	0.034	0.015	0.930	0.020
2 - 3 YR	139	3	12	133.0	0.023	0.013	0.909	0.023
3 - 4 YR	124	4	11	118.5	0.034	0.017	0.878	0.027
4 - 5 YR	109	1	12	103.0	0.010	0.010	0.869	0.028
5 - 6 YR	96	4	10	91.0	0.044	0.021	0.831	0.033
6 - 7 YR	82	2	11	76.5	0.026	0.018	0.809	0.035
7 - 8 YR	69	0	19	59.5	0.0	0.0	0.809	0.035
8 - 9 YR	50	4	5	47.5	0.084	0.040	0.741	0.046
9 -10 YR	41	0	9	36.5	0.0	0.0	0.741	0.046

TABLE III-10 (WOMEN)

LIFE TABLES FOR SECOND MYOCARDIAL INFARCTION FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT, 195C AND OCT, 1970
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#MI IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O 2ND MI CP	ST ERR OF CP SE(CP)
0 - 30 D	53	0	15	45.5	0.0	0.0	1.000	0.0
30-365 D	38	4	2	37.0	0.108	0.051	0.892	0.051
1 - 2 YR	32	3	3	30.5	0.098	0.054	0.804	0.067
2 - 3 YR	26	1	0	26.0	0.038	0.038	0.773	0.071
3 - 4 YR	25	4	2	24.0	0.167	0.076	0.644	0.083
4 - 5 YR	19	1	3	17.5	0.057	0.055	0.608	0.086
5 - 6 YR	15	0	3	13.5	0.0	0.0	0.608	0.086

TABLE III-11 (MEN)

LIFE TABLES FOR CONGESTIVE HEART FAILURE FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	# AT RISK L	#CHF IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CHF CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CHF CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	79	2	11	73.5	0.027	0.019	0.973	0.019	97.3 %	1.9	11907 %
30-365 D	66	1	1	65.5	0.015	0.015	0.958	0.024	96.0 %	2.4	1684 %
1 - 2 YR	64	0	2	63.0	0.0	0.0	0.958	0.024	96.3 %	2.4	739 %
2 - 3 YR	62	2	2	61.0	0.033	0.023	0.927	0.032	93.5 %	3.2	791 %
3 - 4 YR	58	3	3	56.5	0.053	0.030	0.877	0.041	88.8 %	4.1	998 %
4 - 5 YR	52	1	7	48.5	0.021	0.020	0.859	0.044	87.3 %	4.4	919 %
5 - 6 YR	44	1	4	42.0	0.024	0.024	0.839	0.047	85.4 %	4.8	879 %
6 - 7 YR	39	0	4	37.0	0.0	0.0	0.839	0.047	85.7 %	4.8	767 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	# AT RISK L	#CHF IN INT. D	WITHDR. IN INT. W	ADJ. NO. AT RISK L*=L-W/2	INTERVAL MORBIDITY Q=D/L*	ST ERR OF Q SE(Q)	CUM. PROP. W/O CHF CP	ST ERR OF CP SE(CP)	CUM. RATIO W/O CHF CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORBIDITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	188	4	27	174.5	0.023	0.011	0.977	0.011	97.7 %	1.1	10627 %
30-365 D	157	5	4	155.0	0.032	0.014	0.946	0.018	94.8 %	1.8	2086 %
1 - 2 YR	148	4	6	145.0	0.028	0.014	0.919	0.021	92.4 %	2.2	1697 %
2 - 3 YR	138	2	9	133.5	0.015	0.011	0.906	0.023	91.2 %	2.3	1326 %
3 - 4 YR	127	4	11	121.5	0.033	0.016	0.876	0.027	88.5 %	2.7	1212 %
4 - 5 YR	112	2	12	106.0	0.019	0.013	0.859	0.029	87.0 %	2.9	1156 %
5 - 6 YR	98	1	9	93.5	0.011	0.011	0.850	0.030	86.2 %	3.0	1051 %
6 - 7 YR	88	1	13	81.5	0.012	0.012	0.840	0.031	85.3 %	3.2	1047 %
7 - 8 YR	74	2	16	66.0	0.030	0.021	0.814	0.035	83.1 %	3.6	929 %
8 - 9 YR	56	1	4	54.0	0.019	0.018	0.799	0.038	82.0 %	3.9	782 %
9 -10 YR	51	1	11	45.5	0.022	0.022	0.782	0.041	80.4 %	4.2	789 %

CP* IS THE MATCHED CUMULATIVE PROPORTION WITHOUT CHF FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

TABLE III-11 (WOMEN)

LIFE TABLES FOR CONGESTIVE HEART FAILURE FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TOO FEW CASES

TABLE III-12 (MEN)

LIFE TABLES FOR DEATH FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND OCT,1970 (ENTERS RISK ON DATE MI DISCOVERED)
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	20	1	0	20.0	0.050	0.049	0.950	0.049	96.5 %	5.0	323 %
1 - 2 YR	19	1	0	19.0	0.053	0.051	0.900	0.067	92.8 %	6.9	336 %
2 - 3 YR	18	2	0	18.0	0.111	0.074	0.800	0.089	84.0 %	9.4	423 %
3 - 4 YR	16	1	1	15.5	0.065	0.062	0.748	0.097	80.3 %	10.4	373 %
4 - 5 YR	14	1	1	13.5	0.074	0.071	0.693	0.105	75.7 %	11.4	365 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 1 YR	45	3	0	45.0	0.067	0.037	0.933	0.037	94.9 %	3.8	399 %
1 - 2 YR	42	3	1	41.5	0.072	0.040	0.866	0.051	89.4 %	5.3	430 %
2 - 3 YR	38	5	2	37.0	0.135	0.056	0.749	0.066	78.8 %	6.9	501 %
3 - 4 YR	31	2	2	30.0	0.067	0.046	0.699	0.070	75.1 %	7.5	432 %
4 - 5 YR	27	2	2	26.0	0.077	0.052	0.645	0.074	70.4 %	8.1	422 %
5 - 6 YR	23	4	1	22.5	0.178	0.081	0.530	0.080	59.0 %	8.9	468 %
6 - 7 YR	18	1	1	17.5	0.057	0.055	0.500	0.081	56.6 %	9.2	432 %
7 - 8 YR	16	0	0	16.0	0.0	0.0	0.500	0.081	57.1 %	9.3	401 %
8 - 9 YR	16	1	2	15.0	0.067	0.064	0.467	0.082	54.3 %	9.6	379 %
9 -10 YR	13	2	2	12.0	0.167	0.108	0.389	0.085	46.1 %	10.1	390 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

TABLE III-12 (WOMEN)

LIFE TABLES FOR DEATH FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION
MI OCCURRING BETWEEN OCT,1950 AND CCT,1970 (ENTERS RISK ON DATE MI DISCOVEBED)
FRAMINGHAM HEART STUDY

ANALYSIS NOT PRESENTED, TOO FEW CASES

TABLE III-13 (MEN)
LIFE TABLES FOR DEATH FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION INCLUDING SUDDEN DEATH
MI OR SUDDEN DEATH OCCURRING BETWEEN OCT, 1950 AND OCT, 1970
FRAMINGHAM HEART STUDY

MEN AGE 45-54 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR CF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	71	19	0	71.0	0.268	0.053	0.732	0.053	73.3 %	5.3	46496 %
30-365 D	52	2	0	52.0	0.038	0.027	0.704	0.054	70.8 %	5.4	5187 %
1 - 2 YR	50	1	0	50.0	0.020	0.020	0.690	0.055	69.8 %	5.6	2607 %
2 - 3 YR	49	1	2	48.0	0.021	0.021	0.676	0.056	68.9 %	5.7	1699 %
3 - 4 YR	46	2	2	45.0	0.044	0.031	0.646	0.057	66.5 %	5.9	1246 %
4 - 5 YR	42	2	2	41.0	0.049	0.034	0.614	0.058	63.8 %	6.1	1037 %
5 - 6 YR	38	1	2	37.0	0.027	0.027	0.598	0.059	62.6 %	6.2	880 %
6 - 7 YR	35	2	4	33.0	0.061	0.042	0.561	0.061	59.5 %	6.4	783 %
7 - 8 YR	29	3	8	25.0	0.120	0.065	0.494	0.065	53.2 %	7.0	711 %

MEN AGE 55-64 AT DIAGNOSIS

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	118	49	0	118.0	0.415	0.045	0.585	0.045	58.6 %	4.5	30903 %
30-365 D	69	2	0	69.0	0.029	0.020	0.568	0.046	57.6 %	4.6	3159 %
1 - 2 YR	67	2	0	67.0	0.030	0.021	0.551	0.046	56.9 %	4.7	1440 %
2 - 3 YR	65	3	0	65.0	0.046	0.026	0.525	0.046	55.1 %	4.8	1017 %
3 - 4 YR	62	3	1	61.5	0.049	0.027	0.500	0.046	53.3 %	4.9	812 %
4 - 5 YR	58	5	4	56.0	0.089	0.038	0.455	0.046	49.4 %	5.0	697 %
5 - 6 YR	49	2	2	48.0	0.042	0.029	0.436	0.046	48.2 %	5.1	596 %
6 - 7 YR	45	3	4	43.0	0.070	0.039	0.406	0.046	45.7 %	5.2	534 %
7 - 8 YR	38	1	4	36.0	0.028	0.027	0.394	0.046	45.5 %	5.3	458 %
8 - 9 YR	33	1	1	32.5	0.031	0.030	0.382	0.046	45.4 %	5.5	390 %
9 -10 YR	31	1	4	29.0	0.034	0.034	0.369	0.047	44.8 %	5.6	358 %
10-11 YR	26	2	4	24.0	0.083	0.056	0.338	0.047	42.0 %	5.9	341 %

MEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR CF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR CF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	261	99	0	261.0	0.379	0.030	0.621	0.030	62.1 %	3.0	30535 %
30-365 D	162	6	0	162.0	0.037	0.015	0.598	0.030	60.6 %	3.1	3004 %
1 - 2 YR	156	6	0	156.0	0.038	0.015	0.575	0.031	59.1 %	3.1	1589 %
2 - 3 YR	150	7	6	147.0	0.048	0.018	0.547	0.031	57.0 %	3.2	1158 %
3 - 4 YR	137	9	5	134.5	0.067	0.022	0.511	0.031	53.8 %	3.3	971 %
4 - 5 YR	123	8	7	119.5	0.067	0.023	0.477	0.031	50.8 %	3.3	842 %
5 - 6 YR	108	4	6	105.0	0.038	0.019	0.458	0.031	49.5 %	3.4	729 %
6 - 7 YR	98	7	9	93.5	0.075	0.027	0.424	0.032	46.4 %	3.5	665 %
7 - 8 YR	82	5	15	74.5	0.067	0.029	0.396	0.032	44.3 %	3.6	570 %
8 - 9 YR	62	3	3	60.5	0.050	0.028	0.376	0.032	43.2 %	3.7	485 %
9 -10 YR	56	2	10	51.0	0.039	0.027	0.361	0.033	42.1 %	3.8	450 %
10-11 YR	44	2	6	41.0	0.049	0.034	0.344	0.033	40.5 %	3.9	432 %
11-12 YR	36	2	4	34.0	0.059	0.040	0.323	0.034	38.8 %	4.1	409 %
12-13 YR	30	1	4	28.0	0.036	0.035	0.312	0.035	37.9 %	4.3	386 %
13-14 YR	25	2	2	24.0	0.083	0.056	0.286	0.037	35.7 %	4.6	359 %
14-15 YR	21	0	6	18.0	0.0	0.0	0.286	0.037	36.9 %	4.7	316 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATICN FREE OF MI, SEE TEXT

TABLE III-13 (WOMEN)

LIFE TABLES FOR DEATH FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION INCLUDING SUDDEN DEATH
MI OR SUDDEN DEATH OCCURRING BETWEEN OCT, 1950 AND OCT, 1970
FRAMINGHAM HEART STUDY

WOMEN AGE 45-54 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN AGE 55-64 AT DIAGNOSIS

ANALYSIS NOT PRESENTED, TOO FEW CASES

WOMEN ALL AGES

INTERVAL START-END T TO T+DT	NO. ALIVE L	DEATHS IN INT. D	WITHDR. IN INT. W	ADJ. NO. ALIVE L*=L-W/2	INTERVAL MORT. RATE Q=D/L*	ST ERR OF Q SE(Q)	CUMULATIVE SURV. RATE CP	ST ERR OF CP SE(CP)	CUMULATIVE SURV. RATIO CSR=100CP/CP*	ST ERR OF CSR SE(CSR)	CUMULATIVE MORTALITY RATIO CMR=100(1-CP)/(1-CP*)
0 - 30 D	72	34	0	72.0	0.472	0.059	0.528	0.059	52.8 %	5.9	42072 %
30-365 D	38	3	0	38.0	0.079	0.044	0.486	0.059	49.1 %	5.9	5136 %
1 - 2 YR	35	2	2	34.0	0.059	0.040	0.458	0.059	46.8 %	6.0	2479 %
2 - 3 YR	31	1	1	30.5	0.033	0.032	0.443	0.059	45.8 %	6.1	1679 %
3 - 4 YR	29	4	3	27.5	0.145	0.067	0.378	0.058	39.8 %	6.1	1242 %
4 - 5 YR	22	1	3	20.5	0.049	0.048	0.360	0.058	38.0 %	6.2	1199 %
5 - 6 YR	18	1	3	16.5	0.061	0.059	0.338	0.059	36.3 %	6.3	953 %

CP* IS THE MATCHED CUMULATIVE SURVIVAL RATE FOR THE FRAMINGHAM POPULATION FREE OF MI, SEE TEXT

Part IV

Life Tables for Specified Endpoints in the Total Framingham Population Beginning at Examination 1

Table No.	Endpoint
IV-1	Death
IV-2	Sudden Death
IV-3	Cardiovascular Death
IV-4	Coronary Heart Disease
IV-5	Coronary Attack
IV-6	Angina Pectoris
IV-7	Myocardial Infarction
IV-8	Congestive Heart Failure
IV-9	Cerebrovascular Disease
IV-10	Cardiovascular Disease

The total Framingham population in these tables consists of all members of the Framingham cohort, excluding those with the disease pre-existing at the initial examination.

TABLE IV-1 (MEN)

LIFE TABLE FOR DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	1	0	384.0	0.997	0.003	443	0	0	443.0	1.000	0.0	422	1	0	422.0	0.998	0.002
1- 2 YR	383	1	0	383.0	0.995	0.004	443	0	0	443.0	1.000	0.0	421	1	0	421.0	0.995	0.003
2- 3 YR	382	0	0	382.0	0.995	0.004	443	1	0	443.0	0.998	0.002	420	0	0	420.0	0.995	0.003
3- 4 YR	382	1	0	382.0	0.992	0.004	442	2	0	442.0	0.993	0.004	420	1	0	420.0	0.993	0.004
4- 5 YR	381	2	0	381.0	0.987	0.006	440	1	0	440.0	0.991	0.004	419	2	0	419.0	0.988	0.005
5- 6 YR	379	0	0	379.0	0.987	0.006	439	3	0	439.0	0.984	0.006	417	0	0	417.0	0.988	0.005
6- 7 YR	379	1	0	379.0	0.984	0.006	436	1	0	436.0	0.982	0.006	417	5	0	417.0	0.976	0.007
7- 8 YR	378	1	0	378.0	0.982	0.007	435	2	0	435.0	0.977	0.007	412	2	0	412.0	0.972	0.008
8- 9 YR	377	0	0	377.0	0.982	0.007	433	0	0	433.0	0.977	0.007	410	1	0	410.0	0.969	0.008
9-10 YR	377	2	0	377.0	0.977	0.008	433	1	0	433.0	0.975	0.007	409	7	0	409.0	0.953	0.010
10-11 YR	375	1	0	375.0	0.974	0.008	432	3	0	432.0	0.968	0.008	402	4	0	402.0	0.943	0.011
11-12 YR	374	0	0	374.0	0.974	0.008	429	2	0	429.0	0.964	0.009	398	6	0	398.0	0.929	0.013
12-13 YR	374	2	0	374.0	0.969	0.009	427	3	0	427.0	0.957	0.010	392	3	0	392.0	0.922	0.013
13-14 YR	372	0	0	372.0	0.969	0.009	424	1	0	424.0	0.955	0.010	389	8	0	389.0	0.903	0.014
14-15 YR	372	0	0	372.0	0.969	0.009	423	5	0	423.0	0.944	0.011	381	6	0	381.0	0.889	0.015
15-16 YR	372	2	0	372.0	0.964	0.010	418	4	0	418.0	0.935	0.012	375	6	0	375.0	0.874	0.016
16-17 YR	370	6	0	370.0	0.948	0.011	414	7	0	414.0	0.919	0.013	369	4	0	369.0	0.865	0.017
17-18 YR	364	1	0	364.0	0.945	0.012	407	4	1	406.5	0.910	0.014	365	12	0	365.0	0.836	0.018
18-19 YR	363	2	1	362.5	0.940	0.012	402	3	2	401.0	0.903	0.014	353	10	1	352.5	0.813	0.019
19-20 YR	360	0	193	263.5	0.940	0.012	397	6	227	283.5	0.884	0.016	342	8	166	259.0	0.788	0.020
20-21 YR	167	0	167	83.5	0.940	0.012	164	0	163	82.5	0.884	0.016	168	0	168	84.0	0.788	0.020
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.884	0.016	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	357	3	0	357.0	0.992	0.005	374	2	0	374.0	0.995	0.004	279	3	0	279.0	0.989	0.006
1- 2 YR	354	0	0	354.0	0.992	0.005	372	4	0	372.0	0.984	0.006	276	3	0	276.0	0.978	0.009
2- 3 YR	354	3	0	354.0	0.983	0.007	368	5	0	368.0	0.971	0.009	273	6	0	273.0	0.957	0.012
3- 4 YR	351	3	0	351.0	0.975	0.008	363	9	0	363.0	0.947	0.012	267	5	0	267.0	0.939	0.014
4- 5 YR	348	2	0	348.0	0.969	0.009	354	3	0	354.0	0.939	0.012	262	3	0	262.0	0.928	0.015
5- 6 YR	346	3	0	346.0	0.961	0.010	351	5	0	351.0	0.925	0.014	259	3	0	259.0	0.918	0.016
6- 7 YR	343	5	0	343.0	0.947	0.012	346	4	0	346.0	0.914	0.014	256	5	0	256.0	0.900	0.018
7- 8 YR	338	7	0	338.0	0.927	0.014	342	10	0	342.0	0.888	0.016	251	10	0	251.0	0.864	0.021
8- 9 YR	331	3	0	331.0	0.919	0.014	332	5	0	332.0	0.874	0.017	241	11	0	241.0	0.824	0.023
9-10 YR	328	4	0	328.0	0.908	0.015	327	4	0	327.0	0.864	0.018	230	8	0	230.0	0.796	0.024
10-11 YR	324	1	0	324.0	0.905	0.016	323	8	0	323.0	0.842	0.019	222	4	0	222.0	0.781	0.025
11-12 YR	323	9	0	323.0	0.880	0.017	315	11	0	315.0	0.813	0.020	218	3	0	218.0	0.771	0.025
12-13 YR	314	6	0	314.0	0.863	0.018	304	11	0	304.0	0.783	0.021	215	6	0	215.0	0.749	0.026
13-14 YR	308	6	0	308.0	0.846	0.019	293	8	0	293.0	0.762	0.022	209	8	0	209.0	0.720	0.027
14-15 YR	302	4	0	302.0	0.835	0.020	285	6	0	285.0	0.746	0.023	201	6	0	201.0	0.699	0.027
15-16 YR	298	4	0	298.0	0.824	0.020	279	7	0	279.0	0.727	0.023	195	11	0	195.0	0.659	0.028
16-17 YR	294	3	0	294.0	0.815	0.021	272	9	0	272.0	0.703	0.024	184	6	0	184.0	0.638	0.029
17-18 YR	291	7	0	291.0	0.796	0.021	263	7	0	263.0	0.684	0.024	178	10	0	178.0	0.602	0.029
18-19 YR	284	3	2	283.0	0.787	0.022	256	6	1	255.5	0.668	0.024	168	12	0	168.0	0.559	0.030
19-20 YR	279	7	143	207.5	0.761	0.023	249	9	118	190.0	0.637	0.025	156	7	75	118.5	0.526	0.030
20-21 YR	129	0	129	64.5	0.761	0.023	122	0	122	61.0	0.637	0.025	74	0	74	37.0	0.526	0.030
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-1 (WOMEN)

LIFE TABLE FCR DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	1	0	584.0	0.998	0.002	511	0	0	511.0	1.000	0.0
1- 2 YR	443	1	0	443.0	0.998	0.002	583	1	0	583.0	0.997	0.002	511	0	0	511.0	1.000	0.0
2- 3 YR	442	1	0	442.0	0.995	0.003	582	1	0	582.0	0.995	0.003	511	0	0	511.0	1.000	0.0
3- 4 YR	441	0	0	441.0	0.995	0.003	581	0	0	581.0	0.995	0.003	511	1	0	511.0	0.998	0.002
4- 5 YR	441	0	0	441.0	0.995	0.003	581	1	0	581.0	0.993	0.003	510	2	0	510.0	0.994	0.003
5- 6 YR	441	0	0	441.0	0.995	0.003	580	1	0	580.0	0.991	0.004	508	1	0	508.0	0.992	0.004
6- 7 YR	441	2	0	441.0	0.991	0.004	579	1	0	579.0	0.990	0.004	507	2	0	507.0	0.988	0.005
7- 8 YR	439	1	0	439.0	0.989	0.005	578	0	0	578.0	0.990	0.004	505	1	0	505.0	0.986	0.005
8- 9 YR	438	0	0	438.0	0.989	0.005	578	1	0	578.0	0.988	0.005	504	3	0	504.0	0.980	0.006
9-10 YR	438	3	0	438.0	0.982	0.006	577	2	0	577.0	0.985	0.005	501	2	0	501.0	0.977	0.007
10-11 YR	435	1	0	435.0	0.980	0.007	575	3	0	575.0	0.979	0.006	499	3	0	499.0	0.971	0.007
11-12 YR	434	3	0	434.0	0.973	0.008	572	3	0	572.0	0.974	0.007	496	3	0	496.0	0.965	0.008
12-13 YR	431	0	0	431.0	0.973	0.008	569	4	0	569.0	0.967	0.007	493	2	0	493.0	0.961	0.009
13-14 YR	431	0	0	431.0	0.973	0.008	565	6	0	565.0	0.957	0.008	491	6	0	491.0	0.949	0.010
14-15 YR	431	0	0	431.0	0.973	0.008	559	3	0	559.0	0.952	0.009	485	3	0	485.0	0.943	0.010
15-16 YR	431	0	0	431.0	0.973	0.008	556	6	0	556.0	0.942	0.010	482	3	0	482.0	0.937	0.011
16-17 YR	431	2	0	431.0	0.968	0.008	550	3	0	550.0	0.937	0.010	479	3	0	479.0	0.932	0.011
17-18 YR	429	4	0	429.0	0.959	0.009	547	1	0	547.0	0.935	0.010	476	6	0	476.0	0.920	0.012
18-19 YR	425	3	1	424.5	0.953	0.010	546	3	1	545.5	0.930	0.011	470	3	1	469.5	0.914	0.012
19-20 YR	421	3	202	320.0	0.944	0.011	542	5	269	407.5	0.918	0.012	466	6	224	354.0	0.898	0.014
20-21 YR	216	0	216	108.0	0.944	0.011	268	0	267	134.5	0.918	0.012	236	0	235	118.5	0.898	0.014
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.918	0.012	1	0	1	0.5	0.898	0.014

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	451	0	0	451.0	1.000	0.0	432	3	0	432.0	0.993	0.004	372	1	0	372.0	0.997	0.003
1- 2 YR	451	1	0	451.0	0.998	0.002	429	0	0	429.0	0.993	0.004	371	1	0	371.0	0.995	0.004
2- 3 YR	450	0	0	450.0	0.998	0.002	429	2	0	429.0	0.988	0.005	370	0	0	370.0	0.995	0.004
3- 4 YR	450	3	0	450.0	0.991	0.004	427	1	0	427.0	0.986	0.006	370	2	0	370.0	0.989	0.005
4- 5 YR	447	2	0	447.0	0.987	0.005	426	2	0	426.0	0.981	0.006	368	2	0	368.0	0.984	0.007
5- 6 YR	445	3	0	445.0	0.980	0.007	424	3	0	424.0	0.975	0.008	366	2	0	366.0	0.978	0.008
6- 7 YR	442	3	0	442.0	0.973	0.008	421	3	0	421.0	0.968	0.009	364	7	0	364.0	0.960	0.010
7- 8 YR	439	3	0	439.0	0.967	0.008	418	4	0	418.0	0.958	0.010	357	2	0	357.0	0.954	0.011
8- 9 YR	436	3	0	436.0	0.960	0.009	414	6	0	414.0	0.944	0.011	355	4	0	355.0	0.944	0.012
9-10 YR	433	3	0	433.0	0.953	0.010	408	4	0	408.0	0.935	0.012	351	6	0	351.0	0.927	0.013
10-11 YR	430	2	0	430.0	0.949	0.010	404	3	0	404.0	0.928	0.012	345	7	0	345.0	0.909	0.015
11-12 YR	428	3	0	428.0	0.942	0.011	401	6	0	401.0	0.914	0.013	338	2	0	338.0	0.903	0.015
12-13 YR	425	2	0	425.0	0.938	0.011	395	7	0	395.0	0.898	0.015	336	7	0	336.0	0.884	0.017
13-14 YR	423	2	0	423.0	0.933	0.012	388	4	0	388.0	0.889	0.015	329	11	0	329.0	0.855	0.018
14-15 YR	421	4	0	421.0	0.925	0.012	384	7	0	384.0	0.873	0.016	318	7	0	318.0	0.836	0.019
15-16 YR	417	5	0	417.0	0.914	0.013	377	8	0	377.0	0.854	0.017	311	12	0	311.0	0.804	0.021
16-17 YR	412	7	0	412.0	0.898	0.014	369	6	0	369.0	0.840	0.018	299	2	0	299.0	0.798	0.021
17-18 YR	405	3	0	405.0	0.891	0.015	363	7	0	363.0	0.824	0.018	297	11	0	297.0	0.769	0.022
18-19 YR	402	6	1	401.5	0.878	0.015	356	8	2	355.0	0.806	0.019	286	15	0	286.0	0.728	0.023
19-20 YR	395	5	183	303.5	0.864	0.016	346	6	163	264.5	0.787	0.020	271	14	122	210.0	0.680	0.025
20-21 YR	207	0	206	104.0	0.864	0.016	177	0	177	88.5	0.787	0.020	135	0	133	68.5	0.680	0.025
21-22 YR	1	0	1	0.5	0.864	0.016	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.680	0.025

TABLE IV-2 (MEN)

LIFE TABLE FOR SUDDEN DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	0	1	383.5	1.000	0.0	443	0	0	443.0	1.000	0.0	422	0	1	421.5	1.000	0.0
1- 2 YR	383	1	0	383.0	0.997	0.003	443	0	0	443.0	1.000	0.0	421	0	1	420.5	1.000	0.0
2- 3 YR	382	0	0	382.0	0.997	0.003	443	0	1	442.5	1.000	0.0	420	0	0	420.0	1.000	0.0
3- 4 YR	382	0	1	381.5	0.997	0.003	442	1	1	441.5	0.998	0.002	420	0	1	419.5	1.000	0.0
4- 5 YR	381	0	2	380.0	0.997	0.003	440	0	1	439.5	0.998	0.002	419	1	1	418.5	0.998	0.002
5- 6 YR	379	0	0	379.0	0.997	0.003	439	1	2	438.0	0.995	0.003	417	0	0	417.0	0.998	0.002
6- 7 YR	379	0	1	378.5	0.997	0.003	436	0	1	435.5	0.995	0.003	417	1	4	415.0	0.995	0.003
7- 8 YR	378	0	1	377.5	0.997	0.003	435	1	1	434.5	0.993	0.004	412	1	1	411.5	0.993	0.004
8- 9 YR	377	0	0	377.0	0.997	0.003	433	0	0	433.0	0.993	0.004	410	0	1	409.5	0.993	0.004
9-10 YR	377	0	2	376.0	0.997	0.003	433	1	0	433.0	0.991	0.005	409	3	4	407.0	0.985	0.006
10-11 YR	375	0	1	374.5	0.997	0.003	432	0	3	430.5	0.991	0.005	402	1	3	400.5	0.983	0.006
11-12 YR	374	0	0	374.0	0.997	0.003	429	0	2	428.0	0.991	0.005	398	0	6	395.0	0.983	0.006
12-13 YR	374	1	1	373.5	0.995	0.004	427	0	3	425.5	0.991	0.005	392	0	3	390.5	0.983	0.006
13-14 YR	372	0	0	372.0	0.995	0.004	424	1	0	424.0	0.989	0.005	389	1	7	385.5	0.980	0.007
14-15 YR	372	0	0	372.0	0.995	0.004	423	1	4	421.0	0.986	0.006	381	1	5	378.5	0.978	0.007
15-16 YR	372	0	2	371.0	0.995	0.004	418	0	4	416.0	0.986	0.006	375	1	5	372.5	0.975	0.008
16-17 YR	370	1	5	367.5	0.992	0.005	414	5	2	413.0	0.974	0.008	369	0	4	367.0	0.975	0.008
17-18 YR	364	0	1	363.5	0.992	0.005	407	0	5	404.5	0.974	0.008	365	2	10	360.0	0.970	0.009
18-19 YR	363	0	3	361.5	0.992	0.005	402	0	5	399.5	0.974	0.008	353	4	7	349.5	0.959	0.010
19-20 YR	360	0	193	263.5	0.992	0.005	397	0	233	280.5	0.974	0.008	342	2	172	256.0	0.951	0.011
20-21 YR	167	0	167	83.5	0.992	0.005	164	0	163	82.5	0.974	0.008	168	0	168	84.0	0.951	0.011
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.974	0.008	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	357	0	3	355.5	1.000	0.0	374	0	2	373.0	1.000	0.0	279	2	1	278.5	0.993	0.005
1- 2 YR	354	0	0	354.0	1.000	0.0	372	1	3	370.5	0.997	0.003	276	1	2	275.0	0.989	0.006
2- 3 YR	354	0	3	352.5	1.000	0.0	368	2	3	366.5	0.992	0.005	273	0	6	270.0	0.989	0.006
3- 4 YR	351	0	3	349.5	1.000	0.0	363	2	7	359.5	0.986	0.006	267	0	5	264.5	0.989	0.006
4- 5 YR	348	1	1	347.5	0.997	0.003	354	1	2	353.0	0.984	0.007	262	1	2	261.0	0.985	0.007
5- 6 YR	346	1	2	345.0	0.994	0.004	351	1	4	349.0	0.981	0.007	259	2	1	258.5	0.978	0.009
6- 7 YR	343	2	3	341.5	0.988	0.006	346	2	2	345.0	0.975	0.008	256	0	5	253.5	0.978	0.009
7- 8 YR	338	3	4	336.0	0.980	0.008	342	1	9	337.5	0.972	0.009	251	1	9	246.5	0.974	0.010
8- 9 YR	331	1	2	330.0	0.977	0.008	332	5	0	332.0	0.958	0.011	241	1	10	236.0	0.970	0.011
9-10 YR	328	2	2	327.0	0.971	0.009	327	2	2	326.0	0.952	0.011	230	1	7	226.5	0.965	0.011
10-11 YR	324	0	1	323.5	0.971	0.009	323	1	7	319.5	0.949	0.012	222	0	4	220.0	0.965	0.011
11-12 YR	323	3	6	320.0	0.962	0.010	315	2	9	310.5	0.943	0.012	218	0	3	216.5	0.965	0.011
12-13 YR	314	3	3	312.5	0.952	0.012	304	0	11	298.5	0.943	0.012	215	2	4	213.0	0.956	0.013
13-14 YR	308	0	6	305.0	0.952	0.012	293	1	7	289.5	0.939	0.013	209	2	6	206.0	0.947	0.014
14-15 YR	302	0	4	300.0	0.952	0.012	285	2	4	283.0	0.933	0.014	201	0	6	198.0	0.947	0.014
15-16 YR	298	1	3	296.5	0.949	0.012	279	1	6	276.0	0.929	0.014	195	2	9	190.5	0.937	0.016
16-17 YR	294	1	2	293.0	0.946	0.012	272	3	6	269.0	0.919	0.015	184	2	4	182.0	0.927	0.017
17-18 YR	291	3	4	289.0	0.936	0.014	263	1	6	260.0	0.915	0.015	178	1	9	173.5	0.921	0.018
18-19 YR	284	0	5	281.5	0.936	0.014	256	0	7	252.5	0.915	0.015	168	2	10	163.0	0.910	0.019
19-20 YR	279	0	150	204.0	0.936	0.014	249	1	126	186.0	0.910	0.016	156	0	82	115.0	0.910	0.019
20-21 YR	129	0	129	64.5	0.936	0.014	122	0	122	61.0	0.910	0.016	74	0	74	37.0	0.910	0.019
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-2 (WOMEN)

LIFE TABLE FOR SUDDEN DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	0	1	583.5	1.000	0.0	511	0	0	511.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	583	0	1	582.5	1.000	0.0	511	0	0	511.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	582	0	1	581.5	1.000	0.0	511	0	0	511.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	581	0	0	581.0	1.000	0.0	511	0	1	510.5	1.000	0.0
4- 5 YR	441	0	0	441.0	1.000	0.0	581	0	1	580.5	1.000	0.0	510	0	2	509.0	1.000	0.0
5- 6 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	508	0	1	507.5	1.000	0.0
6- 7 YR	441	0	2	440.0	1.000	0.0	579	0	1	578.5	1.000	0.0	507	0	2	506.0	1.000	0.0
7- 8 YR	439	0	1	438.5	1.000	0.0	578	0	0	578.0	1.000	0.0	505	0	1	504.5	1.000	0.0
8- 9 YR	438	0	0	438.0	1.000	0.0	578	0	1	577.5	1.000	0.0	504	1	2	503.0	0.998	0.002
9-10 YR	438	0	3	436.5	1.000	0.0	577	0	2	576.0	1.000	0.0	501	0	2	500.0	0.998	0.002
10-11 YR	435	0	1	434.5	1.000	0.0	575	0	3	573.5	1.000	0.0	499	0	3	497.5	0.998	0.002
11-12 YR	434	0	3	432.5	1.000	0.0	572	0	3	570.5	1.000	0.0	496	0	3	494.5	0.998	0.002
12-13 YR	431	0	0	431.0	1.000	0.0	569	0	4	567.0	1.000	0.0	493	0	2	492.0	0.998	0.002
13-14 YR	431	0	0	431.0	1.000	0.0	565	1	5	562.5	0.998	0.002	491	0	6	488.0	0.998	0.002
14-15 YR	431	0	0	431.0	1.000	0.0	559	1	2	558.0	0.996	0.003	485	0	3	483.5	0.998	0.002
15-16 YR	431	0	0	431.0	1.000	0.0	556	0	6	553.0	0.996	0.003	482	0	3	480.5	0.998	0.002
16-17 YR	431	0	2	430.0	1.000	0.0	550	0	3	548.5	0.996	0.003	479	0	3	477.5	0.998	0.002
17-18 YR	429	0	4	427.0	1.000	0.0	547	0	1	546.5	0.996	0.003	476	1	5	473.5	0.996	0.003
18-19 YR	425	0	4	423.0	1.000	0.0	546	0	4	544.0	0.996	0.003	470	0	4	468.0	0.996	0.003
19-20 YR	421	0	205	318.5	1.000	0.0	542	1	273	405.5	0.994	0.004	466	0	230	351.0	0.996	0.003
20-21 YR	216	0	216	108.0	1.000	0.0	268	0	267	134.5	0.994	0.004	236	0	235	118.5	0.996	0.003
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.994	0.004	1	0	1	0.5	0.996	0.003

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	451	0	0	451.0	1.000	0.0	432	0	3	430.5	1.000	0.0	372	0	1	371.5	1.000	0.0
1- 2 YR	451	0	1	450.5	1.000	0.0	429	0	0	429.0	1.000	0.0	371	0	1	370.5	1.000	0.0
2- 3 YR	450	0	0	450.0	1.000	0.0	429	0	2	428.0	1.000	0.0	370	0	0	370.0	1.000	0.0
3- 4 YR	450	0	3	448.5	1.000	0.0	427	0	1	426.5	1.000	0.0	370	0	2	369.0	1.000	0.0
4- 5 YR	447	0	2	446.0	1.000	0.0	426	0	2	425.0	1.000	0.0	368	0	2	367.0	1.000	0.0
5- 6 YR	445	1	2	444.0	0.998	0.002	424	0	3	422.5	1.000	0.0	366	0	2	365.0	1.000	0.0
6- 7 YR	442	0	3	440.5	0.998	0.002	421	0	3	419.5	1.000	0.0	364	1	6	361.0	0.997	0.003
7- 8 YR	439	0	3	437.5	0.998	0.002	418	0	4	416.0	1.000	0.0	357	0	2	356.0	0.997	0.003
8- 9 YR	436	1	2	435.0	0.995	0.003	414	1	5	411.5	0.998	0.002	355	1	3	353.5	0.994	0.004
9-10 YR	433	0	3	431.5	0.995	0.003	408	0	4	406.0	0.998	0.002	351	0	6	348.0	0.994	0.004
10-11 YR	430	0	2	429.0	0.995	0.003	404	0	3	402.5	0.998	0.002	345	0	7	341.5	0.994	0.004
11-12 YR	428	0	3	426.5	0.995	0.003	401	1	5	398.5	0.995	0.003	338	0	2	337.0	0.994	0.004
12-13 YR	425	0	2	424.0	0.995	0.003	395	1	6	392.0	0.993	0.004	336	2	5	333.5	0.988	0.006
13-14 YR	423	0	2	422.0	0.995	0.003	388	1	3	386.5	0.990	0.005	329	3	8	325.0	0.979	0.008
14-15 YR	421	0	4	419.0	0.995	0.003	384	1	6	381.0	0.987	0.006	318	0	7	314.5	0.979	0.008
15-16 YR	417	2	3	415.5	0.991	0.005	377	0	8	373.0	0.987	0.006	311	0	12	305.0	0.979	0.008
16-17 YR	412	0	7	408.5	0.991	0.005	369	0	6	366.0	0.987	0.006	299	0	2	298.0	0.979	0.008
17-18 YR	405	0	3	403.5	0.991	0.005	363	1	6	360.0	0.985	0.006	297	0	11	291.5	0.979	0.008
18-19 YR	402	1	6	399.0	0.988	0.005	356	0	10	351.0	0.985	0.006	286	1	14	279.0	0.976	0.008
19-20 YR	395	1	187	301.5	0.985	0.006	346	0	169	261.5	0.985	0.006	271	1	135	203.5	0.971	0.010
20-21 YR	207	0	206	104.0	0.985	0.006	177	0	177	88.5	0.985	0.006	135	0	133	68.5	0.971	0.010
21-22 YR	1	0	1	0.5	0.985	0.006	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.971	0.010

TABLE IV-3 (MEN)

LIFE TABLE FOR CARDIOVASCULAR DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	1	0	384.0	0.997	0.003	443	0	0	443.0	1.000	0.0	422	1	0	422.0	0.998	0.002
1- 2 YR	383	1	0	383.0	0.995	0.004	443	0	0	443.0	1.000	0.0	421	0	1	420.5	0.998	0.002
2- 3 YR	382	0	0	382.0	0.995	0.004	443	0	1	442.5	1.000	0.0	420	0	0	420.0	0.998	0.002
3- 4 YR	382	1	0	382.0	0.992	0.004	442	1	1	441.5	0.998	0.002	420	0	1	419.5	0.998	0.002
4- 5 YR	381	1	1	380.5	0.990	0.005	440	0	1	439.5	0.998	0.002	419	1	1	418.5	0.995	0.003
5- 6 YR	379	0	0	379.0	0.990	0.005	439	2	1	438.5	0.993	0.004	417	0	0	417.0	0.995	0.003
6- 7 YR	379	0	1	378.5	0.990	0.005	436	0	1	435.5	0.993	0.004	417	1	4	415.0	0.993	0.004
7- 8 YR	378	0	1	377.5	0.990	0.005	435	2	0	435.0	0.989	0.005	412	2	0	412.0	0.988	0.005
8- 9 YR	377	0	0	377.0	0.990	0.005	433	0	0	433.0	0.989	0.005	410	1	0	410.0	0.986	0.006
9-10 YR	377	1	1	376.5	0.987	0.006	433	1	0	433.0	0.986	0.006	409	3	4	407.0	0.978	0.007
10-11 YR	375	0	1	374.5	0.987	0.006	432	0	3	430.5	0.986	0.006	402	1	3	400.5	0.976	0.008
11-12 YR	374	0	0	374.0	0.987	0.006	429	0	2	428.0	0.986	0.006	398	4	2	397.0	0.966	0.009
12-13 YR	374	2	0	374.0	0.982	0.007	427	0	3	425.5	0.986	0.006	392	2	1	391.5	0.961	0.010
13-14 YR	372	0	0	372.0	0.982	0.007	424	1	0	424.0	0.984	0.006	389	7	1	388.5	0.944	0.011
14-15 YR	372	0	0	372.0	0.982	0.007	423	3	2	422.0	0.977	0.007	381	1	5	378.5	0.941	0.012
15-16 YR	372	2	0	372.0	0.976	0.008	418	0	4	416.0	0.977	0.007	375	3	3	373.5	0.934	0.012
16-17 YR	370	4	2	369.0	0.966	0.009	414	6	1	413.5	0.963	0.009	369	3	1	368.5	0.926	0.013
17-18 YR	364	0	1	363.5	0.966	0.009	407	1	4	405.0	0.960	0.009	365	9	3	363.5	0.903	0.015
18-19 YR	363	0	3	361.5	0.966	0.009	402	0	5	399.5	0.960	0.009	353	8	3	351.5	0.883	0.016
19-20 YR	360	0	193	263.5	0.966	0.009	397	3	230	282.0	0.950	0.011	342	4	170	257.0	0.869	0.017
20-21 YR	167	0	167	83.5	0.966	0.009	164	0	163	82.5	0.950	0.011	168	0	168	84.0	0.869	0.017
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.950	0.011	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	357	1	2	356.0	0.997	0.003	374	0	2	373.0	1.000	0.0	279	2	1	278.5	0.993	0.005
1- 2 YR	354	0	0	354.0	0.997	0.003	372	2	2	371.0	0.995	0.004	276	1	2	275.0	0.989	0.006
2- 3 YR	354	1	2	353.0	0.994	0.004	368	3	2	367.0	0.986	0.006	273	1	5	270.5	0.986	0.007
3- 4 YR	351	1	2	350.0	0.992	0.005	363	9	0	363.0	0.962	0.010	267	3	2	266.0	0.974	0.010
4- 5 YR	348	1	1	347.5	0.989	0.006	354	2	1	353.5	0.957	0.011	262	2	1	261.5	0.967	0.011
5- 6 YR	346	1	2	345.0	0.986	0.006	351	1	4	349.0	0.954	0.011	259	3	0	259.0	0.956	0.012
6- 7 YR	343	4	1	342.5	0.974	0.008	346	4	0	346.0	0.943	0.012	256	4	1	255.5	0.941	0.014
7- 8 YR	338	5	2	337.0	0.960	0.011	342	7	3	340.5	0.923	0.014	251	7	3	249.5	0.914	0.017
8- 9 YR	331	1	2	330.0	0.957	0.011	332	5	0	332.0	0.910	0.015	241	6	5	238.5	0.891	0.019
9-10 YR	328	3	1	327.5	0.948	0.012	327	4	0	327.0	0.898	0.016	230	4	4	228.0	0.876	0.020
10-11 YR	324	1	0	324.0	0.945	0.012	323	7	1	322.5	0.879	0.017	222	1	3	220.5	0.872	0.021
11-12 YR	323	6	3	321.5	0.928	0.014	315	6	5	312.5	0.862	0.018	218	1	2	217.0	0.868	0.021
12-13 YR	314	5	1	313.5	0.913	0.015	304	4	7	300.5	0.851	0.019	215	3	3	213.5	0.856	0.022
13-14 YR	308	2	4	306.0	0.907	0.016	293	5	3	291.5	0.836	0.020	209	3	5	206.5	0.843	0.023
14-15 YR	302	4	0	302.0	0.895	0.017	285	4	2	284.0	0.824	0.020	201	3	3	199.5	0.830	0.023
15-16 YR	298	2	2	297.0	0.889	0.017	279	5	2	278.0	0.809	0.021	195	5	6	192.0	0.809	0.025
16-17 YR	294	2	1	293.5	0.883	0.017	272	8	1	271.5	0.786	0.022	184	4	2	183.0	0.791	0.026
17-18 YR	291	3	4	289.0	0.874	0.018	263	4	3	261.5	0.773	0.022	178	4	6	175.0	0.773	0.027
18-19 YR	284	2	3	282.5	0.867	0.018	256	1	6	253.0	0.770	0.022	168	9	3	166.5	0.731	0.029
19-20 YR	279	2	148	205.0	0.859	0.019	249	4	123	187.5	0.754	0.023	156	3	79	116.5	0.712	0.030
20-21 YR	129	0	129	64.5	0.859	0.019	122	0	122	61.0	0.754	0.023	74	0	74	37.0	0.712	0.030
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-3 (WOMEN)

LIFE TABLE FOR CARDIOVASCULAR DEATH IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	0	1	583.5	1.000	0.0	511	0	0	511.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	583	1	0	583.0	0.998	0.002	511	0	0	511.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	582	0	1	581.5	0.998	0.002	511	0	0	511.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	581	0	0	581.0	0.998	0.002	511	1	0	511.0	0.998	0.002
4- 5 YR	441	0	0	441.0	1.000	0.0	581	0	1	580.5	0.998	0.002	510	0	2	509.0	0.998	0.002
5- 6 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	0.998	0.002	508	0	1	507.5	0.998	0.002
6- 7 YR	441	0	2	440.0	1.000	0.0	579	0	1	578.5	0.998	0.002	507	0	2	506.0	0.998	0.002
7- 8 YR	439	0	1	438.5	1.000	0.0	578	0	0	578.0	0.998	0.002	505	0	1	504.5	0.998	0.002
8- 9 YR	438	0	0	438.0	1.000	0.0	578	1	0	578.0	0.997	0.002	504	1	2	503.0	0.996	0.003
9-10 YR	438	1	2	437.0	0.998	0.002	577	0	2	576.0	0.997	0.002	501	0	2	500.0	0.996	0.003
10-11 YR	435	1	0	435.0	0.995	0.003	575	1	2	574.0	0.995	0.003	499	0	3	497.5	0.996	0.003
11-12 YR	434	2	1	433.5	0.991	0.005	572	1	2	571.0	0.993	0.003	496	0	3	494.5	0.996	0.003
12-13 YR	431	0	0	431.0	0.991	0.005	569	0	4	567.0	0.993	0.003	493	0	2	492.0	0.996	0.003
13-14 YR	431	0	0	431.0	0.991	0.005	565	2	4	563.0	0.990	0.004	491	1	5	488.5	0.994	0.003
14-15 YR	431	0	0	431.0	0.991	0.005	559	1	2	558.0	0.988	0.005	485	0	3	483.5	0.994	0.003
15-16 YR	431	0	0	431.0	0.991	0.005	556	3	3	554.5	0.982	0.006	482	3	0	482.0	0.988	0.005
16-17 YR	431	0	2	430.0	0.991	0.005	550	3	0	550.0	0.977	0.006	479	1	2	478.0	0.986	0.005
17-18 YR	429	2	2	428.0	0.986	0.006	547	0	1	546.5	0.977	0.006	476	2	4	474.0	0.982	0.006
18-19 YR	425	0	4	423.0	0.986	0.006	546	3	1	545.5	0.972	0.007	470	1	3	468.5	0.980	0.006
19-20 YR	421	1	204	319.0	0.983	0.006	542	2	272	406.0	0.967	0.008	466	2	228	352.0	0.974	0.007
20-21 YR	216	0	216	108.0	0.983	0.006	268	0	267	134.5	0.967	0.008	236	0	235	118.5	0.974	0.007
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.967	0.008	1	0	1	0.5	0.974	0.007

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	451	0	0	451.0	1.000	0.0	432	2	1	431.5	0.995	0.003	372	0	1	371.5	1.000	0.0
1- 2 YR	451	1	0	451.0	0.998	0.002	429	0	0	429.0	0.995	0.003	371	0	1	370.5	1.000	0.0
2- 3 YR	450	0	0	450.0	0.998	0.002	429	1	1	428.5	0.993	0.004	370	0	0	370.0	1.000	0.0
3- 4 YR	450	2	1	449.5	0.993	0.004	427	0	1	426.5	0.993	0.004	370	1	1	369.5	0.997	0.003
4- 5 YR	447	1	1	446.5	0.991	0.004	426	1	1	425.5	0.991	0.005	368	2	0	368.0	0.992	0.005
5- 6 YR	445	1	2	444.0	0.989	0.005	424	1	2	423.0	0.988	0.005	366	0	2	365.0	0.992	0.005
6- 7 YR	442	1	2	441.0	0.987	0.005	421	2	1	420.5	0.984	0.006	364	4	3	362.5	0.981	0.007
7- 8 YR	439	0	3	437.5	0.987	0.005	418	1	3	416.5	0.981	0.007	357	1	1	356.5	0.978	0.008
8- 9 YR	436	2	1	435.5	0.982	0.006	414	4	2	413.0	0.972	0.008	355	1	3	353.5	0.975	0.008
9-10 YR	433	1	2	432.0	0.980	0.007	408	1	3	406.5	0.969	0.008	351	5	1	350.5	0.961	0.010
10-11 YR	430	2	0	430.0	0.975	0.007	404	1	2	403.0	0.967	0.009	345	2	5	342.5	0.956	0.011
11-12 YR	428	0	3	426.5	0.975	0.007	401	4	2	400.0	0.957	0.010	338	1	1	337.5	0.953	0.011
12-13 YR	425	0	2	424.0	0.975	0.007	395	2	5	392.5	0.952	0.010	336	4	3	334.5	0.942	0.012
13-14 YR	423	0	2	422.0	0.975	0.007	388	3	1	387.5	0.945	0.011	329	9	2	328.0	0.916	0.015
14-15 YR	421	2	2	420.0	0.971	0.008	384	6	1	383.5	0.930	0.012	318	4	3	316.5	0.904	0.016
15-16 YR	417	3	2	416.0	0.964	0.009	377	3	5	374.5	0.923	0.013	311	8	4	309.0	0.881	0.017
16-17 YR	412	4	3	410.5	0.954	0.010	369	3	3	367.5	0.915	0.014	299	1	1	298.5	0.878	0.017
17-18 YR	405	1	2	404.0	0.952	0.010	363	7	0	363.0	0.898	0.015	297	7	4	295.0	0.857	0.019
18-19 YR	402	3	4	400.0	0.945	0.011	356	3	7	352.5	0.890	0.015	286	9	6	283.0	0.830	0.020
19-20 YR	395	3	185	302.5	0.935	0.012	346	5	164	264.0	0.873	0.017	271	6	130	206.0	0.806	0.022
20-21 YR	207	0	206	104.0	0.935	0.012	177	0	177	88.5	0.873	0.017	135	0	133	68.5	0.806	0.022
21-22 YR	1	0	1	0.5	0.935	0.012	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.806	0.022

TABLE IV-4 (MEN)

LIFE TABLE FOR CORONARY HEART DISEASE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	381	1	1	380.5	0.997	0.003	439	0	0	439.0	1.000	0.0	419	0	1	418.5	1.000	0.0
1- 2 YR	379	2	0	379.0	0.992	0.005	439	1	0	439.0	0.998	0.002	418	1	1	417.5	0.998	0.002
2- 3 YR	377	0	0	377.0	0.992	0.005	438	1	1	437.5	0.995	0.003	416	2	0	416.0	0.993	0.004
3- 4 YR	377	1	0	377.0	0.989	0.005	436	3	1	435.5	0.989	0.005	414	2	1	413.5	0.988	0.005
4- 5 YR	376	0	2	375.0	0.989	0.005	432	2	1	431.5	0.984	0.006	411	4	1	410.5	0.978	0.007
5- 6 YR	374	1	0	374.0	0.987	0.006	429	4	1	428.5	0.975	0.007	406	5	0	406.0	0.966	0.009
6- 7 YR	373	0	1	372.5	0.987	0.006	424	0	1	423.5	0.975	0.007	401	5	3	399.5	0.954	0.010
7- 8 YR	372	1	1	371.5	0.984	0.006	423	3	1	422.5	0.968	0.008	393	2	0	393.0	0.949	0.011
8- 9 YR	370	2	0	370.0	0.979	0.007	419	4	0	419.0	0.959	0.010	391	1	0	391.0	0.947	0.011
9-10 YR	368	2	1	367.5	0.974	0.008	415	3	0	415.0	0.952	0.010	390	7	4	388.0	0.930	0.013
10-11 YR	365	1	1	364.5	0.971	0.009	412	5	3	410.5	0.940	0.011	379	6	3	377.5	0.915	0.014
11-12 YR	363	2	0	363.0	0.966	0.009	404	1	2	403.0	0.938	0.012	370	4	2	369.0	0.905	0.014
12-13 YR	361	5	0	361.0	0.952	0.011	401	2	2	400.0	0.933	0.012	364	9	2	363.0	0.883	0.016
13-14 YR	356	2	0	356.0	0.947	0.012	397	2	0	397.0	0.928	0.012	353	8	3	351.5	0.863	0.017
14-15 YR	354	3	0	354.0	0.939	0.012	395	3	3	393.5	0.921	0.013	342	9	5	339.5	0.840	0.018
15-16 YR	351	1	1	350.5	0.936	0.013	389	2	4	387.0	0.917	0.013	328	4	3	326.5	0.829	0.019
16-17 YR	349	4	2	348.0	0.925	0.014	383	7	0	383.0	0.900	0.015	321	8	2	320.0	0.809	0.020
17-18 YR	343	1	0	343.0	0.923	0.014	376	4	4	374.0	0.890	0.015	311	5	4	309.0	0.796	0.020
18-19 YR	342	2	3	340.5	0.917	0.014	368	7	5	365.5	0.873	0.016	302	10	2	301.0	0.769	0.021
19-20 YR	337	5	178	248.0	0.899	0.016	356	6	206	253.0	0.852	0.018	290	7	139	220.5	0.745	0.022
20-21 YR	154	0	154	77.0	0.899	0.016	144	0	143	72.5	0.852	0.018	144	0	144	72.0	0.745	0.022
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.852	0.018	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	351	2	2	350.0	0.994	0.004	354	4	2	353.0	0.989	0.006	266	6	1	265.5	0.977	0.009
1- 2 YR	347	1	0	347.0	0.991	0.005	348	5	3	346.5	0.974	0.008	259	6	2	258.0	0.955	0.013
2- 3 YR	346	1	2	345.0	0.989	0.006	340	4	2	339.0	0.963	0.010	251	6	4	249.0	0.932	0.016
3- 4 YR	343	3	3	341.5	0.980	0.008	334	5	2	333.0	0.948	0.012	241	5	4	239.0	0.912	0.017
4- 5 YR	337	3	1	336.5	0.971	0.009	327	5	2	326.0	0.934	0.013	232	12	1	231.5	0.865	0.021
5- 6 YR	333	4	2	332.0	0.959	0.011	320	5	4	318.0	0.919	0.015	219	6	0	219.0	0.841	0.023
6- 7 YR	327	9	2	326.0	0.933	0.014	311	4	1	310.5	0.907	0.016	213	1	3	211.5	0.837	0.023
7- 8 YR	316	7	3	314.5	0.912	0.015	306	3	7	302.5	0.898	0.016	209	4	4	207.0	0.821	0.024
8- 9 YR	306	6	2	305.0	0.894	0.017	296	8	0	296.0	0.874	0.018	201	2	6	198.0	0.813	0.024
9-10 YR	298	8	1	297.5	0.870	0.018	288	7	0	288.0	0.853	0.019	193	2	5	190.5	0.804	0.025
10-11 YR	289	4	0	289.0	0.858	0.019	281	6	3	279.5	0.835	0.020	186	7	3	184.5	0.774	0.026
11-12 YR	285	5	4	283.0	0.843	0.020	272	6	5	269.5	0.816	0.021	176	2	3	174.5	0.765	0.027
12-13 YR	276	6	1	275.5	0.825	0.021	261	6	9	256.5	0.797	0.022	171	4	2	170.0	0.747	0.028
13-14 YR	269	2	6	266.0	0.818	0.021	246	9	4	244.0	0.767	0.023	165	3	2	164.0	0.733	0.028
14-15 YR	261	6	2	260.0	0.800	0.022	233	8	1	232.5	0.741	0.024	160	3	4	158.0	0.719	0.029
15-16 YR	253	4	3	251.5	0.787	0.022	224	2	3	222.5	0.734	0.025	153	2	5	150.5	0.710	0.029
16-17 YR	246	1	2	245.0	0.784	0.023	219	5	3	217.5	0.718	0.025	146	5	2	145.0	0.685	0.030
17-18 YR	243	5	3	241.5	0.767	0.023	211	5	4	209.0	0.700	0.026	139	1	6	136.0	0.680	0.030
18-19 YR	235	4	3	233.5	0.754	0.024	202	2	4	200.0	0.693	0.026	132	8	4	130.0	0.638	0.032
19-20 YR	228	5	119	168.5	0.732	0.025	196	4	96	148.0	0.675	0.027	120	1	63	88.5	0.631	0.032
20-21 YR	104	0	104	52.0	0.732	0.025	96	0	96	48.0	0.675	0.027	56	0	56	28.0	0.631	0.032
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-4 (WOMEN)

LIFE TABLE FOR CORONARY HEART DISEASE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	583	0	1	582.5	1.000	0.0	508	0	0	508.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	582	0	1	581.5	1.000	0.0	508	0	0	508.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	581	0	1	580.5	1.000	0.0	508	0	0	508.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	580	0	0	580.0	1.000	0.0	508	1	1	507.5	0.998	0.002
4- 5 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	506	1	2	505.0	0.996	0.003
5- 6 YR	441	0	0	441.0	1.000	0.0	579	0	1	578.5	1.000	0.0	503	3	1	502.5	0.990	0.004
6- 7 YR	441	0	2	440.0	1.000	0.0	578	2	1	577.5	0.997	0.002	499	0	2	498.0	0.990	0.004
7- 8 YR	439	0	1	438.5	1.000	0.0	575	0	0	575.0	0.997	0.002	497	0	1	496.5	0.990	0.004
8- 9 YR	438	0	0	438.0	1.000	0.0	575	0	1	574.5	0.997	0.002	496	2	2	495.0	0.986	0.005
9-10 YR	438	2	2	437.0	0.995	0.003	574	0	2	573.0	0.997	0.002	492	2	2	491.0	0.982	0.006
10-11 YR	434	2	1	433.5	0.991	0.005	572	0	3	570.5	0.997	0.002	488	0	3	486.5	0.982	0.006
11-12 YR	431	0	2	430.0	0.991	0.005	569	0	3	567.5	0.997	0.002	485	1	3	483.5	0.980	0.006
12-13 YR	429	1	0	429.0	0.989	0.005	566	1	4	564.0	0.995	0.003	481	1	2	480.0	0.978	0.007
13-14 YR	428	1	0	428.0	0.986	0.006	561	1	5	558.5	0.993	0.003	478	1	6	475.0	0.976	0.007
14-15 YR	427	1	0	427.0	0.984	0.006	555	4	2	554.0	0.986	0.005	471	0	2	470.0	0.976	0.007
15-16 YR	426	0	0	426.0	0.984	0.006	549	1	5	546.5	0.984	0.005	469	5	2	468.0	0.966	0.008
16-17 YR	426	0	1	425.5	0.984	0.006	543	2	3	541.5	0.980	0.006	462	4	2	461.0	0.957	0.009
17-18 YR	425	4	3	423.5	0.975	0.008	538	3	1	537.5	0.975	0.007	456	7	5	453.5	0.942	0.011
18-19 YR	418	2	4	416.0	0.970	0.008	534	2	4	532.0	0.971	0.007	444	3	3	442.5	0.936	0.011
19-20 YR	412	3	199	312.5	0.961	0.010	528	1	265	395.5	0.969	0.007	438	5	217	329.5	0.922	0.013
20-21 YR	210	0	210	105.0	0.961	0.010	262	0	261	131.5	0.969	0.007	216	0	215	108.5	0.922	0.013
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.969	0.007	1	0	1	0.5	0.922	0.013

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	446	1	0	446.0	0.998	0.002	424	0	3	422.5	1.000	0.0	363	4	0	363.0	0.989	0.005
1- 2 YR	445	4	1	444.5	0.989	0.005	421	4	0	421.0	0.990	0.005	359	3	1	358.5	0.981	0.007
2- 3 YR	440	1	0	440.0	0.987	0.005	417	1	2	416.0	0.988	0.005	355	3	0	355.0	0.972	0.009
3- 4 YR	439	2	3	437.5	0.982	0.006	414	4	1	413.5	0.979	0.007	352	8	1	351.5	0.950	0.011
4- 5 YR	434	2	2	433.0	0.977	0.007	409	3	2	408.0	0.971	0.008	343	1	1	342.5	0.948	0.012
5- 6 YR	430	4	1	429.5	0.968	0.008	404	2	3	402.5	0.967	0.009	341	7	2	340.0	0.928	0.014
6- 7 YR	425	0	3	423.5	0.968	0.008	399	1	2	398.0	0.964	0.009	332	6	4	330.0	0.911	0.015
7- 8 YR	422	1	3	420.5	0.966	0.009	396	3	4	394.0	0.957	0.010	322	5	1	321.5	0.897	0.016
8- 9 YR	418	4	1	417.5	0.957	0.010	389	3	4	387.0	0.949	0.011	316	5	3	314.5	0.883	0.017
9-10 YR	413	4	1	412.5	0.948	0.011	382	5	4	380.0	0.937	0.012	308	2	2	307.0	0.877	0.017
10-11 YR	408	4	1	407.5	0.938	0.012	373	4	3	371.5	0.927	0.013	304	2	5	301.5	0.871	0.018
11-12 YR	403	1	3	401.5	0.936	0.012	366	7	4	364.0	0.909	0.014	297	5	1	296.5	0.856	0.019
12-13 YR	399	2	2	398.0	0.931	0.012	355	4	5	352.5	0.899	0.015	291	5	3	289.5	0.842	0.019
13-14 YR	395	3	2	394.0	0.924	0.013	346	5	2	345.0	0.886	0.016	283	10	5	280.5	0.812	0.021
14-15 YR	390	2	3	388.5	0.919	0.013	339	10	3	337.5	0.859	0.017	268	3	5	265.5	0.802	0.021
15-16 YR	385	6	3	383.5	0.905	0.014	326	2	6	323.0	0.854	0.018	260	0	8	256.0	0.802	0.021
16-17 YR	376	6	6	373.0	0.890	0.015	318	3	3	316.5	0.846	0.018	252	5	2	251.0	0.786	0.022
17-18 YR	364	2	2	363.0	0.886	0.015	312	7	2	311.0	0.827	0.019	245	4	7	241.5	0.773	0.023
18-19 YR	360	6	5	357.5	0.871	0.016	303	3	8	299.0	0.819	0.020	234	6	9	229.5	0.753	0.024
19-20 YR	349	4	164	267.0	0.858	0.017	292	7	138	223.0	0.793	0.021	219	4	111	163.5	0.735	0.025
20-21 YR	181	0	181	90.5	0.858	0.017	147	0	147	73.5	0.793	0.021	104	0	102	53.0	0.735	0.025
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.735	0.025

TABLE IV-5 (MEN)

LIFE TABLE FOR CORONARY ATTACK IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	1	1	383.5	0.997	0.003	442	0	0	442.0	1.000	0.0	420	0	1	419.5	1.000	0.0
1- 2 YR	382	2	0	382.0	0.992	0.005	442	1	0	442.0	0.998	0.002	419	0	1	418.5	1.000	0.0
2- 3 YR	380	0	0	380.0	0.992	0.005	441	1	1	440.5	0.995	0.003	418	2	0	418.0	0.995	0.003
3- 4 YR	380	0	0	380.0	0.992	0.005	439	3	1	438.5	0.989	0.005	416	2	1	415.5	0.990	0.005
4- 5 YR	380	1	2	379.0	0.990	0.005	435	2	1	434.5	0.984	0.006	413	2	1	412.5	0.986	0.006
5- 6 YR	377	1	0	377.0	0.987	0.006	432	3	1	431.5	0.977	0.007	410	4	0	410.0	0.976	0.007
6- 7 YR	376	0	1	375.5	0.987	0.006	428	0	1	427.5	0.977	0.007	406	3	3	404.5	0.969	0.009
7- 8 YR	375	1	1	374.5	0.984	0.006	427	1	1	426.5	0.975	0.007	400	2	0	400.0	0.964	0.009
8- 9 YR	373	1	0	373.0	0.982	0.007	425	3	0	425.0	0.968	0.008	398	0	0	398.0	0.964	0.009
9-10 YR	372	3	1	371.5	0.974	0.008	422	2	0	422.0	0.964	0.009	398	6	4	396.0	0.949	0.011
10-11 YR	368	1	1	367.5	0.971	0.009	420	5	3	418.5	0.952	0.010	388	4	3	386.5	0.939	0.012
11-12 YR	366	2	0	366.0	0.966	0.009	412	1	2	411.0	0.950	0.010	381	4	2	380.0	0.930	0.013
12-13 YR	364	5	0	364.0	0.953	0.011	409	2	3	407.5	0.945	0.011	375	6	2	374.0	0.915	0.014
13-14 YR	359	2	0	359.0	0.947	0.011	404	3	0	404.0	0.938	0.012	367	8	3	365.5	0.895	0.015
14-15 YR	357	1	0	357.0	0.945	0.012	401	2	3	399.5	0.933	0.012	356	4	5	353.5	0.885	0.016
15-16 YR	356	1	1	355.5	0.942	0.012	396	2	4	394.0	0.929	0.012	347	1	3	345.5	0.882	0.016
16-17 YR	354	4	2	353.0	0.931	0.013	390	5	0	390.0	0.917	0.013	343	4	2	342.0	0.872	0.017
17-18 YR	348	1	0	348.0	0.929	0.013	385	3	4	383.0	0.909	0.014	337	6	6	334.0	0.856	0.018
18-19 YR	347	2	3	345.5	0.923	0.014	378	6	5	375.5	0.895	0.015	325	8	3	323.5	0.835	0.019
19-20 YR	342	4	182	251.0	0.908	0.015	367	5	214	260.0	0.878	0.016	314	5	153	237.5	0.817	0.020
20-21 YR	156	0	156	78.0	0.908	0.015	148	0	147	74.5	0.878	0.016	156	0	156	78.0	0.817	0.020
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.878	0.016	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	356	2	2	355.0	0.994	0.004	367	2	2	366.0	0.995	0.004	274	2	1	273.5	0.993	0.005
1- 2 YR	352	1	0	352.0	0.992	0.005	363	3	3	361.5	0.986	0.006	271	3	2	270.0	0.982	0.008
2- 3 YR	351	1	2	350.0	0.989	0.006	357	4	2	356.0	0.975	0.008	266	8	5	263.5	0.952	0.013
3- 4 YR	348	1	3	346.5	0.986	0.006	351	5	3	349.5	0.961	0.010	253	2	4	251.0	0.944	0.014
4- 5 YR	344	3	1	343.5	0.977	0.008	343	1	2	342.0	0.958	0.011	247	11	1	246.5	0.902	0.018
5- 6 YR	340	3	2	339.0	0.969	0.009	340	7	4	338.0	0.939	0.013	235	5	0	235.0	0.883	0.020
6- 7 YR	335	8	2	334.0	0.945	0.012	329	3	1	328.5	0.930	0.014	230	4	3	228.5	0.867	0.021
7- 8 YR	325	6	3	323.5	0.928	0.014	325	2	7	321.5	0.924	0.014	223	3	5	220.5	0.856	0.022
8- 9 YR	316	4	2	315.0	0.916	0.015	316	7	0	316.0	0.904	0.016	215	3	7	211.5	0.844	0.022
9-10 YR	310	6	1	309.5	0.898	0.016	309	7	0	309.0	0.883	0.017	205	2	5	202.5	0.835	0.023
10-11 YR	303	3	0	303.0	0.889	0.017	302	5	4	300.0	0.869	0.018	198	7	3	196.5	0.805	0.025
11-12 YR	300	5	4	298.0	0.875	0.018	293	8	6	290.0	0.845	0.019	188	0	3	186.5	0.805	0.025
12-13 YR	291	7	1	290.5	0.853	0.019	279	3	9	274.5	0.835	0.020	185	5	2	184.0	0.784	0.026
13-14 YR	283	1	6	280.0	0.850	0.019	267	5	4	265.0	0.820	0.021	178	2	4	176.0	0.775	0.026
14-15 YR	276	3	2	275.0	0.841	0.020	258	4	2	257.0	0.807	0.021	172	4	4	170.0	0.756	0.027
15-16 YR	271	4	3	269.5	0.829	0.021	252	2	3	250.5	0.800	0.022	164	4	5	161.5	0.738	0.028
16-17 YR	264	0	2	263.0	0.829	0.021	247	7	3	245.5	0.778	0.023	155	3	2	154.0	0.723	0.029
17-18 YR	262	4	4	260.0	0.816	0.021	237	5	4	235.0	0.761	0.023	150	1	7	146.5	0.718	0.029
18-19 YR	254	2	3	252.5	0.809	0.021	228	3	4	226.0	0.751	0.024	142	9	4	140.0	0.672	0.031
19-20 YR	249	4	130	184.0	0.792	0.023	221	5	109	166.5	0.728	0.025	129	0	70	94.0	0.672	0.031
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	0.728	0.025	59	0	59	29.5	0.672	0.031

TABLE IV-5 (WOMEN)

LIFE TABLE FOR CORONARY ATTACK IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	0	1	583.5	1.000	0.0	511	0	0	511.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	583	0	1	582.5	1.000	0.0	511	0	0	511.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	582	0	1	581.5	1.000	0.0	511	0	0	511.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	581	0	0	581.0	1.000	0.0	511	0	1	510.5	1.000	0.0
4- 5 YR	441	0	0	441.0	1.000	0.0	581	0	1	580.5	1.000	0.0	510	1	2	509.0	0.998	0.002
5- 6 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	507	2	1	506.5	0.994	0.003
6- 7 YR	441	0	2	440.0	1.000	0.0	579	0	1	578.5	1.000	0.0	504	0	2	503.0	0.994	0.003
7- 8 YR	439	0	1	438.5	1.000	0.0	578	0	0	578.0	1.000	0.0	502	0	1	501.5	0.994	0.003
8- 9 YR	438	0	0	438.0	1.000	0.0	578	0	1	577.5	1.000	0.0	501	2	2	500.0	0.990	0.004
9-10 YR	438	1	2	437.0	0.998	0.002	577	0	2	576.0	1.000	0.0	497	2	2	496.0	0.986	0.005
10-11 YR	435	1	1	434.5	0.995	0.003	575	0	3	573.5	1.000	0.0	493	0	3	491.5	0.986	0.005
11-12 YR	433	0	2	432.0	0.995	0.003	572	0	3	570.5	1.000	0.0	490	1	3	488.5	0.984	0.006
12-13 YR	431	1	0	431.0	0.993	0.004	569	1	4	567.0	0.998	0.002	486	0	2	485.0	0.984	0.006
13-14 YR	430	0	0	430.0	0.993	0.004	564	2	5	561.5	0.995	0.003	484	0	6	481.0	0.984	0.006
14-15 YR	430	0	0	430.0	0.993	0.004	557	1	2	556.0	0.993	0.004	478	0	2	477.0	0.984	0.006
15-16 YR	430	0	0	430.0	0.993	0.004	554	1	5	551.5	0.991	0.004	476	4	2	475.0	0.976	0.007
16-17 YR	430	0	2	429.0	0.993	0.004	548	1	3	546.5	0.989	0.004	470	2	2	469.0	0.972	0.007
17-18 YR	428	1	3	426.5	0.991	0.005	544	2	1	543.5	0.986	0.005	466	2	5	463.5	0.967	0.008
18-19 YR	424	0	4	422.0	0.991	0.005	541	3	4	539.0	0.980	0.006	459	0	3	457.5	0.967	0.008
19-20 YR	420	2	203	318.5	0.985	0.006	534	1	269	399.5	0.978	0.006	456	2	224	344.0	0.962	0.009
20-21 YR	215	0	215	107.5	0.985	0.006	264	0	263	132.5	0.978	0.006	230	0	229	115.5	0.962	0.009
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.978	0.006	1	0	1	0.5	0.962	0.009

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	450	1	0	450.0	0.998	0.002	431	0	3	429.5	1.000	0.0	372	0	1	371.5	1.000	0.0
1- 2 YR	449	1	1	448.5	0.996	0.003	428	0	0	428.0	1.000	0.0	371	0	1	370.5	1.000	0.0
2- 3 YR	447	0	0	447.0	0.996	0.003	428	1	2	427.0	0.998	0.002	370	1	0	370.0	0.997	0.003
3- 4 YR	447	0	3	445.5	0.996	0.003	425	0	1	424.5	0.998	0.002	369	4	1	368.5	0.986	0.006
4- 5 YR	444	0	2	443.0	0.996	0.003	424	1	2	423.0	0.995	0.003	364	1	1	363.5	0.984	0.007
5- 6 YR	442	3	2	441.0	0.989	0.005	421	1	3	419.5	0.993	0.004	362	4	2	361.0	0.973	0.008
6- 7 YR	437	0	3	435.5	0.989	0.005	417	0	3	415.5	0.993	0.004	356	3	4	354.0	0.965	0.010
7- 8 YR	434	0	3	432.5	0.989	0.005	414	0	4	412.0	0.993	0.004	349	5	1	348.5	0.951	0.011
8- 9 YR	431	1	1	430.5	0.986	0.005	410	4	4	408.0	0.983	0.006	343	5	3	341.5	0.937	0.013
9-10 YR	429	2	2	428.0	0.982	0.006	402	2	4	400.0	0.978	0.007	335	1	4	333.0	0.934	0.013
10-11 YR	425	2	1	424.5	0.977	0.007	396	1	3	394.5	0.976	0.008	330	1	6	327.0	0.931	0.013
11-12 YR	422	0	3	420.5	0.977	0.007	392	5	4	390.0	0.963	0.009	323	0	2	322.0	0.931	0.013
12-13 YR	419	2	2	418.0	0.973	0.008	383	3	6	380.0	0.956	0.010	321	3	3	319.5	0.922	0.014
13-14 YR	415	1	2	414.0	0.970	0.008	374	5	2	373.0	0.943	0.012	315	8	6	312.0	0.899	0.016
14-15 YR	412	2	3	410.5	0.965	0.009	367	7	3	365.5	0.925	0.013	301	3	6	298.0	0.890	0.017
15-16 YR	407	5	3	405.5	0.954	0.010	357	2	7	353.5	0.920	0.014	292	0	11	286.5	0.890	0.017
16-17 YR	399	2	6	396.0	0.949	0.011	348	4	3	346.5	0.909	0.014	281	3	2	280.0	0.880	0.017
17-18 YR	391	0	2	390.0	0.949	0.011	341	5	2	340.0	0.896	0.015	276	2	7	272.5	0.874	0.018
18-19 YR	389	3	5	386.5	0.941	0.011	334	2	9	329.5	0.890	0.016	267	7	10	262.0	0.850	0.019
19-20 YR	381	2	181	290.5	0.935	0.012	323	5	156	245.0	0.872	0.017	250	2	126	187.0	0.841	0.020
20-21 YR	198	0	197	99.5	0.935	0.012	162	0	162	81.0	0.872	0.017	122	0	120	62.0	0.841	0.020
21-22 YR	1	0	1	0.5	0.935	0.012	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.841	0.020

TABLE IV-6 (MEN)

LIFE TABLE FOR ANGINA PECTORIS IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	383	0	1	382.5	1.000	0.0	442	1	0	442.0	0.998	0.002	421	0	1	420.5	1.000	0.0
1- 2 YR	382	0	1	381.5	1.000	0.0	441	2	0	441.0	0.993	0.004	420	1	1	419.5	0.998	0.002
2- 3 YR	381	0	0	381.0	1.000	0.0	439	0	1	438.5	0.993	0.004	418	2	0	418.0	0.993	0.004
3- 4 YR	381	1	1	380.5	0.997	0.003	438	0	2	437.0	0.993	0.004	416	1	1	415.5	0.990	0.005
4- 5 YR	379	0	2	378.0	0.997	0.003	436	1	1	435.5	0.991	0.005	414	2	2	413.0	0.986	0.006
5- 6 YR	377	0	0	377.0	0.997	0.003	434	2	3	432.5	0.986	0.006	410	4	0	410.0	0.976	0.007
6- 7 YR	377	0	1	376.5	0.997	0.003	429	1	1	428.5	0.984	0.006	406	4	5	403.5	0.966	0.009
7- 8 YR	376	1	1	375.5	0.995	0.004	427	4	2	426.0	0.975	0.008	397	1	1	396.5	0.964	0.009
8- 9 YR	374	2	0	374.0	0.989	0.005	421	1	0	421.0	0.972	0.008	395	1	0	395.0	0.961	0.009
9-10 YR	372	1	2	371.0	0.987	0.006	420	1	1	419.5	0.970	0.008	394	3	6	391.0	0.954	0.010
10-11 YR	369	1	1	368.5	0.984	0.006	418	4	3	416.5	0.961	0.009	385	3	4	383.0	0.947	0.011
11-12 YR	367	1	0	367.0	0.981	0.007	411	1	2	410.0	0.959	0.010	378	1	5	375.5	0.944	0.011
12-13 YR	366	1	0	366.0	0.979	0.007	408	1	2	407.0	0.956	0.010	372	5	3	370.5	0.931	0.013
13-14 YR	365	0	0	365.0	0.979	0.007	405	1	0	405.0	0.954	0.010	364	4	6	361.0	0.921	0.013
14-15 YR	365	2	0	365.0	0.973	0.008	404	1	4	402.0	0.951	0.010	354	5	6	351.0	0.908	0.014
15-16 YR	363	0	1	362.5	0.973	0.008	399	0	4	397.0	0.951	0.010	343	3	6	340.0	0.900	0.015
16-17 YR	362	1	6	359.0	0.971	0.009	395	4	4	393.0	0.942	0.011	334	7	4	332.0	0.881	0.016
17-18 YR	355	0	1	354.5	0.971	0.009	387	2	5	384.5	0.937	0.012	323	0	8	319.0	0.881	0.016
18-19 YR	354	1	3	352.5	0.968	0.009	380	1	5	377.5	0.934	0.012	315	2	8	311.0	0.875	0.017
19-20 YR	350	3	187	256.5	0.957	0.011	374	3	219	264.5	0.924	0.013	305	2	151	229.5	0.868	0.017
20-21 YR	160	1	159	80.5	0.945	0.016	152	0	151	76.5	0.924	0.013	152	0	152	76.0	0.868	0.017
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.924	0.013	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	355	1	3	353.5	0.997	0.003	362	2	2	361.0	0.994	0.004	272	4	3	270.5	0.985	0.007
1- 2 YR	351	1	0	351.0	0.994	0.004	358	3	4	356.0	0.986	0.006	265	5	2	264.0	0.967	0.011
2- 3 YR	350	0	2	349.0	0.994	0.004	351	2	4	349.0	0.980	0.007	258	5	5	255.5	0.948	0.014
3- 4 YR	348	2	3	346.5	0.989	0.006	345	3	5	342.5	0.972	0.009	248	7	4	246.0	0.921	0.017
4- 5 YR	343	2	2	342.0	0.983	0.007	337	4	3	335.5	0.960	0.010	237	5	1	236.5	0.901	0.018
5- 6 YR	339	3	2	338.0	0.974	0.009	330	2	4	328.0	0.954	0.011	231	4	2	230.0	0.886	0.020
6- 7 YR	334	7	4	332.0	0.954	0.011	324	4	4	322.0	0.943	0.012	225	0	3	223.5	0.886	0.020
7- 8 YR	323	5	7	319.5	0.939	0.013	316	3	10	311.0	0.933	0.013	222	4	7	218.5	0.869	0.021
8- 9 YR	311	4	3	309.5	0.926	0.014	303	4	4	301.0	0.921	0.015	211	1	7	207.5	0.865	0.021
9-10 YR	304	6	2	303.0	0.908	0.016	295	2	3	293.5	0.915	0.015	203	1	8	199.0	0.861	0.022
10-11 YR	296	2	0	296.0	0.902	0.016	290	3	4	288.0	0.905	0.016	194	3	4	192.0	0.847	0.023
11-12 YR	294	1	8	290.0	0.899	0.016	283	1	9	278.5	0.902	0.016	187	2	3	185.5	0.838	0.023
12-13 YR	285	2	3	283.5	0.893	0.017	273	4	10	268.0	0.889	0.017	182	0	4	180.0	0.838	0.023
13-14 YR	280	1	6	277.0	0.889	0.017	259	5	7	255.5	0.871	0.019	178	1	3	176.5	0.833	0.024
14-15 YR	273	3	3	271.5	0.880	0.018	247	6	4	245.0	0.850	0.020	174	1	5	171.5	0.829	0.024
15-16 YR	267	1	4	265.0	0.876	0.018	237	1	5	234.5	0.846	0.020	168	1	7	164.5	0.824	0.024
16-17 YR	262	1	2	261.0	0.873	0.018	231	1	7	227.5	0.842	0.021	160	4	4	158.0	0.803	0.026
17-18 YR	259	2	5	256.5	0.866	0.019	223	3	6	220.0	0.831	0.021	152	0	8	148.0	0.803	0.026
18-19 YR	252	3	4	250.0	0.856	0.020	214	0	7	210.5	0.831	0.021	144	1	11	138.5	0.797	0.026
19-20 YR	245	3	127	181.5	0.841	0.021	207	0	106	154.0	0.831	0.021	132	2	69	97.5	0.781	0.028
20-21 YR	115	0	115	57.5	0.841	0.021	101	0	101	50.5	0.831	0.021	61	0	61	30.5	0.781	0.028
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-6 (WOMEN)

LIFE TABLE FOR ANGINA PECTORIS IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	583	0	1	582.5	1.000	0.0	509	0	0	509.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	582	0	1	581.5	1.000	0.0	509	0	0	509.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	581	0	1	580.5	1.000	0.0	509	0	0	509.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	580	0	0	580.0	1.000	0.0	509	1	1	508.5	0.998	0.002
4- 5 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	507	1	2	506.0	0.996	0.003
5- 6 YR	441	0	0	441.0	1.000	0.0	579	0	1	578.5	1.000	0.0	504	1	1	503.5	0.994	0.003
6- 7 YR	441	0	2	440.0	1.000	0.0	578	2	1	577.5	0.997	0.002	502	0	2	501.0	0.994	0.003
7- 8 YR	439	0	1	438.5	1.000	0.0	575	0	0	575.0	0.997	0.002	500	0	1	499.5	0.994	0.003
8- 9 YR	438	0	0	438.0	1.000	0.0	575	0	1	574.5	0.997	0.002	499	1	3	497.5	0.992	0.004
9-10 YR	438	1	3	436.5	0.998	0.002	574	0	2	573.0	0.997	0.002	495	2	2	494.0	0.988	0.005
10-11 YR	434	1	1	433.5	0.995	0.003	572	0	3	570.5	0.997	0.002	491	0	3	489.5	0.988	0.005
11-12 YR	432	0	3	430.5	0.995	0.003	569	0	3	567.5	0.997	0.002	488	1	3	486.5	0.986	0.005
12-13 YR	429	0	0	429.0	0.995	0.003	566	0	4	564.0	0.997	0.002	484	1	2	483.0	0.984	0.006
13-14 YR	429	1	0	429.0	0.993	0.004	562	0	6	559.0	0.997	0.002	481	1	6	478.0	0.982	0.006
14-15 YR	428	1	0	428.0	0.991	0.005	556	3	3	554.5	0.991	0.004	474	0	2	473.0	0.982	0.006
15-16 YR	427	0	0	427.0	0.991	0.005	550	0	6	547.0	0.991	0.004	472	2	3	470.5	0.978	0.007
16-17 YR	427	0	1	426.5	0.991	0.005	544	1	3	542.5	0.989	0.004	467	2	3	465.5	0.974	0.007
17-18 YR	426	3	4	424.0	0.984	0.006	540	2	1	539.5	0.986	0.005	462	7	5	459.5	0.959	0.009
18-19 YR	419	2	4	417.0	0.979	0.007	537	0	4	535.0	0.986	0.005	450	4	3	448.5	0.950	0.010
19-20 YR	413	1	201	312.5	0.976	0.008	533	0	268	399.0	0.986	0.005	443	4	221	332.5	0.939	0.011
20-21 YR	211	0	211	105.5	0.976	0.008	265	0	264	133.0	0.986	0.005	218	0	217	109.5	0.939	0.011
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.986	0.005	1	0	1	0.5	0.939	0.011

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	450	1	0	450.0	0.998	0.002	427	0	3	425.5	1.000	0.0	365	4	1	364.5	0.989	0.005
1- 2 YR	449	3	1	448.5	0.991	0.004	424	4	0	424.0	0.991	0.005	360	3	1	359.5	0.981	0.007
2- 3 YR	445	1	0	445.0	0.989	0.005	420	1	2	419.0	0.988	0.005	356	2	0	356.0	0.975	0.008
3- 4 YR	444	2	3	442.5	0.984	0.006	417	4	1	416.5	0.979	0.007	354	5	2	353.0	0.961	0.010
4- 5 YR	439	2	2	438.0	0.980	0.007	412	2	2	411.0	0.974	0.008	347	0	2	346.0	0.961	0.010
5- 6 YR	435	2	2	434.0	0.975	0.007	408	1	3	406.5	0.972	0.008	345	3	2	344.0	0.953	0.011
6- 7 YR	431	0	3	429.5	0.975	0.007	404	1	2	403.0	0.969	0.008	340	4	6	337.0	0.942	0.012
7- 8 YR	428	2	3	426.5	0.971	0.008	401	3	4	399.0	0.962	0.009	330	3	2	329.0	0.933	0.013
8- 9 YR	423	3	1	422.5	0.964	0.009	394	1	5	391.5	0.959	0.010	325	4	3	323.5	0.922	0.014
9-10 YR	419	3	2	418.0	0.957	0.010	388	3	4	386.0	0.952	0.010	318	2	3	316.5	0.916	0.015
10-11 YR	414	3	2	413.0	0.950	0.010	381	3	3	379.5	0.944	0.011	313	2	6	310.0	0.910	0.015
11-12 YR	409	1	3	407.5	0.948	0.011	375	6	5	372.5	0.929	0.013	305	5	1	304.5	0.895	0.016
12-13 YR	405	1	2	404.0	0.945	0.011	364	3	6	361.0	0.921	0.013	299	4	5	296.5	0.883	0.017
13-14 YR	402	2	2	401.0	0.941	0.011	355	2	3	353.5	0.916	0.014	290	3	10	285.0	0.874	0.018
14-15 YR	398	2	3	396.5	0.936	0.012	350	6	7	346.5	0.900	0.015	277	1	6	274.0	0.870	0.018
15-16 YR	393	1	5	390.5	0.934	0.012	337	1	7	333.5	0.898	0.015	270	1	8	266.0	0.867	0.018
16-17 YR	387	6	7	383.5	0.919	0.013	329	1	5	326.5	0.895	0.015	261	2	2	260.0	0.860	0.019
17-18 YR	374	5	2	373.0	0.907	0.014	323	3	7	319.5	0.887	0.016	257	6	8	253.0	0.840	0.020
18-19 YR	367	3	7	363.5	0.899	0.015	313	1	9	308.5	0.884	0.016	243	3	12	237.0	0.829	0.021
19-20 YR	357	3	167	273.5	0.889	0.016	303	4	147	229.5	0.868	0.018	228	2	113	171.5	0.820	0.022
20-21 YR	187	0	187	93.5	0.889	0.016	152	0	152	76.0	0.868	0.018	113	0	111	57.5	0.820	0.022
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.820	0.022

TABLE IV-7 (MEN)

LIFE TABLE FOR MYOCARDIAL INFARCTION IN THE TOTAL FRAMINGHAM STUDY POPULATION
WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	1	1	383.5	0.997	0.003	442	0	0	442.0	1.000	0.0	421	0	1	420.5	1.000	0.0
1- 2 YR	382	1	1	381.5	0.995	0.004	442	1	0	442.0	0.998	0.002	420	1	1	419.5	0.998	0.002
2- 3 YR	380	0	0	380.0	0.995	0.004	441	1	1	440.5	0.995	0.003	418	2	0	418.0	0.993	0.004
3- 4 YR	380	0	0	380.0	0.995	0.004	439	2	2	438.0	0.991	0.005	416	1	1	415.5	0.990	0.005
4- 5 YR	380	1	2	379.0	0.992	0.005	435	1	1	434.5	0.989	0.005	414	0	2	413.0	0.990	0.005
5- 6 YR	377	0	0	377.0	0.992	0.005	433	1	2	432.0	0.986	0.006	412	4	0	412.0	0.981	0.007
6- 7 YR	377	0	1	376.5	0.992	0.005	430	0	1	429.5	0.986	0.006	408	1	5	405.5	0.978	0.007
7- 8 YR	376	1	1	375.5	0.990	0.005	429	0	2	428.0	0.986	0.006	402	2	0	402.0	0.974	0.008
8- 9 YR	374	0	0	374.0	0.990	0.005	427	3	0	427.0	0.979	0.007	400	0	0	400.0	0.974	0.008
9-10 YR	374	1	2	373.0	0.987	0.006	424	1	1	423.5	0.977	0.007	400	3	6	397.0	0.966	0.009
10-11 YR	371	0	1	370.5	0.987	0.006	422	4	3	420.5	0.968	0.008	391	3	4	389.0	0.959	0.010
11-12 YR	370	2	0	370.0	0.982	0.007	415	1	2	414.0	0.965	0.009	384	4	2	383.0	0.949	0.011
12-13 YR	368	6	0	368.0	0.966	0.009	412	2	3	410.5	0.961	0.009	378	7	2	377.0	0.931	0.013
13-14 YR	362	2	0	362.0	0.960	0.010	407	3	0	407.0	0.954	0.010	369	3	6	366.0	0.923	0.013
14-15 YR	360	1	0	360.0	0.958	0.010	404	1	3	402.5	0.951	0.010	360	3	6	357.0	0.916	0.014
15-16 YR	359	2	1	358.5	0.952	0.011	400	1	4	398.0	0.949	0.011	351	1	3	349.5	0.913	0.014
16-17 YR	356	1	5	353.5	0.949	0.011	395	1	3	393.5	0.947	0.011	347	4	2	346.0	0.903	0.015
17-18 YR	350	1	0	350.0	0.947	0.012	391	2	4	389.0	0.942	0.011	341	2	9	336.5	0.897	0.015
18-19 YR	349	2	3	347.5	0.941	0.012	385	4	5	382.5	0.932	0.012	330	5	7	326.5	0.883	0.016
19-20 YR	344	4	183	252.5	0.926	0.014	376	5	218	267.0	0.914	0.014	318	4	158	239.0	0.869	0.018
20-21 YR	157	0	157	78.5	0.926	0.014	153	0	152	77.0	0.914	0.014	156	0	156	78.0	0.869	0.018
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.914	0.014	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	356	1	3	354.5	0.997	0.003	367	2	2	366.0	0.995	0.004	276	0	3	274.5	1.000	0.0
1- 2 YR	352	1	0	352.0	0.994	0.004	363	2	4	361.0	0.989	0.005	273	2	3	271.5	0.993	0.005
2- 3 YR	351	1	2	350.0	0.992	0.005	357	2	4	355.0	0.983	0.007	268	6	6	265.0	0.970	0.010
3- 4 YR	348	1	3	346.5	0.989	0.006	351	1	7	347.5	0.981	0.007	256	1	4	254.0	0.966	0.011
4- 5 YR	344	2	2	343.0	0.983	0.007	343	0	3	341.5	0.981	0.007	251	9	3	249.5	0.931	0.016
5- 6 YR	340	2	3	338.5	0.977	0.008	340	5	5	337.5	0.966	0.010	239	4	1	238.5	0.916	0.017
6- 7 YR	335	2	5	332.5	0.971	0.009	330	1	3	328.5	0.963	0.010	234	3	4	232.0	0.904	0.018
7- 8 YR	328	4	6	325.0	0.959	0.011	326	0	9	321.5	0.963	0.010	227	1	7	223.5	0.900	0.019
8- 9 YR	318	3	3	316.5	0.950	0.012	317	2	4	315.0	0.957	0.011	219	2	8	215.0	0.892	0.019
9-10 YR	312	3	3	310.5	0.941	0.013	311	4	2	310.0	0.945	0.012	209	1	7	205.5	0.887	0.020
10-11 YR	306	3	0	306.0	0.932	0.014	305	5	4	303.0	0.929	0.014	201	7	3	199.5	0.856	0.022
11-12 YR	303	2	7	299.5	0.926	0.014	296	6	8	292.0	0.910	0.016	191	0	3	189.5	0.856	0.022
12-13 YR	294	4	3	292.5	0.913	0.015	282	3	9	277.5	0.900	0.017	188	4	2	187.0	0.838	0.024
13-14 YR	287	1	6	284.0	0.910	0.016	270	4	6	267.0	0.887	0.018	182	1	6	179.0	0.833	0.024
14-15 YR	280	3	3	278.5	0.900	0.017	260	3	3	258.5	0.876	0.018	175	4	4	173.0	0.814	0.025
15-16 YR	274	3	4	272.0	0.890	0.017	254	1	4	252.0	0.873	0.019	167	4	5	164.5	0.794	0.027
16-17 YR	267	0	2	266.0	0.890	0.017	249	3	6	246.0	0.862	0.019	158	3	2	157.0	0.779	0.027
17-18 YR	265	1	7	261.5	0.887	0.018	240	3	5	237.5	0.851	0.020	153	2	7	149.5	0.768	0.028
18-19 YR	257	2	3	255.5	0.880	0.018	232	2	5	229.5	0.844	0.021	144	4	8	140.0	0.747	0.029
19-20 YR	252	4	131	186.5	0.861	0.020	225	4	113	168.5	0.824	0.022	132	0	73	95.5	0.747	0.029
20-21 YR	117	0	117	58.5	0.861	0.020	109	0	108	54.0	0.824	0.022	59	0	59	29.5	0.747	0.029
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-7 (WOMEN)

LIFE TABLE FOR MYOCARDIAL INFARCTION IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	0	1	583.5	1.000	0.0	511	0	0	511.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	583	0	1	582.5	1.000	0.0	511	0	0	511.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	582	0	1	581.5	1.000	0.0	511	0	0	511.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	581	0	0	581.0	1.000	0.0	511	0	1	510.5	1.000	0.0
4- 5 YR	441	0	0	441.0	1.000	0.0	581	0	1	580.5	1.000	0.0	510	1	2	509.0	0.998	0.002
5- 6 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	507	1	1	506.5	0.996	0.003
6- 7 YR	441	0	2	440.0	1.000	0.0	579	0	1	578.5	1.000	0.0	505	0	2	504.0	0.996	0.003
7- 8 YR	439	0	1	438.5	1.000	0.0	578	0	0	578.0	1.000	0.0	503	0	1	502.5	0.996	0.003
8- 9 YR	438	0	0	438.0	1.000	0.0	578	0	1	577.5	1.000	0.0	502	1	3	500.5	0.994	0.003
9-10 YR	438	1	2	437.0	0.998	0.002	577	0	2	576.0	1.000	0.0	498	1	2	497.0	0.992	0.004
10-11 YR	435	1	1	434.5	0.995	0.003	575	0	3	573.5	1.000	0.0	495	0	3	493.5	0.992	0.004
11-12 YR	433	0	2	432.0	0.995	0.003	572	0	3	570.5	1.000	0.0	492	1	3	490.5	0.990	0.004
12-13 YR	431	1	0	431.0	0.993	0.004	569	1	4	567.0	0.998	0.002	488	0	2	487.0	0.990	0.004
13-14 YR	430	0	0	430.0	0.993	0.004	564	2	5	561.5	0.995	0.003	486	0	6	483.0	0.990	0.004
14-15 YR	430	0	0	430.0	0.993	0.004	557	0	3	555.5	0.995	0.003	480	0	2	479.0	0.990	0.004
15-16 YR	430	0	0	430.0	0.993	0.004	554	0	6	551.0	0.995	0.003	478	2	3	476.5	0.986	0.005
16-17 YR	430	0	2	429.0	0.993	0.004	548	0	3	546.5	0.995	0.003	473	1	2	472.0	0.984	0.006
17-18 YR	428	0	4	426.0	0.993	0.004	545	2	1	544.5	0.991	0.004	470	1	6	467.0	0.982	0.006
18-19 YR	424	0	4	422.0	0.993	0.004	542	1	4	540.0	0.989	0.004	463	0	3	461.5	0.982	0.006
19-20 YR	420	2	203	318.5	0.987	0.006	537	0	273	400.5	0.989	0.004	460	0	227	346.5	0.982	0.006
20-21 YR	215	0	215	107.5	0.987	0.006	264	0	263	132.5	0.989	0.004	233	0	232	117.0	0.982	0.006
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.989	0.004	1	0	1	0.5	0.982	0.006

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	450	1	0	450.0	0.998	0.002	431	0	3	429.5	1.000	0.0	372	0	1	371.5	1.000	0.0
1- 2 YR	449	1	1	448.5	0.996	0.003	428	0	0	428.0	1.000	0.0	371	0	1	370.5	1.000	0.0
2- 3 YR	447	0	0	447.0	0.996	0.003	428	1	2	427.0	0.998	0.002	370	1	0	370.0	0.997	0.003
3- 4 YR	447	0	3	445.5	0.996	0.003	425	0	1	424.5	0.998	0.002	369	3	1	368.5	0.989	0.005
4- 5 YR	444	0	2	443.0	0.996	0.003	424	1	2	423.0	0.995	0.003	365	0	2	364.0	0.989	0.005
5- 6 YR	442	1	3	440.5	0.993	0.004	421	1	3	419.5	0.993	0.004	363	4	2	362.0	0.978	0.008
6- 7 YR	438	0	3	436.5	0.993	0.004	417	0	3	415.5	0.993	0.004	357	0	6	354.0	0.978	0.008
7- 8 YR	435	0	3	433.5	0.993	0.004	414	0	4	412.0	0.993	0.004	351	3	1	350.5	0.970	0.009
8- 9 YR	432	0	1	431.5	0.993	0.004	410	2	5	407.5	0.988	0.005	347	4	4	345.0	0.959	0.010
9-10 YR	431	0	3	429.5	0.993	0.004	403	1	4	401.0	0.986	0.006	339	1	4	337.0	0.956	0.011
10-11 YR	428	0	2	427.0	0.993	0.004	398	1	3	396.5	0.983	0.006	334	0	6	331.0	0.956	0.011
11-12 YR	426	0	3	424.5	0.993	0.004	394	1	5	391.5	0.981	0.007	328	1	2	327.0	0.953	0.011
12-13 YR	423	2	2	422.0	0.989	0.005	388	0	7	384.5	0.981	0.007	325	0	5	322.5	0.953	0.011
13-14 YR	419	1	2	418.0	0.986	0.006	381	3	3	379.5	0.973	0.008	320	5	8	316.0	0.938	0.013
14-15 YR	416	2	3	414.5	0.981	0.006	375	5	5	372.5	0.960	0.010	307	2	6	304.0	0.932	0.013
15-16 YR	411	1	5	408.5	0.979	0.007	365	1	8	361.0	0.957	0.010	299	0	11	293.5	0.932	0.013
16-17 YR	405	2	6	402.0	0.974	0.008	356	1	3	354.5	0.954	0.011	288	2	2	287.0	0.925	0.014
17-18 YR	397	0	2	396.0	0.974	0.008	352	4	3	350.5	0.944	0.012	284	1	8	280.0	0.922	0.014
18-19 YR	395	2	6	392.0	0.969	0.008	345	3	9	340.5	0.935	0.013	275	2	13	268.5	0.915	0.015
19-20 YR	387	1	184	295.0	0.966	0.009	333	5	158	254.0	0.917	0.015	260	1	133	193.5	0.910	0.016
20-21 YR	202	0	201	101.5	0.966	0.009	170	0	170	85.0	0.917	0.015	126	1	123	64.5	0.896	0.021
21-22 YR	1	0	1	0.5	0.966	0.009	0	0	0	0.0	0.0	0.0	2	0	2	1.0	0.896	0.021

TABLE IV-8 (MEN)

LIFE TABLE FOR CONGESTIVE HEART FAILURE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	384	1	0	384.0	0.997	0.003	443	0	0	443.0	1.000	0.0	422	0	1	421.5	1.000	0.0
1- 2 YR	383	0	1	382.5	0.997	0.003	443	0	0	443.0	1.000	0.0	421	0	1	420.5	1.000	0.0
2- 3 YR	382	0	0	382.0	0.997	0.003	443	1	1	442.5	0.998	0.002	420	0	0	420.0	1.000	0.0
3- 4 YR	382	0	1	381.5	0.997	0.003	441	0	2	440.0	0.998	0.002	420	0	1	419.5	1.000	0.0
4- 5 YR	381	0	2	380.0	0.997	0.003	439	0	1	438.5	0.998	0.002	419	1	2	418.0	0.998	0.002
5- 6 YR	379	0	0	379.0	0.997	0.003	438	0	3	436.5	0.998	0.002	416	0	0	416.0	0.998	0.002
6- 7 YR	379	1	0	379.0	0.995	0.004	435	0	1	434.5	0.998	0.002	416	0	4	414.0	0.998	0.002
7- 8 YR	378	0	1	377.5	0.995	0.004	434	0	2	433.0	0.998	0.002	412	0	2	411.0	0.998	0.002
8- 9 YR	377	0	0	377.0	0.995	0.004	432	0	0	432.0	0.998	0.002	410	1	1	409.5	0.995	0.003
9-10 YR	377	0	2	376.0	0.995	0.004	432	0	1	431.5	0.998	0.002	408	3	6	405.0	0.988	0.005
10-11 YR	375	0	1	374.5	0.995	0.004	431	1	3	429.5	0.995	0.003	399	0	4	397.0	0.988	0.005
11-12 YR	374	1	0	374.0	0.992	0.005	427	1	2	426.0	0.993	0.004	395	1	5	392.5	0.985	0.006
12-13 YR	373	0	2	372.0	0.992	0.005	424	0	3	422.5	0.993	0.004	389	0	3	387.5	0.985	0.006
13-14 YR	371	0	0	371.0	0.992	0.005	421	1	1	420.5	0.991	0.005	386	3	7	382.5	0.978	0.007
14-15 YR	371	0	0	371.0	0.992	0.005	419	1	3	417.5	0.988	0.005	376	1	5	373.5	0.975	0.008
15-16 YR	371	2	1	370.5	0.987	0.006	415	0	4	413.0	0.988	0.005	370	1	6	367.0	0.972	0.008
16-17 YR	368	1	3	366.5	0.984	0.006	411	1	6	408.0	0.986	0.006	363	2	2	362.0	0.967	0.009
17-18 YR	364	0	1	363.5	0.984	0.006	404	1	4	402.0	0.983	0.006	359	1	8	355.0	0.964	0.009
18-19 YR	363	0	3	361.5	0.984	0.006	399	1	5	396.5	0.981	0.007	350	0	11	344.5	0.964	0.009
19-20 YR	360	0	193	263.5	0.984	0.006	393	0	230	278.0	0.981	0.007	339	4	169	254.5	0.949	0.012
20-21 YR	167	0	167	83.5	0.984	0.006	163	0	162	82.0	0.981	0.007	166	0	166	83.0	0.949	0.012
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.981	0.007	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	357	0	3	355.5	1.000	0.0	372	0	2	371.0	1.000	0.0	276	0	3	274.5	1.000	0.0
1- 2 YR	354	0	0	354.0	1.000	0.0	370	3	3	368.5	0.992	0.005	273	0	3	271.5	1.000	0.0
2- 3 YR	354	0	3	352.5	1.000	0.0	364	2	5	361.5	0.986	0.006	270	1	6	267.0	0.996	0.004
3- 4 YR	351	1	2	350.0	0.997	0.003	357	0	6	354.0	0.986	0.006	263	2	5	260.5	0.989	0.007
4- 5 YR	348	1	2	347.0	0.994	0.004	351	0	3	349.5	0.986	0.006	256	0	3	254.5	0.989	0.007
5- 6 YR	345	2	3	343.5	0.988	0.006	348	6	5	345.5	0.969	0.009	253	5	1	252.5	0.969	0.011
6- 7 YR	340	0	4	338.0	0.988	0.006	337	2	3	335.5	0.963	0.010	247	1	5	244.5	0.965	0.011
7- 8 YR	336	1	7	332.5	0.986	0.006	332	2	6	329.0	0.958	0.011	241	1	7	237.5	0.961	0.012
8- 9 YR	328	1	3	326.5	0.982	0.007	324	0	3	322.5	0.958	0.011	233	2	8	229.0	0.953	0.013
9-10 YR	324	0	4	322.0	0.982	0.007	321	0	4	319.0	0.958	0.011	223	2	6	220.0	0.944	0.015
10-11 YR	320	1	1	319.5	0.979	0.008	317	0	8	313.0	0.958	0.011	215	2	4	213.0	0.935	0.016
11-12 YR	318	2	7	314.5	0.973	0.009	309	1	10	304.0	0.954	0.011	209	2	3	207.5	0.926	0.017
12-13 YR	309	0	4	307.0	0.973	0.009	298	2	9	293.5	0.948	0.012	204	1	5	201.5	0.921	0.017
13-14 YR	305	1	6	302.0	0.970	0.009	287	0	8	283.0	0.948	0.012	198	1	6	195.0	0.917	0.018
14-15 YR	298	1	3	296.5	0.967	0.010	279	1	6	276.0	0.945	0.012	191	2	4	189.0	0.907	0.019
15-16 YR	294	2	2	293.0	0.960	0.011	272	1	5	269.5	0.941	0.013	185	1	7	181.5	0.902	0.020
16-17 YR	290	2	2	289.0	0.953	0.012	266	1	7	262.5	0.937	0.013	177	1	5	174.5	0.897	0.020
17-18 YR	286	3	5	283.5	0.943	0.013	258	4	5	255.5	0.923	0.015	171	4	8	167.0	0.875	0.022
18-19 YR	278	4	3	276.5	0.930	0.014	249	6	6	246.0	0.900	0.017	159	4	8	155.0	0.853	0.024
19-20 YR	271	3	142	200.0	0.916	0.016	237	2	119	177.5	0.890	0.018	147	2	76	109.0	0.837	0.026
20-21 YR	126	0	126	63.0	0.916	0.016	116	0	116	58.0	0.890	0.018	69	0	69	34.5	0.837	0.026
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-8 (WOMEN)

LIFE TABLE FOR CONGESTIVE HEART FAILURE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	583	0	1	582.5	1.000	0.0	508	0	0	508.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	582	0	1	581.5	1.000	0.0	508	0	0	508.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	581	0	1	580.5	1.000	0.0	508	0	0	508.0	1.000	0.0
3- 4 YR	441	0	0	441.0	1.000	0.0	580	0	0	580.0	1.000	0.0	508	0	1	507.5	1.000	0.0
4- 5 YR	441	0	0	441.0	1.000	0.0	580	0	1	579.5	1.000	0.0	507	1	1	506.5	0.998	0.002
5- 6 YR	441	0	0	441.0	1.000	0.0	579	0	1	578.5	1.000	0.0	505	1	1	504.5	0.996	0.003
6- 7 YR	441	0	2	440.0	1.000	0.0	578	0	1	577.5	1.000	0.0	503	0	2	502.0	0.996	0.003
7- 8 YR	439	0	1	438.5	1.000	0.0	577	2	0	577.0	0.997	0.002	501	0	1	500.5	0.996	0.003
8- 9 YR	438	0	0	438.0	1.000	0.0	575	1	1	574.5	0.995	0.003	500	1	2	499.0	0.994	0.003
9-10 YR	438	0	3	436.5	1.000	0.0	573	0	2	572.0	0.995	0.003	497	0	2	496.0	0.994	0.003
10-11 YR	435	0	1	434.5	1.000	0.0	571	0	3	569.5	0.995	0.003	495	1	3	493.5	0.992	0.004
11-12 YR	434	0	3	432.5	1.000	0.0	568	1	3	566.5	0.993	0.003	491	0	3	489.5	0.992	0.004
12-13 YR	431	0	0	431.0	1.000	0.0	564	0	4	562.0	0.993	0.003	488	0	2	487.0	0.992	0.004
13-14 YR	431	0	0	431.0	1.000	0.0	560	0	5	557.5	0.993	0.003	486	1	6	483.0	0.990	0.004
14-15 YR	431	0	0	431.0	1.000	0.0	555	0	3	553.5	0.993	0.003	479	0	3	477.5	0.990	0.004
15-16 YR	431	0	0	431.0	1.000	0.0	552	2	5	549.5	0.989	0.004	476	1	3	474.5	0.988	0.005
16-17 YR	431	0	2	430.0	1.000	0.0	545	4	1	544.5	0.982	0.006	472	1	3	470.5	0.986	0.005
17-18 YR	429	0	4	427.0	1.000	0.0	540	0	1	539.5	0.982	0.006	468	1	5	465.5	0.984	0.006
18-19 YR	425	0	4	423.0	1.000	0.0	539	1	3	537.5	0.980	0.006	462	1	4	460.0	0.982	0.006
19-20 YR	421	2	204	319.0	0.994	0.004	535	0	271	399.5	0.980	0.006	457	0	224	345.0	0.982	0.006
20-21 YR	215	1	214	108.0	0.985	0.010	264	0	263	132.5	0.980	0.006	233	0	232	117.0	0.982	0.006
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.980	0.006	1	0	1	0.5	0.982	0.006

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	449	0	0	449.0	1.000	0.0	427	0	3	425.5	1.000	0.0	371	0	1	370.5	1.000	0.0
1- 2 YR	449	0	0	449.0	1.000	0.0	424	0	0	424.0	1.000	0.0	370	1	1	369.5	0.997	0.003
2- 3 YR	449	0	0	449.0	1.000	0.0	424	0	1	423.5	1.000	0.0	368	0	0	368.0	0.997	0.003
3- 4 YR	449	0	3	447.5	1.000	0.0	423	1	1	422.5	0.998	0.002	368	2	2	367.0	0.992	0.005
4- 5 YR	446	0	2	445.0	1.000	0.0	421	1	1	420.5	0.995	0.003	364	1	1	363.5	0.989	0.005
5- 6 YR	444	1	3	442.5	0.998	0.002	419	2	2	418.0	0.990	0.005	362	0	2	361.0	0.989	0.005
6- 7 YR	440	1	3	438.5	0.995	0.003	415	1	2	414.0	0.988	0.005	360	0	7	356.5	0.989	0.005
7- 8 YR	436	0	2	435.0	0.995	0.003	412	1	4	410.0	0.986	0.006	353	1	2	352.0	0.986	0.006
8- 9 YR	434	0	3	432.5	0.995	0.003	407	0	6	404.0	0.986	0.006	350	4	4	348.0	0.975	0.008
9-10 YR	431	1	3	429.5	0.993	0.004	401	2	3	399.5	0.981	0.007	342	1	5	339.5	0.972	0.009
10-11 YR	427	0	2	426.0	0.993	0.004	396	2	3	394.5	0.976	0.008	336	2	7	332.5	0.966	0.010
11-12 YR	425	1	3	423.5	0.991	0.005	391	3	3	389.5	0.968	0.009	327	1	0	327.0	0.963	0.010
12-13 YR	421	0	2	420.0	0.991	0.005	385	3	5	382.5	0.961	0.010	326	1	6	323.0	0.960	0.010
13-14 YR	419	1	2	418.0	0.988	0.005	377	3	4	375.0	0.953	0.011	319	2	7	315.5	0.954	0.011
14-15 YR	416	0	3	414.5	0.988	0.005	370	0	4	368.0	0.953	0.011	310	0	3	308.5	0.954	0.011
15-16 YR	413	3	5	410.5	0.981	0.007	366	4	6	363.0	0.942	0.012	307	2	9	302.5	0.948	0.012
16-17 YR	405	2	4	403.0	0.976	0.007	356	1	3	354.5	0.940	0.012	296	0	2	295.0	0.948	0.012
17-18 YR	399	3	3	397.5	0.969	0.008	352	5	4	350.0	0.926	0.013	294	8	7	290.5	0.922	0.015
18-19 YR	393	1	6	390.0	0.966	0.009	343	2	7	339.5	0.921	0.014	279	8	12	273.0	0.895	0.017
19-20 YR	386	2	182	295.0	0.960	0.010	334	5	157	255.5	0.903	0.016	259	2	130	194.0	0.886	0.018
20-21 YR	202	1	200	102.0	0.951	0.014	172	0	172	86.0	0.903	0.016	127	0	126	64.0	0.886	0.018
21-22 YR	1	0	1	0.5	0.951	0.014	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.886	0.018

TABLE IV-9 (MEN)

LIFE TABLE FOR CEREBROVASCULAR ACCIDENT IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	383	0	1	382.5	1.000	0.0	443	0	0	443.0	1.000	0.0	422	1	0	422.0	0.998	0.002
1- 2 YR	382	0	1	381.5	1.000	0.0	443	0	0	443.0	1.000	0.0	421	0	1	420.5	0.998	0.002
2- 3 YR	381	0	0	381.0	1.000	0.0	443	0	1	442.5	1.000	0.0	420	0	0	420.0	0.998	0.002
3- 4 YR	381	1	0	381.0	0.997	0.003	442	0	2	441.0	1.000	0.0	420	0	1	419.5	0.998	0.002
4- 5 YR	380	1	2	379.0	0.995	0.004	440	0	1	439.5	1.000	0.0	419	0	2	418.0	0.998	0.002
5- 6 YR	377	0	0	377.0	0.995	0.004	439	0	3	437.5	1.000	0.0	417	0	0	417.0	0.998	0.002
6- 7 YR	377	0	1	376.5	0.995	0.004	436	0	1	435.5	1.000	0.0	417	1	5	414.5	0.995	0.003
7- 8 YR	376	0	1	375.5	0.995	0.004	435	0	2	434.0	1.000	0.0	411	0	2	410.0	0.995	0.003
8- 9 YR	375	0	0	375.0	0.995	0.004	433	0	0	433.0	1.000	0.0	409	1	0	409.0	0.993	0.004
9-10 YR	375	0	2	374.0	0.995	0.004	433	1	1	432.5	0.998	0.002	408	1	7	404.5	0.990	0.005
10-11 YR	373	0	1	372.5	0.995	0.004	431	1	3	429.5	0.995	0.003	400	3	4	398.0	0.983	0.006
11-12 YR	372	0	0	372.0	0.995	0.004	427	2	2	426.0	0.991	0.005	393	0	6	390.0	0.983	0.006
12-13 YR	372	0	2	371.0	0.995	0.004	423	1	3	421.5	0.988	0.005	387	1	3	385.5	0.980	0.007
13-14 YR	370	0	0	370.0	0.995	0.004	419	0	1	418.5	0.988	0.005	383	2	6	380.0	0.975	0.008
14-15 YR	370	0	0	370.0	0.995	0.004	418	1	5	415.5	0.986	0.006	375	4	6	372.0	0.965	0.009
15-16 YR	370	0	1	369.5	0.995	0.004	412	0	4	410.0	0.986	0.006	365	1	6	362.0	0.962	0.010
16-17 YR	369	0	6	366.0	0.995	0.004	408	1	7	404.5	0.984	0.006	358	0	3	356.5	0.962	0.010
17-18 YR	363	1	1	362.5	0.992	0.005	400	1	4	398.0	0.981	0.007	355	0	10	350.0	0.962	0.010
18-19 YR	361	1	3	359.5	0.989	0.005	395	1	5	392.5	0.979	0.007	345	1	9	340.5	0.959	0.010
19-20 YR	357	1	191	261.5	0.985	0.007	389	0	227	275.5	0.979	0.007	335	1	169	250.5	0.955	0.011
20-21 YR	165	0	165	82.5	0.985	0.007	162	0	161	81.5	0.979	0.007	165	0	165	82.5	0.955	0.011
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.979	0.007	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	356	0	3	354.5	1.000	0.0	368	0	2	367.0	1.000	0.0	274	0	2	273.0	1.000	0.0
1- 2 YR	353	1	0	353.0	0.997	0.003	366	0	4	364.0	1.000	0.0	272	0	3	270.5	1.000	0.0
2- 3 YR	352	1	3	350.5	0.994	0.004	362	0	5	359.5	1.000	0.0	269	0	5	266.5	1.000	0.0
3- 4 YR	348	0	3	346.5	0.994	0.004	357	1	9	352.5	0.997	0.003	264	1	3	262.5	0.996	0.004
4- 5 YR	345	1	2	344.0	0.991	0.005	347	2	3	345.5	0.991	0.005	260	0	3	258.5	0.996	0.004
5- 6 YR	342	2	2	341.0	0.986	0.006	342	3	5	339.5	0.983	0.007	257	2	3	255.5	0.988	0.007
6- 7 YR	338	0	5	335.5	0.986	0.006	334	0	2	333.0	0.983	0.007	252	0	3	250.5	0.988	0.007
7- 8 YR	333	2	6	330.0	0.980	0.008	332	1	6	329.0	0.980	0.008	249	4	9	244.5	0.972	0.010
8- 9 YR	325	0	3	323.5	0.980	0.008	325	0	5	322.5	0.980	0.008	236	2	8	232.0	0.964	0.012
9-10 YR	322	0	4	320.0	0.980	0.008	320	2	4	318.0	0.973	0.009	226	2	7	222.5	0.955	0.013
10-11 YR	318	0	1	317.5	0.980	0.008	314	2	6	311.0	0.967	0.010	217	0	3	215.5	0.955	0.013
11-12 YR	317	3	7	313.5	0.970	0.009	306	0	11	300.5	0.967	0.010	214	0	3	212.5	0.955	0.013
12-13 YR	307	0	5	304.5	0.970	0.009	295	2	10	290.0	0.961	0.011	211	2	6	208.0	0.946	0.015
13-14 YR	302	2	4	300.0	0.964	0.010	283	5	5	280.5	0.943	0.013	203	2	7	199.5	0.937	0.016
14-15 YR	296	0	4	294.0	0.964	0.010	273	2	6	270.0	0.936	0.014	194	1	5	191.5	0.932	0.017
15-16 YR	292	1	4	290.0	0.960	0.011	265	3	4	263.0	0.926	0.015	188	1	9	183.5	0.927	0.017
16-17 YR	287	1	3	285.5	0.957	0.011	258	4	6	255.0	0.911	0.016	178	3	5	175.5	0.911	0.019
17-18 YR	283	2	5	280.5	0.950	0.012	248	2	7	244.5	0.904	0.017	170	1	9	165.5	0.905	0.020
18-19 YR	276	2	5	273.5	0.943	0.013	239	1	5	236.5	0.900	0.017	160	0	11	154.5	0.905	0.020
19-20 YR	269	2	143	197.5	0.934	0.015	233	3	117	174.5	0.884	0.019	149	5	75	111.5	0.865	0.026
20-21 YR	124	1	123	62.5	0.919	0.021	113	0	113	56.5	0.884	0.019	69	0	69	34.5	0.865	0.026
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-9 (WOMEN)

LIFE TABLE FOR CEREBROVASCULAR ACCIDENT IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	0	0	443.0	1.000	0.0	584	0	1	583.5	1.000	0.0	511	0	0	511.0	1.000	0.0
1- 2 YR	443	0	1	442.5	1.000	0.0	583	0	1	582.5	1.000	0.0	511	0	0	511.0	1.000	0.0
2- 3 YR	442	0	1	441.5	1.000	0.0	582	0	1	581.5	1.000	0.0	511	1	0	511.0	0.998	0.002
3- 4 YR	441	0	0	441.0	1.000	0.0	581	0	0	581.0	1.000	0.0	510	0	1	509.5	0.998	0.002
4- 5 YR	441	0	0	441.0	1.000	0.0	581	0	1	580.5	1.000	0.0	509	0	2	508.0	0.998	0.002
5- 6 YR	441	1	0	441.0	0.998	0.002	580	1	1	579.5	0.998	0.002	507	0	1	506.5	0.998	0.002
6- 7 YR	440	0	2	439.0	0.998	0.002	578	0	1	577.5	0.998	0.002	506	0	2	505.0	0.998	0.002
7- 8 YR	438	0	1	437.5	0.998	0.002	577	1	0	577.0	0.997	0.002	504	0	1	503.5	0.998	0.002
8- 9 YR	437	0	0	437.0	0.998	0.002	576	0	1	575.5	0.997	0.002	503	1	3	501.5	0.996	0.003
9-10 YR	437	1	3	435.5	0.995	0.003	575	0	2	574.0	0.997	0.002	499	1	2	498.0	0.994	0.003
10-11 YR	433	0	1	432.5	0.995	0.003	573	1	2	572.0	0.995	0.003	496	1	3	494.5	0.992	0.004
11-12 YR	432	0	3	430.5	0.995	0.003	570	2	2	569.0	0.991	0.004	492	0	3	490.5	0.992	0.004
12-13 YR	429	0	0	429.0	0.995	0.003	566	0	4	564.0	0.991	0.004	489	1	2	488.0	0.990	0.004
13-14 YR	429	0	0	429.0	0.995	0.003	562	0	5	559.5	0.991	0.004	486	0	6	483.0	0.990	0.004
14-15 YR	429	0	0	429.0	0.995	0.003	557	0	3	555.5	0.991	0.004	480	0	3	478.5	0.990	0.004
15-16 YR	429	0	0	429.0	0.995	0.003	554	0	6	551.0	0.991	0.004	477	2	1	476.5	0.986	0.005
16-17 YR	429	0	2	428.0	0.995	0.003	548	0	2	547.0	0.991	0.004	474	0	3	472.5	0.986	0.005
17-18 YR	427	1	3	425.5	0.993	0.004	546	0	1	545.5	0.991	0.004	471	1	5	468.5	0.984	0.006
18-19 YR	423	1	4	421.0	0.991	0.005	545	3	3	543.5	0.986	0.005	465	1	4	463.0	0.982	0.006
19-20 YR	418	0	203	316.5	0.991	0.005	539	1	271	403.5	0.983	0.006	460	4	224	348.0	0.970	0.008
20-21 YR	215	0	215	107.5	0.991	0.005	267	0	266	134.0	0.983	0.006	232	0	231	116.5	0.970	0.008
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.983	0.006	1	0	1	0.5	0.970	0.008

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	447	0	0	447.0	1.000	0.0	428	2	2	427.0	0.995	0.003	371	0	1	370.5	1.000	0.0
1- 2 YR	447	0	1	446.5	1.000	0.0	424	1	0	424.0	0.993	0.004	370	0	1	369.5	1.000	0.0
2- 3 YR	446	0	0	446.0	1.000	0.0	423	1	1	422.5	0.991	0.005	369	1	0	369.0	0.997	0.003
3- 4 YR	446	0	3	444.5	1.000	0.0	421	1	1	420.5	0.988	0.005	368	0	2	367.0	0.997	0.003
4- 5 YR	443	0	1	442.5	1.000	0.0	419	0	2	418.0	0.988	0.005	366	3	2	365.0	0.989	0.005
5- 6 YR	442	0	3	440.5	1.000	0.0	417	1	3	415.5	0.986	0.006	361	1	2	360.0	0.986	0.006
6- 7 YR	439	1	3	437.5	0.998	0.002	413	2	3	411.5	0.981	0.007	358	2	6	355.0	0.981	0.007
7- 8 YR	435	1	3	433.5	0.995	0.003	408	3	3	406.5	0.974	0.008	350	1	2	349.0	0.978	0.008
8- 9 YR	431	0	2	430.0	0.995	0.003	402	1	5	399.5	0.971	0.008	347	1	4	345.0	0.975	0.008
9-10 YR	429	1	3	427.5	0.993	0.004	396	2	4	394.0	0.966	0.009	342	3	5	339.5	0.967	0.010
10-11 YR	425	1	2	424.0	0.991	0.005	390	1	2	389.0	0.964	0.009	334	5	5	331.5	0.952	0.011
11-12 YR	422	0	3	420.5	0.991	0.005	387	2	2	386.0	0.959	0.010	324	1	1	323.5	0.949	0.012
12-13 YR	419	0	2	418.0	0.991	0.005	383	1	5	380.5	0.956	0.010	322	2	6	319.0	0.943	0.012
13-14 YR	417	1	2	416.0	0.988	0.005	377	3	4	375.0	0.949	0.011	314	3	10	309.0	0.934	0.013
14-15 YR	414	2	3	412.5	0.984	0.006	370	0	6	367.0	0.949	0.011	301	1	4	299.0	0.931	0.014
15-16 YR	409	1	5	406.5	0.981	0.007	364	2	8	360.0	0.944	0.011	296	7	9	291.5	0.908	0.016
16-17 YR	403	3	6	400.0	0.974	0.008	354	3	5	351.5	0.936	0.012	280	2	2	279.0	0.902	0.016
17-18 YR	394	3	2	393.0	0.966	0.009	346	5	4	344.0	0.922	0.014	276	4	6	273.0	0.889	0.017
18-19 YR	389	2	6	386.0	0.961	0.009	337	3	6	334.0	0.914	0.014	266	3	12	260.0	0.878	0.018
19-20 YR	381	1	180	291.0	0.958	0.010	328	1	164	246.0	0.910	0.015	251	5	124	189.0	0.855	0.020
20-21 YR	200	0	199	100.5	0.958	0.010	163	0	163	81.5	0.910	0.015	122	0	121	61.5	0.855	0.020
21-22 YR	1	0	1	0.5	0.958	0.010	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.855	0.020

TABLE IV-10 (MEN)

LIFE TABLE FOR CARDIOVASCULAR DISEASE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

MEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	380	2	0	380.0	0.995	0.004	436	0	0	436.0	1.000	0.0	418	0	0	418.0	1.000	0.0
1- 2 YR	378	2	0	378.0	0.989	0.005	436	2	0	436.0	0.995	0.003	418	1	1	417.5	0.998	0.002
2- 3 YR	376	0	0	376.0	0.989	0.005	434	1	1	433.5	0.993	0.004	416	2	0	416.0	0.993	0.004
3- 4 YR	376	1	0	376.0	0.987	0.006	432	3	1	431.5	0.986	0.006	414	2	1	413.5	0.988	0.005
4- 5 YR	375	2	1	374.5	0.982	0.007	428	2	1	427.5	0.982	0.006	411	5	1	410.5	0.976	0.008
5- 6 YR	372	1	0	372.0	0.979	0.007	425	4	1	424.5	0.972	0.008	405	6	0	405.0	0.962	0.009
6- 7 YR	371	1	0	371.0	0.976	0.008	420	0	1	419.5	0.972	0.008	399	7	2	398.0	0.945	0.011
7- 8 YR	370	1	1	369.5	0.974	0.008	419	4	0	419.0	0.963	0.009	390	2	0	390.0	0.940	0.012
8- 9 YR	368	2	0	368.0	0.968	0.009	415	5	0	415.0	0.951	0.010	388	1	0	388.0	0.937	0.012
9-10 YR	366	2	1	365.5	0.963	0.010	410	3	0	410.0	0.945	0.011	387	10	4	385.0	0.913	0.014
10-11 YR	363	1	1	362.5	0.960	0.010	407	7	3	405.5	0.928	0.012	373	8	3	371.5	0.893	0.015
11-12 YR	361	3	0	361.0	0.952	0.011	397	5	2	396.0	0.916	0.013	362	5	2	361.0	0.881	0.016
12-13 YR	358	5	0	358.0	0.939	0.012	390	3	2	389.0	0.909	0.014	355	9	1	354.5	0.859	0.017
13-14 YR	353	2	0	353.0	0.934	0.013	385	4	0	385.0	0.900	0.014	345	10	1	344.5	0.834	0.018
14-15 YR	351	3	0	351.0	0.926	0.013	381	4	2	380.0	0.890	0.015	334	11	4	332.0	0.806	0.020
15-16 YR	348	2	0	348.0	0.920	0.014	375	3	4	373.0	0.883	0.016	319	9	2	318.0	0.783	0.020
16-17 YR	346	4	2	345.0	0.910	0.015	368	7	0	368.0	0.867	0.016	308	9	0	308.0	0.760	0.021
17-18 YR	340	3	0	340.0	0.902	0.015	361	6	3	359.5	0.852	0.017	299	5	2	298.0	0.748	0.022
18-19 YR	337	4	3	335.5	0.891	0.016	352	7	5	349.5	0.835	0.018	292	9	1	291.5	0.725	0.022
19-20 YR	330	5	172	244.0	0.873	0.018	340	7	196	242.0	0.811	0.020	282	9	133	215.5	0.694	0.024
20-21 YR	153	0	153	76.5	0.873	0.018	137	0	136	69.0	0.811	0.020	140	0	140	70.0	0.694	0.024
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.811	0.020	0	0	0	0.0	0.0	0.0

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	349	2	2	348.0	0.994	0.004	346	3	2	345.0	0.991	0.005	255	6	1	254.5	0.976	0.010
1- 2 YR	345	4	0	345.0	0.983	0.007	341	5	2	340.0	0.977	0.008	248	6	2	247.0	0.953	0.013
2- 3 YR	341	2	2	340.0	0.977	0.008	334	8	2	333.0	0.953	0.011	240	8	3	238.5	0.921	0.017
3- 4 YR	337	4	2	336.0	0.965	0.010	324	7	0	324.0	0.933	0.014	229	11	2	228.0	0.876	0.021
4- 5 YR	331	4	1	330.5	0.954	0.011	317	7	1	316.5	0.912	0.015	216	11	1	215.5	0.832	0.024
5- 6 YR	326	6	2	325.0	0.936	0.013	309	12	4	307.0	0.876	0.018	204	7	0	204.0	0.803	0.025
6- 7 YR	318	9	1	317.5	0.909	0.016	293	4	0	293.0	0.864	0.019	197	2	1	196.5	0.795	0.026
7- 8 YR	308	10	2	307.0	0.880	0.018	289	5	3	287.5	0.849	0.019	194	6	2	193.0	0.770	0.027
8- 9 YR	296	8	2	295.0	0.856	0.019	281	7	0	281.0	0.828	0.021	186	4	2	185.0	0.754	0.027
9-10 YR	286	8	1	285.5	0.832	0.020	274	12	0	274.0	0.792	0.022	180	2	2	179.0	0.745	0.028
10-11 YR	277	4	0	277.0	0.820	0.021	262	9	1	261.5	0.765	0.023	176	6	2	175.0	0.720	0.029
11-12 YR	273	9	2	272.0	0.793	0.022	252	7	3	250.5	0.743	0.024	168	4	2	167.0	0.702	0.029
12-13 YR	262	6	0	262.0	0.775	0.023	242	10	3	240.5	0.712	0.025	162	4	2	161.0	0.685	0.030
13-14 YR	256	5	4	254.0	0.759	0.023	229	13	1	228.5	0.672	0.026	156	4	2	155.0	0.667	0.030
14-15 YR	247	5	0	247.0	0.744	0.024	215	7	1	214.5	0.650	0.026	150	6	2	149.0	0.640	0.031
15-16 YR	242	6	2	241.0	0.726	0.024	207	5	0	207.0	0.634	0.027	142	3	3	140.5	0.627	0.031
16-17 YR	234	4	1	233.5	0.713	0.025	202	9	1	201.5	0.606	0.027	136	6	2	135.0	0.599	0.032
17-18 YR	229	6	1	228.5	0.694	0.025	192	9	2	191.0	0.577	0.027	128	7	4	126.0	0.566	0.033
18-19 YR	222	7	2	221.0	0.672	0.026	181	6	3	179.5	0.558	0.028	117	8	2	116.0	0.527	0.033
19-20 YR	213	5	112	157.0	0.651	0.027	172	3	85	129.5	0.545	0.028	107	5	58	78.0	0.493	0.034
20-21 YR	96	1	95	48.5	0.638	0.029	84	0	84	42.0	0.545	0.028	44	0	44	22.0	0.493	0.034
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0

TABLE IV-10 (WOMEN)

LIFE TABLE FOR CARDIOVASCULAR DISEASE IN THE TOTAL FRAMINGHAM STUDY POPULATION WITH AGE AND FOLLOW-UP BEGINNING AT EXAMINATION 1

WOMEN

	AGE 30-34						AGE 35-39						AGE 40-44					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	443	1	0	443.0	0.998	0.002	582	0	1	581.5	1.000	0.0	506	0	0	506.0	1.000	0.0
1- 2 YR	442	0	1	441.5	0.998	0.002	581	1	0	581.0	0.998	0.002	506	0	0	506.0	1.000	0.0
2- 3 YR	441	0	1	440.5	0.998	0.002	580	0	1	579.5	0.998	0.002	506	1	0	506.0	0.998	0.002
3- 4 YR	440	0	0	440.0	0.998	0.002	579	0	0	579.0	0.998	0.002	505	2	0	505.0	0.994	0.003
4- 5 YR	440	0	0	440.0	0.998	0.002	579	1	1	578.5	0.997	0.002	503	2	1	502.5	0.990	0.004
5- 6 YR	440	1	0	440.0	0.995	0.003	577	1	1	576.5	0.995	0.003	500	4	1	499.5	0.982	0.006
6- 7 YR	439	0	2	438.0	0.995	0.003	575	2	1	574.5	0.991	0.004	495	0	2	494.0	0.982	0.006
7- 8 YR	437	0	1	436.5	0.995	0.003	572	3	0	572.0	0.986	0.005	493	0	1	492.5	0.982	0.006
8- 9 YR	436	1	0	436.0	0.993	0.004	569	2	0	569.0	0.983	0.005	492	4	1	491.5	0.974	0.007
9-10 YR	435	3	2	434.0	0.986	0.006	567	0	2	566.0	0.983	0.005	487	3	2	486.0	0.968	0.008
10-11 YR	430	3	0	430.0	0.979	0.007	565	1	2	564.0	0.981	0.006	482	3	3	480.5	0.962	0.009
11-12 YR	427	1	1	426.5	0.977	0.007	562	3	2	561.0	0.976	0.006	476	1	3	474.5	0.960	0.009
12-13 YR	425	1	0	425.0	0.975	0.007	557	2	4	555.0	0.972	0.007	472	2	2	471.0	0.956	0.009
13-14 YR	424	1	0	424.0	0.973	0.008	551	0	4	549.0	0.972	0.007	468	3	5	465.5	0.950	0.010
14-15 YR	423	1	0	423.0	0.970	0.008	547	4	2	546.0	0.965	0.008	460	0	2	459.0	0.950	0.010
15-16 YR	422	0	0	422.0	0.970	0.008	541	2	3	539.5	0.961	0.008	458	8	0	458.0	0.933	0.011
16-17 YR	422	0	1	421.5	0.970	0.008	536	6	0	536.0	0.951	0.009	450	5	2	449.0	0.923	0.012
17-18 YR	421	5	2	420.0	0.959	0.010	530	4	1	529.5	0.944	0.010	443	10	3	441.5	0.902	0.013
18-19 YR	414	2	4	412.0	0.954	0.010	525	6	1	524.5	0.933	0.011	430	5	3	428.5	0.891	0.014
19-20 YR	408	5	197	309.5	0.939	0.012	518	2	260	388.0	0.928	0.011	422	10	203	320.5	0.864	0.016
20-21 YR	206	1	205	103.5	0.930	0.015	256	0	255	128.5	0.928	0.011	209	0	208	105.0	0.864	0.016
21-22 YR	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.928	0.011	1	0	1	0.5	0.864	0.016

	AGE 45-49						AGE 50-54						AGE 55-59					
INTERVAL	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)	L	D	W	L*	CP	SE(CP)
0- 1 YR	438	1	0	438.0	0.998	0.002	413	3	1	412.5	0.993	0.004	360	4	0	360.0	0.989	0.006
1- 2 YR	437	4	0	437.0	0.989	0.005	409	5	0	409.0	0.981	0.007	356	4	1	355.5	0.978	0.008
2- 3 YR	433	1	0	433.0	0.986	0.006	404	3	1	403.5	0.973	0.008	351	4	0	351.0	0.967	0.009
3- 4 YR	432	4	1	431.5	0.977	0.007	400	6	1	399.5	0.959	0.010	347	8	1	346.5	0.944	0.012
4- 5 YR	427	1	1	426.5	0.975	0.007	393	3	1	392.5	0.951	0.011	338	4	0	338.0	0.933	0.013
5- 6 YR	425	5	1	424.5	0.963	0.009	389	4	2	388.0	0.942	0.012	334	9	2	333.0	0.908	0.015
6- 7 YR	419	3	2	418.0	0.956	0.010	383	2	1	382.5	0.937	0.012	323	6	3	321.5	0.891	0.016
7- 8 YR	414	1	2	413.0	0.954	0.010	380	7	3	378.5	0.919	0.013	314	6	1	313.5	0.874	0.018
8- 9 YR	411	5	1	410.5	0.943	0.011	370	6	2	369.0	0.904	0.015	307	7	3	305.5	0.854	0.019
9-10 YR	405	6	1	404.5	0.929	0.012	362	7	3	360.5	0.887	0.016	297	8	0	297.0	0.831	0.020
10-11 YR	398	4	0	398.0	0.919	0.013	352	4	2	351.0	0.877	0.016	289	7	4	287.0	0.811	0.021
11-12 YR	394	2	3	392.5	0.915	0.013	346	9	1	345.5	0.854	0.018	278	4	0	278.0	0.799	0.021
12-13 YR	389	2	2	388.0	0.910	0.014	336	5	4	334.0	0.841	0.018	274	7	3	272.5	0.778	0.022
13-14 YR	385	5	2	384.0	0.898	0.015	327	9	1	326.5	0.818	0.019	264	14	2	263.0	0.737	0.024
14-15 YR	378	4	2	377.0	0.888	0.015	317	9	1	316.5	0.795	0.020	248	4	2	247.0	0.725	0.024
15-16 YR	372	10	2	371.0	0.865	0.017	307	6	4	305.0	0.779	0.021	242	7	2	241.0	0.704	0.025
16-17 YR	360	9	3	358.5	0.843	0.018	297	5	2	296.0	0.766	0.021	233	10	1	232.5	0.674	0.025
17-18 YR	348	6	2	347.0	0.828	0.018	290	12	0	290.0	0.734	0.022	222	6	3	220.5	0.655	0.026
18-19 YR	340	6	4	338.0	0.814	0.019	278	6	5	275.5	0.718	0.023	213	13	6	210.0	0.615	0.026
19-20 YR	330	6	155	252.5	0.794	0.020	267	6	132	201.0	0.697	0.024	194	7	96	146.0	0.585	0.027
20-21 YR	169	0	169	84.5	0.794	0.020	129	0	129	64.5	0.697	0.024	91	0	90	46.0	0.585	0.027
21-22 YR	0	0	0	0.0	0.0	0.0	0	0	0	0.0	0.0	0.0	1	0	1	0.5	0.585	0.027

Part V

Graphs of the Cumulative Probability of Having Specified Endpoint Events in those with Myocardial Infarction and Angina Pectoris and in those Free of Myocardial Infarction and Angina Pectoris

Endpoint events following Angina Pectoris Uncomplicated:

Graph No.

V-1	Death
V-2	Sudden Death
V-3	Cardiovascular Death
V-4	Coronary Attack
V-5	Myocardial Infarction
V-6	Congestive Heart Failure
V-7	Cerebrovascular Accident

Endpoint events following Recognized Myocardial Infarction:

V-8	Death
V-9	Angina Pectoris
V-10	Second Myocardial Infarction
V-11	Congestive Heart Failure

Endpoint events following Unrecognized Myocardial Infarction:

V-12	Death

Endpoint events following Recognized Myocardial Infarction (including Sudden Death):

V-13	Death

Graphs are not presented for yearly intervals where there were too few cases. See text for description.

FIGURE V-1

DEATH FOLLOWING UNCOMPLICATED ANGINA PECTORIS

COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS

ALL AGES



FIGURE V-2

SUDDEN DEATH FOLLOWING UNCOMPLICATED ANGINA PECTORIS

COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS

ALL AGES



FIGURE V-3

CARDIOVASCULAR DEATH FOLLOWING UNCOMPLICATED ANGINA PECTORIS
COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS
ALL AGES



FIGURE V-4

CORONARY ATTACK FOLLOWING UNCOMPLICATED ANGINA PECTORIS
COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS
ALL AGES



FIGURE V-5

MYOCARDIAL INFARCTION FOLLOWING UNCOMPLICATED ANGINA PECTORIS
COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS
ALL AGES



FIGURE V-6

CONGESTIVE HEART FAILURE FOLLOWING UNCOMPLICATED ANGINA PECTORIS

COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS

ALL AGES



FIGURE V-7

CEREBROVASCULAR ACCIDENT FOLLOWING UNCOMPLICATED ANGINA PECTORIS
COMPARED WITH THOSE FREE OF UNCOMPLICATED ANGINA PECTORIS
ALL AGES



FIGURE V-8

DEATH FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
COMPARED WITH THOSE FREE OF MYOCARDIAL INFARCTION
ALL AGES



FIGURE V-9

ANGINA PECTORIS FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION COMPARED WITH THOSE FREE OF MYOCARDIAL INFARCTION

ALL AGES



FIGURE Ⅴ-10

SECOND MYOCARDIAL INFARCTION

FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION

ALL AGES



FIGURE V-11

CONGESTIVE HEART FAILURE FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION COMPARED WITH THOSE FREE OF RECOGNIZED MYOCARDIAL INFARCTION

ALL AGES



FIGURE V-12

DEATH FOLLOWING UNRECOGNIZED MYOCARDIAL INFARCTION

COMPARED WITH THOSE FREE OF MYOCARDIAL INFARCTION

ALL AGES



FIGURE V-13

DEATH (INCLUDING SUDDEN DEATH) FOLLOWING RECOGNIZED MYOCARDIAL INFARCTION
COMPARED WITH THOSE FREE OF MYOCARDIAL INFARCTION
ALL AGES



* (SUDDEN DEATHS ARE INCLUDED AS IMMEDIATE MORTALITY
AND APPEAR IN 30 DAY INTERVAL)

Part VI

Survival Following Myocardial Infarction and Angina Pectoris with Reference to Measured Characteristics

Table No.	Persons with Angina Pectoris Uncomplicated
VI-1a,b	Pre-measured characteristics and 5-year mortality
VI-2a,b	Post-measured characteristics and 5-year mortality
VI-3a,b	Change in characteristics and 5-year mortality
VI-4a,b	Pre-measured characteristics and 5-10 year mortality

Table No.	Persons with Recognized Myocardial Infarction
VI-5a,b	Pre-measured characteristics and 30-day mortality
VI-6a,b	Pre-measured characteristics and 30-day to 5-year mortality
VI-7a,b	Post-measured characteristics and 5-year mortality
VI-8a,b	Change in characteristics and 5-year mortality
VI-9a,b	Pre-measured characteristics and 5-10 year mortality

Part VI, continued

Comparison of risk factor coefficients in those with angina pectoris uncomplicated, myocardial infarction recognized, and in those free of coronary heart disease.

VI-10	Pre-measured characteristics and 5-year mortality
VI-11	Post-measured characteristics and 5-year mortality
VI-12	Change in characteristics and 5 year mortality.
VI-13	Pre-measured characteristics and 5-10 year mortality

---

a tables: For each factor and method of analysis the chi-square statistics for regression are displayed, a sign (+ or -) indicates the direction of the relationship, and the number of deaths from the population at risk are shown.

b tables: For those factors which are significantly associated with mortality in table a, the observed and expected number of deaths in the categories of the factor are displayed, along with the ratio observed to expected. The expected number of deaths are computed based on the null hypothesis of no association between mortality and the factor under consideration.

VI-1a

Pre-measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	0.03 (+) 1/	19/120	0.39 (+)	12/86
Contribution in addition to age by:				
Systolic blood pressure	4.75 (+)	19/120	1.11 (+)	12/86
Diastolic blood pressure	1.94 (+)	19/120	0.06 (+)	12/86
Serum cholesterol	0.50 (+)	17/110	1.52 (+)	10/76
Phospholipid	0.00 (+)	17/84	7.94 (-)	10/50
Blood glucose	4.28 (+)	16/90	0.06 (-)	9/56
Metropolitan relative weight	0.00 (-)	19/120	0.72 (-)	12/86
Vital capacity/height	1.46 (-)	19/119	1.34 (-)	12/85
Pulse rate	2.29 (-)	14/101	6.59 (-)	7/67
Cigarettes smoked	4.50 (-)	14/90	7.46 (-)	7/56
Hypertension	8.98 (+)	19/120	1.78 (+)	12/86
Heart enlargement-X-ray	10.33 (+)	18/118	1.68 (+)	12/85
Left ventricular hypertrophy-ECG	0.42 (+)	19/120	1.01 (+)	12/86
Intraventricular block	0.09 (-)	19/120	0.08 (+)	12/86
Non-specific T or ST abnormality	6.24 (+)	19/120	0.21 (-)	12/86
Albumin in urine	0.35 (+)	18/105	0.54 (+)	11/71
Glucose intolerance	0.06 (+)	19/120	0.00 (-)	12/86

1/ (+) = positive association
(-) = negative association

VI-1b

Pre-measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Systolic blood pressure			
less than 130	1	5.93	0.17
130-153	9	6.53	1.38
greater than 153	9	6.54	1.38
Blood glucose			
less than 75	3	5.26	0.57
75-94	7	8.03	0.87
greater than 94	6	2.71	2.21
Cigarettes/day			
none	11	7.16	1.56
less than 20	1	1.83	0.55
20	2	2.56	0.78
greater than 20	0	2.46	0.00
Hypertension			
none	2	6.81	0.29
borderline	7	7.33	0.95
definite	10	4.86	2.06
Heart enlargement-X-ray			
none	9	14.02	0.64
questionable	3	1.98	1.52
definite	6	2.00	3.00
Non-specific T or ST abnormality			
no	13	16.57	0.78
yes	6	2.43	2.47

VI-2a

Post-measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated
Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	0.19 (+) 1/	20/126	0.51 (+)	13/91
Contribution in addition to age by:				
Systolic blood pressure	7.25 (+)	20/126	0.20 (+)	13/91
Diastolic blood pressure	4.05 (+)	20/126	0.03 (+)	13/91
Serum cholesterol	0.05 (+)	20/123	1.30 (+)	13/90
Phospholipid	0.23 (+)	18/93	0.71 (-)	11/62
Blood glucose	1.03 (+)	19/96	1.36 (+)	12/65
Metropolitan relative weight	0.57 (-)	20/126	1.00 (-)	13/91
Vital capacity/height	0.01 (-)	19/124	2.96 (-)	12/90
Pulse rate	0.11 (+)	13/102	0.57 (+)	6/67
Cigarettes smoked	0.09 (-)	13/91	0.85 (+)	6/56
Hypertension	6.20 (+)	20/126	0.73 (+)	13/91
Heart enlargement-X-ray	11.06 (+)	20/125	1.48 (+)	13/90
Left ventricular hypertrophy-ECG	6.06 (+)	20/126	0.51 (+)	13/91
Intraventricular block	0.04 (+)	20/126	0.62 (+)	13/91
Non-specific T or ST abnormality	0.19 (+)	20/126	0.72 (-)	13/91
Albumin in urine	0.22 (+)	17/107	1.02 (+)	10/73
Glucose intolerance	6.98 (+)	20/126	2.18 (+)	13/91

1/ (+) = positive association
(-) = negative association

VI-2b

Post-measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	#Deaths Expected	Ratio O/E
Systolic blood pressure			
less than 130	2	5.15	0.39
130-153	6	8.53	0.70
greater than 153	12	6.32	1.90
Diastolic blood pressure			
less than 85	5	9.39	0.53
85-94	7	5.58	1.25
greater than 94	8	5.02	1.59
Hypertension			
normal	3	6.41	0.47
borderline	7	8.52	0.82
definite	10	5.06	1.98
Heart enlargement-X-ray			
none	10	14.36	0.70
questionable	1	2.87	0.35
definite	9	2.77	3.25
Left ventricular hypertrophy-ECG			
none	15	17.75	0.85
questionable	1	1.08	0.93
definite	4	1.17	3.42
Glucose intolerance			
no	14	17.72	0.79
yes	6	2.28	2.63

VI-3a

Change in Measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	0.19 (+)1/	19/120	0.41 (+)	12/86
Contribution in addition to age by:				
Systolic blood pressure	0.02 (-)	19/120	0.78 (+)	12/86
Diastolic blood pressure	0.05 (+)	19/120	0.01 (+)	12/86
Serum cholesterol	0.30 (-)	17/107	0.01 (+)	10/75
Phospholipid	* *	15/62	6.61 (+)	8/32
Blood glucose	* *	15/62	0.05 (-)	8/32
Metropolitan relative weight	0.64 (-)	19/120	0.00 (-)	12/86
Vital capacity/height	0.03 (+)	18/117	0.45 (-)	11/85
Pulse rate	0.05 (-)	10/85	* *	3/51
Cigarettes smoked	* *	10/63	* *	3/29
Hypertension	0.27 (-)	19/120	0.15 (-)	12/86
Heart enlargement-X-ray	0.17 (+)	18/118	0.02 (+)	12/85
Left ventricular hypertrophy-ECG	3.03 (+)	19/120	* *	12/86
Intraventricular block	1.74 (+)	19/120	1.63 (+)	12/86
Non-specific T or ST abnormality	2.17 (-)	19/120	0.30 (-)	12/86
Albumin in urine	* *	16/91	* *	12/83
Glucose intolerance	13.22 (+)	19/120	* *	12/86

1/ (+) = positive association
(-) = negative association
* = analysis not done, too few cases

VI-3b

Change in Measured Characteristics and 5-Year Mortality Following Angina Pectoris Uncomplicated Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Glucose intolerance			
negative after AP	13	17.04	0.76
positive before and after AP	2	1.31	1.53
newly positive after AP	4	0.64	6.25

VI-4a

Pre-measured Characteristics and Mortality between 5 and 10 Years Following Angina Pectoris Uncomplicated Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	1.03 (+) 1/	18/74	0.93 (+)	12/43
Contribution in addition to age by:				
Systolic blood pressure	0.44 (-)	18/74	0.57 (-)	12/43
Diastolic blood pressure	0.16 (-)	18/74	0.26 (-)	12/43
Serum cholesterol	5.12 (+)	16/66	2.85 (+)	10/36
Phospholipid	3.44 (+)	9/40	0.00 (+)	7/29
Blood glucose	0.00 (0)	12/47	1.38 (-)	10/36
Metropolitan relative weight	0.04 (+)	18/74	0.00 (-)	12/43
Vital capacity/height	0.18 (-)	18/73	0.32 (-)	12/42
Pulse rate	0.05 (+)	14/60	0.20 (+)	8/29
Cigarettes smoked	1.62 (+)	12/49	5.69 (+)	8/29
Hypertension	0.74 (-)	18/74	0.09 (-)	12/43
Heart enlargement-X-ray	0.54 (-)	17/73	0.23 (-)	11/42
Left ventricular hypertrophy-ECG	0.02 (-)	18/74	0.02 (-)	12/43
Intraventricular block	5.35 (+)	18/74	* *	12/43
Non-specific T or ST abnormality	16.62 (+)	18/74	8.86 (+)	12/43
Albumin in urine	0.86 (+)	15/60	* *	9/30
Glucose intolerance	0.19 (+)	18/74	0.52 (+)	12/43

1/ (+) = positive association
(-) = negative association
(0) = no association
* = analysis not done, too few cases

VI-4b

Pre-measured Characteristics and Mortality between 5 and 10 Years Following Angina Pectoris Uncomplicated Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Serum cholesterol			
less than 226	2	6.99	0.29
226-267	10	6.22	1.61
greater than 267	4	2.79	1.43
Intraventricular block			
no	15	17.00	0.88
yes	3	1.00	3.00
Non-specific T or ST abnormality			
no	11	16.14	0.68
yes	7	1.86	3.76

VI-5a

Pre-measured Characteristics and 30-Day Mortality Following Myocardial Infarction Recognized Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	15.10 (+) 1/	27/174	12.82 (+)	27/174
Contribution in addition to age by:				
Systolic blood pressure	3.01 (-)	27/174	0.17 (-)	27/174
Diastolic blood pressure	0.31 (-)	27/174	0.01 (-)	27/174
Serum cholesterol	0.00 (+)	27/166	0.53 (+)	27/166
Phospholipid	1.79 (+)	19/113	3.61 (+)	19/113
Blood glucose	0.28 (-)	14/114	0.32 (+)	14/114
Metropolitan relative weight	0.06 (+)	27/173	0.04 (-)	27/173
Vital capacity/height	1.06 (+)	25/169	1.38 (+)	25/169
Pulse rate	0.01 (-)	25/142	0.28 (+)	25/142
Cigarettes smoked	2.11 (-)	21/115	2.11 (-)	21/115
Hypertension	2.41 (-)	27/174	1.61 (-)	27/174
Heart enlargement-X-ray	1.33 (-)	27/173	1.18 (-)	27/173
Left ventricular hypertrophy-ECG	1.15 (+)	27/174	1.36 (+)	27/174
Intraventricular block	0.23 (-)	27/174	0.27 (-)	27/174
Non-specific T or ST abnormality	0.73 (-)	27/174	0.06 (-)	27/174
Albumin in urine	2.34 (+)	25/154	1.51 (+)	25/154
Glucose intolerance	0.26 (+)	27/174	0.20 (+)	27/174

1/ (+) = positive association
(-) = negative association

VI-5b

Pre-measured Characteristics and 30-Day Mortality Following Myocardial Infarction Recognized
Men Only; Mantel-Haenszel, Observed and Expected Deaths

There were no statistically significant variables in Table VI-5a

VI-6a

Pre-measured Characteristics and 30-Day to 5-Year Mortality Following Myocardial Infarction Recognized Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	8.14 (+) 1/	32/147	2.81 (+)	24/121
Contribution in addition to age by:				
Systolic blood pressure	8.35 (+)	32/147	8.90 (+)	24/121
Diastolic blood pressure	3.84 (+)	32/147	5.17 (+)	24/121
Serum cholesterol	0.28 (+)	32/139	0.25 (+)	24/113
Phospholipid	0.34 (-)	21/94	0.76 (-)	14/69
Blood glucose	0.03 (+)	25/100	0.03 (-)	17/76
Metropolitan relative weight	0.00 (+)	31/146	0.13 (+)	23/120
Vital capacity/height	0.44 (-)	31/144	1.03 (-)	24/120
Pulse rate	4.30 (+)	27/117	7.05 (+)	19/91
Cigarettes smoked	1.20 (+)	24/94	0.79 (+)	16/68
Hypertension	6.25 (+)	32/147	7.38 (+)	24/121
Heart enlargement-X-ray	1.45 (+)	32/146	1.40 (+)	24/121
Left ventricular hypertrophy-ECG	3.34 (+)	32/147	2.20 (+)	24/121
Intraventricular block	0.36 (+)	32/147	0.07 (+)	24/121
Non-specific T or ST abnormality	0.52 (+)	32/147	1.98 (+)	24/121
Albumin in urine	0.11 (+)	27/129	0.11 (+)	20/104
Glucose intolerance	0.00 (+)	32/147	0.25 (+)	24/121

1/ (+)= positive association
(-)= negative association

VI-6b

Pre-measured Characteristics and 30-Day to 5-Year Mortality Following Myocardial Infarction Recognized
Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Systolic blood pressure			
less than 130	4	8.67	0.46
130-153	9	12.11	0.74
greater than 153	19	11.22	1.69
Diastolic blood pressure			
less than 85	11	14.40	0.76
85-94	9	10.78	0.83
greater than 94	12	6.82	1.76
Pulse rate			
less than 70	6	7.01	0.86
70-79	5	10.91	0.46
greater than 79	16	9.08	1.76
Hypertension			
none	5	8.62	0.58
borderline	11	13.89	0.79
definite	16	9.49	1.69
Left ventricular hypertrophy-ECG			
none	27	29.39	0.92
questionable	1	0.98	1.02
definite	4	1.63	2.45

($p < .07$ for LVH)

VI-7a

Post-measured Characteristics and 5-Year Mortality Following Myocardial Infarction Recognized Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	1.51 (+) 1/	32/139	1.81 (+)	23/108
Contribution in addition to age by:				
Systolic blood pressure	0.43 (+)	32/139	1.63 (+)	23/108
Diastolic blood pressure	0.25 (+)	32/139	0.00 (+)	23/108
Serum cholesterol	0.02 (+)	30/128	0.61 (-)	21/100
Phospholipid	0.04 (-)	19/97	0.00 (+)	10/68
Blood glucose	1.43 (+)	21/92	0.01 (-)	13/63
Metropolitan relative weight	0.00 (-)	32/138	0.47 (-)	23/107
Vital capacity/height	0.00 (+)	32/135	1.35 (-)	23/105
Pulse rate	3.09 (+)	28/116	7.14 (+)	19/85
Cigarettes smoked	0.22 (-)	21/99	1.98 (-)	12/68
Hypertension	0.11 (+)	32/139	0.07 (+)	23/108
Heart enlargement-X-ray	7.82 (+)	32/139	3.47 (+)	23/108
Left ventricular hypertrophy-ECG	11.93 (+)	32/139	8.06 (+)	23/108
Intraventricular block	3.18 (+)	32/139	2.32 (+)	23/108
Non-specific T or ST abnormality	2.51 (+)	32/139	0.54 (+)	23/108
Albumin in urine	0.20 (+)	30/117	0.16 (+)	21/86
Glucose intolerance	1.98 (+)	32/139	1.24 (+)	23/108

1/ (+) = positive association
(-) = negative association

VI-7b

Post-measured Characteristics and 5-Year Mortality Following Myocardial Infarction Recognized Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Heart enlargement-X-ray			
none	12	18.54	0.65
questionable	6	5.51	1.09
definite	14	7.95	1.76
Left ventricular hypertrophy-ECG			
none	25	29.57	0.85
questionable	1	0.75	1.33
definite	6	1.68	3.57

VI-8a

Change in Measured Characteristics and 5-Year Mortality Following Myocardial Infarction Recognized Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel			Walker-Duncan		
	Chi-square		#Deaths/ #At risk	Chi-square		#Deaths/ #At risk
Age only	1.51	(+) 1/	31/135	0.67	(+)	22/104
Contribution in addition to age by:						
Systolic blood pressure	8.83	(-)	31/135	3.93	(-)	22/104
Diastolic blood pressure	5.51	(-)	31/135	7.19	(-)	22/104
Serum cholesterol	4.80	(-)	29/117	1.95	(-)	20/89
Phospholipid	*	*	13/65	0.66	(+)	5/37
Blood glucose	*	*	13/55	1.92	(+)	5/28
Metropolitan relative weight	3.61	(-)	31/135	1.72	(-)	22/104
Vital capacity/height	0.24	(-)	31/129	0.09	(-)	22/100
Pulse rate	1.27	(+)	25/96	0.64	(+)	16/65
Cigarettes smoked	*	*	15/60	0.00	(+)	6/29
Hypertension	4.80	(-)	31/135	6.32	(-)	22/104
Heart enlargement-X-ray	2.04	(+)	31/134	1.98	(+)	22/104
Left ventricular hypertrophy-ECG	0.06	(+)	31/135	0.00	(+)	22/104
Intraventricular block	4.78	(+)	31/135	2.96	(+)	22/104
Non-specific T or ST abnormality	0.94	(+)	31/135	0.66	(+)	22/104
Albumin in urine	*	*	*	*	*	*
Glucose intolerance	0.72	(+)	31/135	1.42	(+)	22/104

1/ (+) = positive association
(-) = negative association
* = analysis not done, too few cases

VI-8b

Change in Measured Characteristics and 5-Year Mortality Following Myocardial Infarction Recognized
Men Only; Mantel-Haenszel, Observed and Expected Deaths

	#Deaths		
Variable	Observed	Expected	Ratio O/E
Systolic blood pressure			
decrease of 20 or more	16	8.80	1.82
decrease of 5 to 19	7	7.50	0.93
decrease of 4 to increase	8	14.70	0.54
Diastolic blood pressure			
decrease of 10 or more	18	10.18	1.77
decrease of 0 to 10	7	12.65	0.55
any increase	6	8.17	0.73
Serum cholesterol			
decrease of 5 or more	18	13.13	1.37
decrease of 4 to increase of 4	4	2.68	1.49
increase of 5 or more	7	13.20	0.53
Metropolitan relative weight			
decrease of 10 or more	10	6.89	1.45
decrease of 5 to 9	9	6.65	1.35
decrease of 4 to increase	12	17.46	0.69
Hypertension			
decrease	17	10.99	1.55
no change	12	16.38	0.73
increase	2	3.64	0.55
Intraventricular block			
decrease	0	0.23	0.00
no change	28	29.84	0.94
increase	3	0.93	3.23

VI-9a

Pre-measured Characteristics and Mortality between 5 and 10 Years Following Myocardial Infarction Recognized Men Only; Chi-square Statistics, One Degree of Freedom

	Mantel-Haenszel		Walker-Duncan	
	Chi-square	#Deaths/ #At risk	Chi-square	#Deaths/ #At risk
Age only	0.21 (+) 1/	20/97	0.63 (+)	14/56
Other factors only				
Systolic blood pressure	1.02 (+)	20/97	0.17 (-)	14/56
Diastolic blood pressure	4.07 (+)	20/97	0.04 (+)	14/56
Serum cholesterol	0.33 (+)	20/89	0.00 (-)	14/48
Phospholipid	0.64 (-)	12/55	0.03 (-)	11/35
Blood glucose	0.04 (+)	14/59	0.42 (+)	11/41
Metropolitan relative weight	0.01 (+)	20/97	2.76 (-)	14/56
Vital capacity/height	3.46 (-)	19/96	2.32 (-)	13/55
Pulse rate	2.62 (+)	12/72	0.01 (+)	6/31
Cigarettes smoked	0.20 (+)	7/72	0.11 (+)	6/29
Hypertension	0.67 (+)	20/97	0.36 (-)	14/56
Heart enlargement-X-ray	0.10 (+)	20/97	0.18 (+)	14/56
Left ventricular hypertrophy-ECG	0.48 (+)	20/97	0.21 (+)	14/56
Intraventricular block	4.51 (+)	20/97	* *	14/56
Non-specific T or ST abnormality	0.31 (+)	20/97	0.72 (+)	14/56
Albumin in urine	0.83 (+)	17/84	0.61 (+)	11/44
Glucose intolerance	0.02 (-)	20/97	0.54 (-)	14/56

1/ (+) = positive association
(-) = negative association
* = analysis not done, too few cases

VI-9b

Pre-measured Characteristics and Mortality between 5 and 10 Years Following Myocardial Infarction Recognized Men Only; Mantel-Haenszel, Observed and Expected Deaths

Variable	#Deaths Observed	Expected	Ratio O/E
Diastolic blood pressure			
less than 85	4	8.58	0.46
85-94	9	6.86	1.31
greater than 94	7	4.56	1.54
Vital Capacity/height			
less than 45	7	3.87	1.81
45-54	7	7.11	0.98
greater than 54	5	8.02	0.62
Intraventricular block			
No	18	19.49	0.92
Yes	2	0.51	3.92

VI-10

Pre-measured Characteristics and 5-Year Mortality Following Angina Pectoris, Myocardial Infarction Recognized, and in Those Free of Coronary Heart Disease Men Only; Standardized Regression Coefficients and Standard Errors in Logistic Model

	With APU		With MI		Free of CHD	
	Coeff.	S.E.	Coeff.	S.E.	Coeff.	S.E.
Age only:	0.199	0.322	0.394	0.241	0.824	0.122
Contribution in addition to age by:						
Systolic blood pressure	0.306	0.284	0.696	0.245	0.548	0.087
Diastolic blood pressure	0.080	0.310	0.533	0.243	0.362	0.098
Serum cholesterol	0.401	0.320	0.120	0.240	0.007	0.122
Phospholipid	-1.145	0.475	-0.268	0.308	0.292	0.125
Blood glucose	-0.100	0.397	-0.055	0.285	0.115	0.082
Metropolitan relative weight	-0.274	0.325	0.084	0.235	0.120	0.115
Vital capacity/height	-0.385	0.336	-0.263	0.261	-0.364	0.122
Pulse rate	-1.075	0.473	0.703	0.282	*	*
Cigarettes smoked	-1.805	1.018	0.264	0.300	*	*
Hypertension	0.419	0.318	0.655	0.254	0.458	0.101
Heart enlargement X-ray	0.350	0.258	0.258	0.215	0.371	0.073
Left ventricular hypertrophy-ECG	0.268	0.251	0.289	0.191	0.360	0.054
Intra-ventricular block	0.088	0.299	0.053	0.213	0.069	0.098
Non-specific T or ST abnormality	-0.157	0.359	0.308	0.213	0.030	0.102
Albumin in urine	0.203	0.260	0.075	0.217	0.149	0.068
Glucose intolerance	-0.007	0.313	0.108	0.213	0.202	0.073

* = analysis not done, measurement not taken at Exam 3

VI-11

Post-measured Characteristics and 5-Year Mortality Following Angina Pectoris, Myocardial Infarction Recognized, and in Those Free of Coronary Heart Disease Men Only; Standardized Regression Coefficients and Standard Errors in Logistic Model

	With APU		With MI		Free of CHD	
	Coeff.	S.E.	Coeff.	S.E.	Coeff.	S.E.
Age only:	0.219	0.312	0.326	0.247	0.784	0.119
Contribution in addition to age by:						
Systolic blood pressure	0.133	0.294	0.297	0.231	0.560	0.089
Diastolic blood pressure	0.052	0.299	0.004	0.240	0.552	0.096
Serum cholesterol	0.350	0.309	-0.196	0.254	0.025	0.114
Phospholipid	-0.289	0.344	0.002	0.386	0.047	0.115
Blood glucose	0.325	0.271	-0.018	0.309	0.213	0.067
Metropolitan relative weight	-0.313	0.315	-0.163	0.241	0.021	0.114
Vital capacity/height	-0.564	0.333	-0.055	0.264	-0.531	0.121
Pulse rate	0.302	0.413	0.704	0.276	0.326	0.105
Cigarettes smoked	0.416	0.455	-0.537	0.420	0.284	0.116
Hypertension	0.262	0.307	0.063	0.239	0.462	0.103
Heart enlargement X-ray	0.326	0.258	0.435	0.233	0.357	0.069
Left ventricular hypertrophy-ECG	0.194	0.259	0.600	0.225	0.373	0.055
Intra-ventricular block	0.220	0.266	0.307	0.196	0.106	0.088
Non-specific T or ST abnormality	-0.283	0.350	0.165	0.220	0.026	0.102
Albumin in urine	0.285	0.261	0.094	0.238	*	*
Glucose intolerance	0.366	0.235	0.236	0.205	0.176	0.078

* = analysis not done, measurement not taken at Exam 4

VI-12

Change in Measured Characteristics and 5-Year Mortality Following Angina Pectoris, Myocardial Infarction Recognized, and in Those Free of Coronary Heart Disease Men Only; Standardized Regression Coefficients and Standard Errors in Logistic Model

	With APU		With MI		Free of CHD	
	Coeff.	S.E.	Coeff.	S.E.	Coeff.	S.E.
Age only:	0.205	0.323	0.201	0.248	0.813	0.129
Contribution in addition to age by change in:						
Systolic blood pressure	-0.277	0.312	-0.461	0.235	-0.047	0.111
Diastolic blood pressure	0.026	0.320	-0.673	0.267	0.294	0.120
Serum cholesterol	0.025	0.343	-0.366	0.265	-0.032	0.124
Phospholipid	1.092	0.487	0.381	0.471	-0.337	0.132
Blood glucose	-0.090	0.440	0.911	0.727	0.034	0.126
Metropolitan relative weight	-0.005	0.321	-0.395	0.241	-0.357	0.108
Vital capacity/height	-0.223	0.337	-0.076	0.245	-0.019	0.119
Pulse rate	*	*	0.231	0.293	*	*
Cigarettes smoked	*	*	0.027	0.509	*	*
Hypertension	-0.122	0.315	-0.596	0.243	-0.034	0.124
Heart enlargement X-ray	0.040	0.312	0.332	0.236	0.006	0.109
Left ventricular hypertrophy-ECG	*	*	0.010	0.237	0.173	0.079
Intra-ventricular block	0.298	0.220	0.391	0.240	*	*
Non-specific T or ST abnormality	-0.188	0.356	0.203	0.248	-0.019	0.117
Albumin in urine	*	*	*	*	*	*
Glucose intolerance	*	*	0.304	0.262	-0.054	0.112

* = analysis not done, too few cases or measurement not taken at required examination

VI-13

Pre-measured Characteristics and Mortality between 5 and 10 years Following Angina Pectoris, Myocardial Infarction Recognized, and in Those Free of Coronary Heart Disease Men Only; Standardized Regression Coefficients and Standard Errors in Logistic Model

	With APU		With MI		Free of CHD	
	Coeff.	S.E.	Coeff.	S.E.	Coeff.	S.E.
Age only:	0.346	0.370	0.312	0.351	0.650	0.104
Contribution in addition to age by:						
Systolic blood pressure	-0.282	0.385	-0.200	0.325	0.277	0.087
Diastolic blood pressure	-0.195	0.360	0.058	0.314	0.282	0.092
Serum cholesterol	0.672	0.415	-0.013	0.331	0.037	0.105
Phospholipid	0.029	0.503	-0.181	0.390	0.139	0.109
Blood glucose	-0.605	0.612	0.188	0.331	0.273	0.064
Metropolitan relative weight	-0.024	0.364	-0.572	0.347	-0.016	0.104
Vital capacity/height	-0.205	0.366	-0.404	0.337	-0.279	0.108
Pulse rate	0.191	0.430	0.248	0.511	*	*
Cigarettes smoked	1.099	0.534	0.127	0.479	*	*
Hypertension	-0.111	0.360	-0.204	0.318	0.317	0.091
Heart enlargement X-ray	-0.181	0.392	0.088	0.306	0.138	0.081
Left ventricular hypertrophy-ECG	-0.052	0.354	0.114	0.290	0.225	0.056
Intra-ventricular block	*	*	*	*	-0.025	0.105
Non-specific T or ST abnormality	0.921	0.363	0.393	0.321	0.119	0.084
Albumin in urine	*	*	0.259	0.311	0.170	0.061
Glucose intolerance	0.241	0.329	-0.261	0.378	0.122	0.074

* = analysis not done, too few cases or measurements not taken at required examination

Part I

References and List of Previous Sections

References

1. Ederer F: How close is Greenwood's approximation to the standard error of the 5-year survival rate when the number of cases in the sample is small? Methodological Note No. 7, National Cancer Institute, 1958.

2. Walker SH, Duncan DB: Estimation of the probability of an event as a function of several independent variables. Biometrics 54: 167-179, 1967.

3. Hankey BF, Myers MH: Evaluating differences in survival between two groups of patients. J Chron Dis 24: 523-531, 1971.

THE
FRAMINGHAM
STUDY

An Epidemiological Investigation
of Cardiovascular Disease

Editors: William B. Kannel, M.D. and Tavia Gordon

PREVIOUS SECTIONS

PREVIOUS SECTIONS

Section 1. Introduction and general background
Tavia Gordon and William B. Kannel

Section 2. Follow-up to the eighth examination
Tavia Gordon

Section 3. Some characteristics of the Framingham cohort on the first 7 examinations by broad age groups
Christine Cole, Esther Allen, Manning Feinleib

Notes: Dewey Shurtleff, William P. Castelli, Lloyd E. Hawes, and Patricia M. McNamara

Section 4. Some characteristics of the Framingham cohort on the first 7 examinations by 5-year age groups
Dewey Shurtleff

Section 5. Bivariate correlations among some characteristics of the Framingham cohort at Exam 2
Dewey Shurtleff

Section 6. Smoothed average annual incidence rates by age at exam preceding event, and sex
Manning Feinleib

Section 7. Average two-year incidence rates by age at exam preceding event and sex, with total number of events and total population at risk
Manning Feinleib

Section 8. Two-year incidence by exam interval by age at Exam 1 and sex
Manning Feinleib

Criteria: William B. Kannel, William P. Castelli, and Patricia M. McNamara

PREVIOUS SECTIONS

Section 9. Population alive with specified events by sex, age and level of characteristic at exam
Dewey Shurtleff

Section 10. Incidence of Coronary Heart Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 11. Incidence of Myocardial Infarction by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 12. Incidence of Angina Pectoris Uncomplicated by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 13. Incidence of Sudden Death from Coronary Heart Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 14. Incidence of Non-Sudden Death from Coronary Heart Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 15. Incidence of Cerebrovascular Accident by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 16. Incidence of Brain Infarction by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

PREVIOUS SECTIONS

Section 17. Incidence of Intermittent Claudication by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 18. Incidence of Congestive Heart Failure by sex, age and level of characteristics at exam for 22 characteristics
Dewey Shurtleff

Section 19. Incidence of Death by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 20. Incidence of Death from Coronary Heart Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 21. Incidence of Death from Cardiovascular Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 22. Incidence of Death from Cause other than Cardiovascular Disease by sex, age and level of characteristic at exam for 22 characteristics
Dewey Shurtleff

Section 23. Serum cholesterol, systolic blood pressure and Framingham relative weight as discriminators of cardiovascular disease
Tavia Gordon and Joel I. Verter

Section 24. The Framingham Diet Study: Diet and the regulation of serum cholesterol

PREVIOUS SECTIONS

Section 25. Survival following certain cardiovascular events
Joyce Schiffman

Section 26. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 16-year follow-up.
Dewey Shurtleff

Section 27. Coronary Heart Disease, Atherothrombotic Brain Infarction, Intermittent Claudication--A multivariate analysis of some factors related to their incidence: Framingham Study, 16-year follow-up.
Tavia Gordon, Paul Sorlie, and William B. Kannel

Section 28. The Framingham Study: The probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics.
Daniel McGee

Section 29. Means at each examination and inter-examination variation of specified characteristics: Framingham Study, Exam 1 to Exam 10.
Tavia Gordon and Dewey Shurtleff

Section 30. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Study, 18-year follow-up.
Dewey Shurtleff

Section 31. The results of the Framingham Study applied to four other U.S.-based epidemiologic studies of cardiovascular disease.
Daniel McGee and Tavia Gordon

☆ U. S. GOVERNMENT PRINTING OFFICE : 1977 720-075/7337

DATE DUE

~~FEB 27 1991~~

(R)

~~SEP 2 1991~~

~~JUN 26 1991~~

GAYLORD

PRINTED IN U.S.A.

DISCRIMINATION PROHIBITED: Under provisions of applicable public laws enacted by Congress since 1964, no person in the United States shall, on the ground of race, color, national origin, sex, or handicap, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance. In addition, Executive Order 11141 prohibits discrimination on the basis of age by contractors and subcontractors in the performance of Federal contracts. Therefore, the National Heart, Lung, and Blood Institute must be operated in compliance with these laws and executive order.

LIBRARY
NIH
Amazing Research.
Amazing Help.
http://nihlibrary.nih.gov

10 Center Drive
Bethesda, MD 20892-1150
301-496-1080

NIH LIBRARY
4 0124 5221

NIH LIBRARY
3 1496 00191 7197

~~DEC 20 1988~~

~~JUL 9 1997~~

~~AUG 7 1997~~

DHEW PUBLICATION NO. (NIH) 77-1247